

16.2.7 Adverse Event Listings (Each Participant)

- Listing 16.2.7.1.1 Solicited Adverse Reactions Safety Set
- Listing 16.2.7.1.2 Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set
- Listing 16.2.7.2 Solicited Local Adverse Reactions Safety Set
- Listing 16.2.7.3 Solicited Systemic Adverse Reactions Safety Set
- Listing 16.2.7.4 Solicited Adverse Reactions Ongoing 7 Days after Injection Safety Set
- Listing 16.2.7.5 Solicited Rash Assessed by Healthcare Provider Safety Set
- Listing 16.2.7.6 Lymphadenopathy Assessed by Healthcare Provider Safety Set
- Listing 16.2.7.7 Unsolicited Adverse Events Safety Set
- Listing 16.2.7.8 Serious Adverse Events Safety Set
- Listing 16.2.7.9 Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine Safety Set
- Listing 16.2.7.10 Unsolicited Adverse Events Leading to Discontinuation from Participation in the Study Safety Set
- Listing 16.2.7.11 Unsolicited Medically-Attended Adverse Events Safety Set
- Listing 16.2.7.12 Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19 Safety Set

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011030; Age (Years): 42; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011056; Age (Years): 30; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011056; Age (Years): 30; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011057; Age (Years): 50; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011064; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2011064; Age (Years): 34; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1					G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G2	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
2	5	G0	G0	G0	G0	G1	G0	G1	G0	G0	G1	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011069; Age (Years): 51; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011070; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3					G0							
	4					G0							

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2011070; Age (Years): 50; Gender: F; Race: WHITE													
1	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G2	G2	G0	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011088; Age (Years): 47; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021061; Age (Years): 38; Gender: M; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE													
1	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021078; Age (Years): 40; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021078; Age (Years): 40; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021082; Age (Years): 47; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021089; Age (Years): 40; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021107; Age (Years): 26; Gender: F; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021135; Age (Years): 43; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021135; Age (Years): 43; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021138; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021138; Age (Years): 52; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1\$	G0	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1\$	G1	G1	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G1\$	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G1\$	G1\$	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G1	G0	G0	G0	G1	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021161; Age (Years): 53; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021162; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021162; Age (Years): 37; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G3\$	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE														
2	5	G0	G0	G0	G0	G0	G0		G3\$	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G3\$	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G3\$	G0	G0	G0	G0	No
Subject ID: US2031001; Age (Years): 42; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031009; Age (Years): 36; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
Subject ID: US2031014; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2031014; Age (Years): 36; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031022; Age (Years): 35; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031022; Age (Years): 35; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031023; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031040; Age (Years): 30; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031040; Age (Years): 30; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G2	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G2	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031043; Age (Years): 46; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031045; Age (Years): 41; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031049; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031058; Age (Years): 48; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031071; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031071; Age (Years): 36; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G2	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G1	G0	No
	3	G1	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1\$	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G1	G0	G0	G1	G0	No
	6	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041005; Age (Years): 22; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041011; Age (Years): 51; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041020; Age (Years): 45; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041029; Age (Years): 48; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041029; Age (Years): 48; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041034; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041042; Age (Years): 35; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041043; Age (Years): 47; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041043; Age (Years): 47; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041056; Age (Years): 23; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041059; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041059; Age (Years): 38; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041062; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041078; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
Subject ID: US2041090; Age (Years): 21; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G1	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051044; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051044; Age (Years): 38; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061003; Age (Years): 35; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061015; Age (Years): 19; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G1	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G1\$	G0	G0	G2	G0	No
	7	G0	G0	G0	G0	G0	G3\$	G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061022; Age (Years): 44; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G1	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061022; Age (Years): 44; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061024; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061032; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071012; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071012; Age (Years): 40; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071014; Age (Years): 18; Gender: M; Race: WHITE													
1	1					G0							
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071014; Age (Years): 18; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071017; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071017; Age (Years): 36; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071022; Age (Years): 29; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071042; Age (Years): 43; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G1	G0	G2	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071050; Age (Years): 45; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G2	G1	G0	G1	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071059; Age (Years): 32; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2071064; Age (Years): 26; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071064; Age (Years): 26; Gender: F; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071066; Age (Years): 25; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071066; Age (Years): 25; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071070; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081026; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081026; Age (Years): 49; Gender: F; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081042; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE													
2	1*					G0							
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	G0	No
	6	G1	G0	G0	G2	G0	G0	G2	G2	G2	G0	G0	No
	7	G0	G0	G0	G1	G0	G0	G1	G1	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash	
					Swelling/ Tenderness									
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE														
2	4	G0	G0	G0	G1	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
Subject ID: US2081058; Age (Years): 20; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011020; Age (Years): 27; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G1	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011061; Age (Years): 39; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/	Chills	Rash	
			(Redness)	(Hardness)	Swelling/ Tenderness						Vomiting			
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE														
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
Subject ID: US2011087; Age (Years): 33; Gender: M; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011087; Age (Years): 33; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011090; Age (Years): 29; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011091; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011092; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011092; Age (Years): 40; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G2	G0	G1	G1	G2	G0	G0	G1	G2	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G2	G2	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G2	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G2	G2	G1	G0	G0	No
	3	G1	G0	G0	G1	G0	G1	G2	G2	G1	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G1	G0	G0	G0	G1	G1	G1	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011102; Age (Years): 41; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G2	G0	G0	G2	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	1	G2	G0	G0	G1	G0	G1	G2	G2	G1	G1	G1	No
	2	G2	G0	G0	G0	G0	G1	G1	G2	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G2	G1	G1	G1	G0	G1	No
	4	G1	G0	G0	G0	G0	G2	G1	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G3\$	G2	G3	G3	G3	G1	G3	No
	2	G2	G0	G0	G0	G3\$	G2	G3\$	G3	G3	G0	G3\$	No
	3	G1	G0	G0	G0	G0	G1	G3\$	G3\$	G3\$	G0	G1	No
	4	G1	G0	G0	G0	G0	G2	G3\$	G3\$	G3\$	G0	G0	No
	5							G3\$	G3\$	G3\$			
	6	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G3\$	G0	G0	No
	7	G1	G0	G0	G0	G0	G1	G3\$	G3\$	G3\$	G0	G0	No
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G0	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021090; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021090; Age (Years): 54; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2021147; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G0	G1	G2	G1	G0	G2	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	4	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G1	No
	5	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G3\$	G1	G0	G0	G0	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0		G0		G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0		G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
Subject ID: US2031002; Age (Years): 42; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031002; Age (Years): 42; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G1	G0	G2	G1	G1	G1	G1	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	4	G1	G0	G0	G1	G0	G0	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G3\$	G0	G0	G0		G1	G1	G3\$	G3\$	G0	G0	No
	2	G3\$	G0	G0	G2	G0	G2	G2	G3	G3	G2	G2	No
	3	G3\$	G0	G0	G2	G0	G1	G0	G3\$	G3\$	G0	G0	No
	4	G3\$	G0	G0	G1	G0	G1	G0	G3\$	G3\$	G0	G0	No
	5	G3\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G3\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G3\$	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031011; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G1	G1	G1	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
Subject ID: US2031016; Age (Years): 21; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	1	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031016; Age (Years): 21; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G1	G0	G0	G0	G2	G2	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G0	G2	G1	G1	G2	No
	3	G0	G0	G0	G0	G0	G1	G0	G2	G1	G0	G1	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G2	G0	G0	G0	No
Subject ID: US2031051; Age (Years): 48; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031056; Age (Years): 48; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G2	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G1	No
	5	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G2	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
Subject ID: US2031066; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G1	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031066; Age (Years): 40; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031072; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	1	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G1	G2	G3	G3	G2	G2	G2	No
	3	G0	G0	G0	G0	G0	G2	G1	G3\$	G1	G1	G1	No
	4	G1	G0	G0	G0		G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE													
1	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G0	G1	G0	G2	G2	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G1	G1	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041003; Age (Years): 18; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041003; Age (Years): 18; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
Subject ID: US2041006; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041006; Age (Years): 33; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2041007; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041012; Age (Years): 32; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041013; Age (Years): 38; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041013; Age (Years): 38; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041023; Age (Years): 53; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G2	G2	G0	G0	G1	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G2	G0	G0	G2	G1	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041027; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041027; Age (Years): 40; Gender: F; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G3	G0	G0	G0	G0	G0	G2	G2	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041030; Age (Years): 43; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2041030; Age (Years): 43; Gender: F; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041036; Age (Years): 42; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041036; Age (Years): 42; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041049; Age (Years): 23; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G0	G1	G0	G1	G1	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041053; Age (Years): 28; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041053; Age (Years): 28; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041055; Age (Years): 20; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2041058; Age (Years): 39; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041058; Age (Years): 39; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041064; Age (Years): 43; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G1		G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041075; Age (Years): 35; Gender: M; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041075; Age (Years): 35; Gender: M; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1\$	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1\$	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE													
2	3	G1	G0	G0	G0	G0	G1		G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1\$	G1	G1	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G2	G2	G1	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G2	G1	G0	G0	G0	No
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041088; Age (Years): 18; Gender: M; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041091; Age (Years): 21; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041091; Age (Years): 21; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051008; Age (Years): 48; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G2	G0	G0	G1	G0	G0	G2	G2	G2	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051009; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE													
1	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G0	G1	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051018; Age (Years): 25; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G3	G2	G0	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051018; Age (Years): 25; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051027; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G1	G0	G1	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G1	G0	G3\$	G3\$	G3\$	G0	G0	G1	No
	2	G2	G0	G0	G2	G0	G3	G3	G3	G3	G2	G2	No
	3	G2	G0	G0	G0	G0	G3\$	G3\$	G3\$	G3\$	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051031; Age (Years): 35; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3					G0							
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G1	G1	G2	G3	G3	G0	G2	No
	2	G2	G0	G0	G0	G2	G2	G2	G3\$	G3	G0	G2	No
	3	G1	G0	G0	G0	G0	G2	G2	G1	G3\$	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G1	G0	G3\$	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G3\$	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G2	G0	G3\$	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G3\$	G0	G0	No
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051038; Age (Years): 28; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G1	G1	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051043; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051048; Age (Years): 31; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051048; Age (Years): 31; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061006; Age (Years): 35; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2061006; Age (Years): 35; Gender: F; Race: WHITE														
1	1	G1	G0	G0	G1	G0	G0		G2	G2	G2	G1	G2	No
	2	G1	G0	G0	G1	G0	G2	G1	G1	G1	G0	G0	No	
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	1	G2	G0	G0	G1	G0	G2	G1	G1	G1	G1	G1	No	
	2	G2	G0	G0	G2	G0	G2	G2	G2	G2	G1	G2	No	
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	3	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No	
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No	
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE													
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G3	G3	G2	G1	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061011; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061011; Age (Years): 49; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061013; Age (Years): 41; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G1	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061019; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE													
2	1*	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G2	G2	G0	G0	G1	G1	G0	G0	G1	G0	No
	3	G1	G2	G1	G0	G0	G2	G0	G0	G0	G1	G0	No
	4	G0	G1	G1	G0	G0	G2	G0	G1	G0	G0	G0	No
	5	G0	G0	G1	G0	G0	G2	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G2	G0	G0	G0	G1	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
Subject ID: US2071003; Age (Years): 42; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G2	G2	G0	G0	G1	G0	No
	3	G1	G1	G1	G0	G0	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071003; Age (Years): 42; Gender: F; Race: WHITE													
2	4	G1	G0	G1	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1\$	G1\$	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1\$	G1\$	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1\$	G1\$	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G2	G2	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G2	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071029; Age (Years): 18; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE													
1	4	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G2	G2	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071032; Age (Years): 24; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071032; Age (Years): 24; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071033; Age (Years): 26; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2071033; Age (Years): 26; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071063; Age (Years): 37; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071067; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G2	G2	G2	G3	G3	G0	G2	No
	3	G0	G0	G0	G0	G0	G2	G3	G3	G3	G1	G3	No
	4	G0	G0	G0	G0	G0	G2	G2	G2	G2	G1	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071074; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071074; Age (Years): 40; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G1	G1	G0	G1	G0	G0	No
	3	G0	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G0	G1	G0	G0	G0	Yes
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2081039; Age (Years): 21; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G2	G0	G0	G0	G1	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G2	G2	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081041; Age (Years): 41; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011018; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN													
1	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G2	G0	G3	G0	G2	G3	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011041; Age (Years): 28; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011046; Age (Years): 21; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G2	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011059; Age (Years): 46; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011059; Age (Years): 46; Gender: M; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011065; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2011065; Age (Years): 51; Gender: M; Race: WHITE														
2	5	G0	G0	G0	G0	G0	G2		G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011080; Age (Years): 49; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011085; Age (Years): 31; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G1	G0	G0	G0	G0	G0	No
	3	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011103; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011103; Age (Years): 51; Gender: M; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021063; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	2	G2	G0	G0	G0	G0	G0	G3	G3	G2	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021067; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021068; Age (Years): 40; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021068; Age (Years): 40; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G3	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G2	G3	G2	G2	G2	G2	No
	3	G0	G0	G0	G0	G0	G1	G3\$	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G2	G0	G2	G2	G2	G2	G0	G1	No
	2	G2	G0	G0	G2	G0	G3	G3	G3	G3	G1	G2	No
	3	G1	G0	G0	G1	G0	G2	G3\$	G3\$	G3\$	G1	G1	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE													
2	4	G1	G0	G0	G1	G0	G1		G3\$	G3\$	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G3\$	G3\$	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021093; Age (Years): 35; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G3	G3	G0	G2	G2	No
	3	G1	G0	G0	G0	G0	G0	G3\$	G3\$	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G1	G1	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021145; Age (Years): 43; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G1	G2	G2	G2	G0	G2	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021145; Age (Years): 43; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021151; Age (Years): 30; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G3	G3	G2	G2	G3\$	G2	G2	No
	3	G0	G0	G0	G0	G0	G3\$	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G2	G2	G2	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G2	G1	G0	G0	G1	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G3\$	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G3\$	G2	G2	G2	G1	G2	No
	3	G0	G0	G0	G0	G0	G3\$	G1	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1\$	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G1	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G1	G0	G1\$	G0	G3\$	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G1\$	G0	G3\$	G2	G0	G3	G3	G0	G2	No
	3	G1	G0	G1\$	G0	G3\$	G0	G0	G3\$	G3\$	G0	G0	No
	4	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G2	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031012; Age (Years): 44; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031013; Age (Years): 41; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G0	G0	G0	G1	G2	G2	G1	G0	G0	No
	3	G1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031019; Age (Years): 52; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031019; Age (Years): 52; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031020; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031020; Age (Years): 50; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031021; Age (Years): 41; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G2	G2	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031021; Age (Years): 41; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031026; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G1	G0	G2	G0	G0	G2	G0	No
	3	G0	G0	G0	G0	G0	G0	G2	G0	G0	G2	G2	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031027; Age (Years): 46; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	7	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2031037; Age (Years): 35; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G1	G2	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031037; Age (Years): 35; Gender: M; Race: WHITE													
2	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031047; Age (Years): 43; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	2	G1	G0	G0	G0	G1	G0	G1	G0	G2	G1	G1	Yes
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031050; Age (Years): 51; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G3\$	G2	G3	G3	G3	G0	G2	No
	3	G0	G0	G0	G0	G3	G2	G3\$	G3\$	G3	G2	G2	No
	4	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031060; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031060; Age (Years): 50; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G1	No
	2	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031062; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031062; Age (Years): 33; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G1		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G1	G1	G1	G1	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G0	G1	No
	4	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G2	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031084; Age (Years): 50; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031084; Age (Years): 50; Gender: M; Race: WHITE													
1	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G1	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1\$	G0	G0	G0	G0	No
	6							G1\$					
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G1	G2	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041024; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G2	G1	G0	G1	No
	2	G1	G0	G1	G0	G2	G2	G3	G3	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2041024; Age (Years): 51; Gender: M; Race: WHITE														
2	5	G0	G0	G0	G0	G0	G0		G1	G1	G0	G1	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	G0	No
Subject ID: US2041026; Age (Years): 50; Gender: M; Race: WHITE														
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041041; Age (Years): 37; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	Yes
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041048; Age (Years): 25; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G2	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G1	G0	G1	G2	G2	G2	G2	G0	No
	2	G1	G0	G0	G0	G0	G2	G3	G3	G3	G1	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041048; Age (Years): 25; Gender: F; Race: WHITE													
2	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041060; Age (Years): 19; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1	G0	G1	G1	G0	G0	G0	G1	No
	2	G1	G0	G1\$	G0	G0	G0	G1	G0	G0	G0	G1	No
	3	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G1	G0	G1	G1	No
	2	G1	G0	G0	G1	G1	G1	G1	G1	G1	G1	G1	No
	3	G1	G0	G0	G1	G0	G0	G0	G1	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	No
	5	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
Subject ID: US2041079; Age (Years): 26; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local			Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041079; Age (Years): 26; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G3	G3	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041080; Age (Years): 26; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G2	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041080; Age (Years): 26; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041084; Age (Years): 52; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G2	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051001; Age (Years): 31; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051002; Age (Years): 30; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051002; Age (Years): 30; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G1	G0	G2	G1	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051003; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2051003; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G0	G0	G0	G1	G0	G0	G0	G0	G0	Yes
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051013; Age (Years): 22; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051013; Age (Years): 22; Gender: M; Race: WHITE													
1	1	G2	G0	G0	G2	G0	G0	G2	G0	G0	G0	G0	No
	2	G2	G0	G0	G2	G0	G0	G0	G0	G0	G0	G0	No
	3	G2	G0	G0	G2	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G1	G2	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G2	G0	G2	G1	G0	G0	G1	G0	No
	3	G1	G0	G0	G1	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G2	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G0	G0	G0	G1	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G1	G2	G2	G2	G2	G1	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G2	G1	G1	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051024; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G2	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051025; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051026; Age (Years): 49; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051026; Age (Years): 49; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G2	G0	G0	G2	No
	3	G2	G0	G0	G0	G0	G2	G3	G2	G0	G0	G2	No
	4	G2	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051028; Age (Years): 23; Gender: M; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051029; Age (Years): 28; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051029; Age (Years): 28; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051030; Age (Years): 43; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051030; Age (Years): 43; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G2	G2	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G2	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G0	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	Yes
	3	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G1	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G2	G0	G0	G1	G0	G2	G2	G1	G0	G1	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G2	G0	G1	No
	2	G1	G0	G0	G0	G0	G1	G2	G1	G2	G1	G2	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G2	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G2	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
Subject ID: US2061010; Age (Years): 43; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G2	G2	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G2	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061020; Age (Years): 54; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061020; Age (Years): 54; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G3\$	G0	G1	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G3\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1\$	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	7	G1\$	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
Subject ID: US2061025; Age (Years): 32; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G1	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061025; Age (Years): 32; Gender: M; Race: WHITE													
2	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061027; Age (Years): 44; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G1\$	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G1	G2	G2	G3	G3	G0	G2	No
	3	G1	G1	G1	G0	G2	G2	G3	G3	G3	G0	G2	No
	4	G1	G0	G1\$	G0	G1	G2	G2	G3	G3	G0	G2	No
	5	G1	G0	G1\$	G0	G1	G2	G2	G2	G2	G1	G1	No
	6	G0	G0	G1\$	G0	G2	G2	G2	G2	G2	G1	G1	No
	7	G0	G0	G1\$	G0	G0	G2	G2	G1	G1	G1	G0	No
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G2	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071038; Age (Years): 27; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G1	G0	G1	G0	G1	G0	G1	No
	3	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G3	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071040; Age (Years): 33; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071040; Age (Years): 33; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071051; Age (Years): 32; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071051; Age (Years): 32; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G2	G1	G0	G0	G0	G0	No
	3	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071068; Age (Years): 53; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071068; Age (Years): 53; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071069; Age (Years): 18; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G1	G2	G0	G0	G0	G2	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071071; Age (Years): 45; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071077; Age (Years): 29; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081023; Age (Years): 53; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2	G1	G1	G1	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE													
1	6	G0	G0	G0	G1	G0	G0		G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G3	G2	G2	G1	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G2	Yes
	3	G1	G1	G1	G0	G0	G0	G2	G0	G0	G0	G2	No
	4	G1	G0	G0	G0		G0	G0	G0	G0	G0	G1	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0		G0		G0		G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G2	G2	G0	G1	G2	No
Subject ID: US2081051; Age (Years): 50; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081062; Age (Years): 36; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081062; Age (Years): 36; Gender: M; Race: WHITE													
1	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G1	G1	G1	G1	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G1	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G2	G2	G3	G1	G2	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE													
2	2	G2	G0	G0	G0	G0	G2	G3	G3	G1	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011007; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011109; Age (Years): 76; Gender: F; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011109; Age (Years): 76; Gender: F; Race: ASIAN													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011114; Age (Years): 61; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011116; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011124; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011124; Age (Years): 60; Gender: F; Race: WHITE													
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011126; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011155; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G1	No
	6	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
Subject ID: US2011156; Age (Years): 73; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2011156; Age (Years): 73; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021021; Age (Years): 71; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G1	G1	G1	G1	G1	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021185; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021185; Age (Years): 55; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021189; Age (Years): 75; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021198; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021198; Age (Years): 63; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
Subject ID: US2021219; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G3	G0	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021222; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031085; Age (Years): 71; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2031085; Age (Years): 71; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031095; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031098; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031110; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031116; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031124; Age (Years): 59; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031124; Age (Years): 59; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031131; Age (Years): 72; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041102; Age (Years): 61; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041115; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041115; Age (Years): 70; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041121; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041121; Age (Years): 65; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041132; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041151; Age (Years): 57; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041151; Age (Years): 57; Gender: M; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041166; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051055; Age (Years): 59; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051055; Age (Years): 59; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051063; Age (Years): 56; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051063; Age (Years): 56; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0								
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051073; Age (Years): 74; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051086; Age (Years): 77; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051087; Age (Years): 74; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051087; Age (Years): 74; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051089; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G2	G0	G0	G2	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051089; Age (Years): 56; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051098; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051098; Age (Years): 55; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051112; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1\$	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1\$	G1\$	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G1\$	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1					G0							
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061055; Age (Years): 84; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	2						G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071041; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071041; Age (Years): 64; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071084; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071084; Age (Years): 64; Gender: M; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071086; Age (Years): 68; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071088; Age (Years): 70; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071088; Age (Years): 70; Gender: M; Race: WHITE													
1	2	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071094; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G2	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071094; Age (Years): 63; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
Subject ID: US2071098; Age (Years): 65; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071105; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071105; Age (Years): 65; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081004; Age (Years): 60; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081015; Age (Years): 55; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081029; Age (Years): 55; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081029; Age (Years): 55; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081065; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary		Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/	Tenderness								
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE														
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081077; Age (Years): 66; Gender: F; Race: WHITE														
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081077; Age (Years): 66; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081080; Age (Years): 69; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2081080; Age (Years): 69; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081087; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081097; Age (Years): 76; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081113; Age (Years): 60; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081113; Age (Years): 60; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081119; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081125; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011012; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G2	G1	G2	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G3	G0	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011032; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2011032; Age (Years): 58; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G2	G0	G0	G0	G0	G2	G1	G0	G0	G0	No
	3	G1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
2	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011117; Age (Years): 79; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0							
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G2	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1\$	G1\$	G0	G0	No
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011127; Age (Years): 63; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011127; Age (Years): 63; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G2	G0	G0	G1	G2	G1	G2	G0	G2	No
	3	G1	G0	G1	G0	G0	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE													
2	4	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011138; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011153; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G3	G1	G1	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021004; Age (Years): 72; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2021004; Age (Years): 72; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G1	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021020; Age (Years): 72; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G2	G0	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G2	G2	G0	G0	G0	G0	No
	7						G1\$	G1\$					
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G2	G0	G0	G1	G2	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G3	G2	G2	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021047; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021047; Age (Years): 65; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021133; Age (Years): 75; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021133; Age (Years): 75; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021190; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021192; Age (Years): 62; Gender: M; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G2	G2	G2	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G2	G1	G0	G2	G2	G2	G0	G0	No
	3	G2	G0	G0	G1	G0	G0	G0	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G2	G0	G0	G0	G1	Yes
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G3	G3	G3	G2	G0	G2	Yes
	2	G1	G0	G0	G0	G0	G1	G3	G3	G0	G0	G3	Yes
	3	G1	G0	G0	G0	G0	G1	G3\$	G3\$	G0	G0	G1	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G2	G3	G2	G0	G0	G2	No
	5	G0	G0	G0	G0	G0	G2	G0	G2	G0	G0	G2	No
	6	G0	G0	G0	G0	G0	G1	G3	G1	G0	G0	G1	No
	7	G0	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	No
Subject ID: US2021220; Age (Years): 76; Gender: M; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G1\$	No
	4	G0	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G1\$	No
	5	G0	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G1\$	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031086; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary		Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling	Swelling/ Tenderness								
Subject ID: US2031086; Age (Years): 68; Gender: F; Race: WHITE														
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031096; Age (Years): 73; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031096; Age (Years): 73; Gender: F; Race: WHITE													
2	2	G1	G0	G1	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G1	G1	G1	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G1	G1	G1	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031104; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G0	G1	G1	G1	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031108; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031109; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031128; Age (Years): 74; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031128; Age (Years): 74; Gender: F; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041094; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041100; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	No
	2	G2	G0	G0	G2	G0	G2	G3	G3	G3	G1	G2	No
	3	G1	G0	G0	G0	G0	G1	G2\$	G2\$	G2\$	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2					G0	G0	G0	G0	G0	G0	G0	No
	3					G0							
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5					G0							
	6	G1	G0	G0	G0	G0							
	7					G0							
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G3	G1	G2	G0	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041106; Age (Years): 76; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE													
1	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G1	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041111; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041111; Age (Years): 66; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041113; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G0	G0	G1	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2041118; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041127; Age (Years): 69; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041127; Age (Years): 69; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G1	G2	G2	G2	G1	G2	No
	2	G0	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041139; Age (Years): 69; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041145; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G0	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G2	G0	G2	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G2	G1	G0	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G2	G1	G0	G1	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	6	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	1	G2\$	G0	G0	G0	G0	G0	G1	G2	G1	G0	G0	No
	2	G2\$	G0	G0	G1	G0	G1	G1	G2	G2	G0	G1	No
	3	G2\$	G0	G0	G1	G0	G1	G2	G1	G1	G0	G1	No
	4	G2\$	G0	G0	G1	G0	G1	G1	G1	G1	G0	G0	No
	5	G2\$	G0	G0	G1	G0	G1	G1	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE														
2	6	G2\$	G0	G0	G1	G0	G0		G1	G1	G1	G0	G0	No
	7	G2\$	G0	G0	G1	G0	G1		G1	G1	G0	G0	G0	No
Subject ID: US2051059; Age (Years): 57; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1		G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0		G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1		G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1		G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G1	G0	G2		G2	G2	G2	G2	G0	No
	3	G2	G0	G1	G2	G0	G2		G2	G2	G2	G2	G0	No
	4	G1	G0	G1	G1	G0	G1		G0	G0	G1	G1	G0	No
	5	G1	G0	G1	G1	G0	G0		G0	G0	G1	G0	G0	No
	6	G1	G0	G1	G1	G0	G1		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1		G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051060; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
Subject ID: US2051071; Age (Years): 71; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G1	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051078; Age (Years): 73; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051081; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051081; Age (Years): 69; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G2	G1	G2	G2	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051092; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051092; Age (Years): 65; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051094; Age (Years): 57; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051095; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2051095; Age (Years): 58; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G2	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G1	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G1	G1	G1	No
	4	G0	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G3	G3	G2	G2	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051100; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051100; Age (Years): 68; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051103; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G3	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G2	G2	G0	G2	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051105; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G2	G2	G2	G2	G1	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G0	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No
	2	G2	G0	G0	G0	G0	G2	G3	G3	G3	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER													
2	4	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061057; Age (Years): 79; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061064; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061064; Age (Years): 68; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071007; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G1	G1	G0	G0	G1	G1	G1	G1	G0	G0	No
	3	G1	G2	G2	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071007; Age (Years): 58; Gender: F; Race: WHITE													
2	4	G1	G2	G2	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G1	G2	G2	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G1	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071024; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G3	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071083; Age (Years): 87; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071083; Age (Years): 87; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071099; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081003; Age (Years): 64; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081003; Age (Years): 64; Gender: F; Race: WHITE													
1	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	2	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081020; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081020; Age (Years): 61; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G2	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081085; Age (Years): 63; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2081085; Age (Years): 63; Gender: F; Race: WHITE													
1	4	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G3	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081090; Age (Years): 63; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081090; Age (Years): 63; Gender: M; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	Yes
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	Yes
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G1	G2	G0	G1	G1	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G1	G2	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G2	G2	G1	G1	G1	No
	5	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G2	G2	G0	G0	G0	G2	G0	G0	G0	G1	No
	4	G1	G2	G2	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
Subject ID: US2081110; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081110; Age (Years): 62; Gender: F; Race: WHITE													
1	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G1	G0	G1	G0	G0	G0	G2	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011004; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	2	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness						Vomiting		
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G2	G2	G0	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011113; Age (Years): 63; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011113; Age (Years): 63; Gender: F; Race: BLACK OR AFRICAN AMERICAN													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011118; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011118; Age (Years): 60; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G2	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3	G2	G0	G0	G2	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE													
1	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G1	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011128; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2011128; Age (Years): 61; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G2	G0	G2	G0	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011139; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011139; Age (Years): 66; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G0	G0	G1	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011149; Age (Years): 74; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G3	G3	G3	G2	G2	G2	G2	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2011149; Age (Years): 74; Gender: F; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011159; Age (Years): 72; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2011162; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G1	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G1	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G0	G0	G2	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021031; Age (Years): 72; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021114; Age (Years): 67; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021115; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2021115; Age (Years): 59; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1	G0	G0	G0	G1	G0	G1	G0	No
	2	G1	G0	G0	G0	G0	G2	G1	G2	G2	G1	G1	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021186; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021186; Age (Years): 60; Gender: F; Race: WHITE													
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G1	G1	No
	3	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G2	G0	G0	G2	G0	G0	G2	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G0	G1	G2	G2	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021232; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	3	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G2	G0	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021234; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031091; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031091; Age (Years): 61; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G3\$	G3	G3	G2	G0	G2	No
	3	G0	G0	G0	G0	G0	G3\$	G0	G3\$	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G3\$	G0	G0	G0	G0	G0	No
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G2	G0	G0	G0	G1	G0	G0	G0	G1	No
	3	G0	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031101; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031111; Age (Years): 87; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G3\$	G0	G3\$	G3\$	G0	G0	No
	2	G0	G0	G0	G0	G0	G3	G3	G3	G3	G2	G2	No
	3	G0	G0	G0	G0	G0	G3\$	G3\$	G3\$	G3\$	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031122; Age (Years): 56; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2031122; Age (Years): 56; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041096; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041096; Age (Years): 64; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041107; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G2	G1	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041108; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G1	G1	G0	G0	G0	G2	G2	G1	G0	G1	No
	3	G1	G1	G1	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G1	G1	G1	G0	G0	G0	G2	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041117; Age (Years): 73; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041117; Age (Years): 73; Gender: F; Race: WHITE													
2	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G1	No	
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G2	G2	G2	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G1	G0	G0	G0	G3	G2	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041122; Age (Years): 82; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G3	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041123; Age (Years): 60; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041123; Age (Years): 60; Gender: F; Race: WHITE													
1	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G2	G2	G2	G1	G2	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041125; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041125; Age (Years): 57; Gender: F; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7						G1\$						
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G2	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE													
2	3	G1	G1	G0	G0	G0	G1	G0	G0	G0	G0	G0	Yes
	4	G1	G1	G1	G1	G0	G1	G0	G0	G0	G0	G0	Yes
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	Yes
	6	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G1	G0	G2	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041136; Age (Years): 56; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE													
1	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041149; Age (Years): 65; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041149; Age (Years): 65; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051054; Age (Years): 63; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G0	G2	G2	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051064; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G2	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	3	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G2	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1\$	G0	G0	G1	G0	No
	4	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction									
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary		Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/			
					Swelling/	Tenderness						Vomiting	Chills	Rash	
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE															
1	6	G0	G0	G0	G0		G0	G0		G1\$	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0		G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G1		G0	G1		G1	G0	G0	G1	G0	No
	2	G1	G0	G0	G0		G0	G1		G2	G0	G1	G0	G2	No
	3	G1	G0	G0	G0		G0	G1		G2	G0	G0	G2	G1	No
	4	G1	G0	G0	G0		G0	G0		G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
Subject ID: US2051070; Age (Years): 63; Gender: M; Race: WHITE															
1	1*	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051070; Age (Years): 63; Gender: M; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G2	G0	G1	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE													
2	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051075; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051077; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051084; Age (Years): 61; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051084; Age (Years): 61; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051085; Age (Years): 65; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051085; Age (Years): 65; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G2	G0	G2	No
	3	G1	G0	G0	G0	G2	G1	G1	G1	G1	G0	G1	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	Yes
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G1	G0	G1	G1	G1	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051097; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G3	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051101; Age (Years): 62; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G1	No
	2	G1	G0	G0	G0	G0	G2	G2	G2	G2	G0	G2	No
	3	G0	G0	G0	G1	G0	G2	G2	G2	G2	G0	G2	No
	4	G0	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G2	G1	G1	G0	G2	No
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051104; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G3\$	G3\$	G3\$	G0	G1	No
	2	G1	G0	G0	G0	G0	G1	G3\$	G3\$	G3\$	G1	G1	No
	3	G1	G0	G0	G0	G0	G0	G3\$	G3\$	G3\$	G2	G2	No
	4	G1	G0	G0	G0	G0	G2	G3	G3	G3	G3	G3	No
	5	G0	G0	G0	G0	G0	G0	G3\$	G3\$	G3\$	G1	G1	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE													
1	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G2	G0	G0	G2	No
	3	G0	G0	G0	G0	G1	G1	G2	G2	G0	G0	G2	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE													
1	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G0	G1	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051111; Age (Years): 70; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G1	G0	G0	G2	G0	G0	G2	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash	
Subject ID: US2051111; Age (Years): 70; Gender: F; Race: WHITE														
2	3	G0	G0	G0	G1	G0	G0		G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
Subject ID: US2061036; Age (Years): 56; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0		G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0		G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0		G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G2		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0		G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061036; Age (Years): 56; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061045; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G2	G0	G0	G1	No
	3	G1	G0	G0	G0	G1	G1	G1	G2	G0	G1	G2	No
	4	G1	G3	G0	G0	G0	G0	G0	G0	G0	G1	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061063; Age (Years): 56; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2061063; Age (Years): 56; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071006; Age (Years): 71; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2071006; Age (Years): 71; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G1	G1	G0	G1	No
	3	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071013; Age (Years): 73; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071013; Age (Years): 73; Gender: F; Race: WHITE													
2	1	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G3	G0	G0	G1	G0	G1	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G2	G1	G0	G1	G0	G0	G0	G0	G0	No
	3	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G1	G1	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE													
2	5	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G1	G2	G1	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G2	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G1	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE													
1	4	G0	G0	G0	G0	G0							
	5	G0	G0	G0	G0	G0							
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0							
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5					G0							
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE													
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071093; Age (Years): 67; Gender: F; Race: WHITE													
1	2			G1\$									
	3			G1\$									
	4			G1\$									
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1					G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE													
1	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE													
1	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	2	G0	G0	G0	G0	G0	G1	G0	G1	G1	G1	G0	No
	3	G1	G0	G0	G0	G1	G2	G2	G2	G2	G0	G1	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G2	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE													
2	5	G0	G0	G0	G0		G0		G0		G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081002; Age (Years): 69; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081014; Age (Years): 67; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary		Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling	Tenderness								
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE														
1	5	G0	G0	G0	G0		G0		G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0		G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0		G0	G0	G0	G0	G0	No
2	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G1	G2	G2	G2	G0	G0	G2	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G1	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081019; Age (Years): 76; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G1	G1	G0		G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G1	G1	G0		G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081019; Age (Years): 76; Gender: F; Race: WHITE													
2	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081035; Age (Years): 68; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G1\$	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G3	G2	G2	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE													
2	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G1	G1	G0	G0	G0	G3	G3	G0	G0	G2	No
	3	G1	G3	G2	G1	G0	G0	G1\$	G2\$	G0	G0	G0	No
	4	G1	G1	G1	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE													
2	5	G1	G1\$	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G1\$	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081081; Age (Years): 56; Gender: F; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G1	G1	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G1	G1	G1	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081088; Age (Years): 63; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G3	G2	G0	G0	G2	No
	2	G0	G0	G0	G0	G1	G0	G2	G2	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G1	G1	G0	G0	No
	3	G0	G0	G0	G0	G0	G2	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G1	G2	G3	G3	G3	G0	G0	No
	3	G0	G0	G0	G0	G0	G1	G2\$	G2	G2	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE													
2	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE													
1	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G1	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G1	G2	G0	G2	G0	G0	No
	3	G1	G0	G0	G1	G0	G1	G1	G0	G1	G0	G0	No
	4	G1	G0	G0	G1	G0	G1	G0	G0	G1	G0	G0	No
	5	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
	6	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE													
2	7	G0	G0	G0	G0	G0	G1	G0	G0	G1	G0	G0	No
Subject ID: US2081108; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081116; Age (Years): 75; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081116; Age (Years): 75; Gender: M; Race: WHITE													
1	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G2	G2	G1	G1	G0	G2	Yes
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081117; Age (Years): 66; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081117; Age (Years): 66; Gender: F; Race: WHITE													
1	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G2	G0	G0	G0	G0	G0	G0	G1	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary		Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/	Tenderness								
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE														
2	1	G0	G0	G0	G0		G0	G0		G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0	G0	G1	G1	G1	G0	G0	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	5	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	6	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	7	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE														
1	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0		G0	G1	G0	G2	G0	G0	G0	No
	5	G0	G0	G0	G0		G0	G1	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0			G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0		G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070101.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.1
Solicited Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE													
2	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G2	G0	G0	G0	G0	G2	G2\$	G2	G2	G1	G1	No
	3	G2	G0	G0	G0	G0	G2	G2	G2	G2	G1	G1	No
	4	G2	G0	G0	G0	G0	G2	G2	G2	G2	G1	G2	No
	5	G1	G0	G0	G0	G0	G1	G2	G2	G2	G1	G1	No
	6	G0	G0	G0	G0	G0	G0	G2\$	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G2	G2	G0	G0	G2\$	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local			Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE													
2	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G1	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local			Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary Swelling/ Tenderness	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash

There are no observations for this section.

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema	Swelling	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			(Redness)	(Hardness)	Swelling/ Tenderness								
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE													
1	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
2	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination		Local				Systemic Reaction							
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE													
1	1*	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	1	G0	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	2	G1	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	3	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	4	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	5	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	6	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No
	7	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.1.2
Solicited Adverse Reactions for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination		Local			Systemic Reaction								
Dose #	Day	Pain	Erythema (Redness)	Swelling (Hardness)	Axillary	Fever	Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
					Swelling/ Tenderness								

There are no observations for this section.

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\11602070102.sas 19NOV2020 01:38 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011030; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE								
2020-06-08	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-06	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE								
2020-06-01	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-01	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011056; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	6	G0	0	G0
	3	G0	G0	6	G0	0	G0
	4	G0	G0	6	G0	0	G0
	5	G0	G0	6	G0	0	G0
	6	G0	G0	5	G0	0	G0
	7	G0	G0	5	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ <u>Tenderness</u> Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011056; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-30	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011057; Age (Years): 50; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011057; Age (Years): 50; Gender: M; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-30	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011064; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1						
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE							
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G1	G0	0	G0	2	G0
	1	G1	G0	0	G1\$		G0
	2	G1	G0	0	G1\$		G0
	3	G1	G0	0	G1\$		G0
	4	G1	G0	0	G1\$		G0
	5	G1	G0	0	G1\$		G0
	6	G1	G0	0	G1\$		G0
7	G1	G0	0	G1\$		G0	
Subject ID: US2011069; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011069; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011070; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3						
	4						
	5	G1	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011070; Age (Years): 50; Gender: F; Race: WHITE							
2020-07-06	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-30	7	G0	G0	0	G0	0	G0
Subject ID: US2011088; Age (Years): 47; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
Subject ID: US2021061; Age (Years): 38; Gender: M; Race: ASIAN							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2021061; Age (Years): 38; Gender: M; Race: ASIAN								
2020-06-02	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-30	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-06-04	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G1	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE							
2020-06-04	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-02	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021078; Age (Years): 40; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021078; Age (Years): 40; Gender: M; Race: WHITE							
2020-07-01	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021082; Age (Years): 47; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021082; Age (Years): 47; Gender: M; Race: WHITE							
2020-07-07	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021089; Age (Years): 40; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021089; Age (Years): 40; Gender: M; Race: WHITE							
2020-07-08	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-03	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021107; Age (Years): 26; Gender: F; Race: ASIAN							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021107; Age (Years): 26; Gender: F; Race: ASIAN							
2020-07-02	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-21	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE							
2020-07-21	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2021135; Age (Years): 43; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-05	1*	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE								
2020-06-08	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-07	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
2020-07-06	6	G0	G0	0	G0	0	G0	
	Subject ID: US2021138; Age (Years): 52; Gender: F; Race: WHITE							
	2020-06-04	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
		3	G0	G0	0	G0	0	G0
		5	G0	G0	0	G0	0	G0
		6	G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0	
2020-07-06		1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021138; Age (Years): 52; Gender: F; Race: WHITE							
2020-07-06	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE							
2020-07-06	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G1
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE							
2020-07-13	7	G0	G0	0	G0	0	G0
Subject ID: US2021161; Age (Years): 53; Gender: F; Race: WHITE							
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021162; Age (Years): 37; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE							
2020-07-08	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031001; Age (Years): 42; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031001; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031009; Age (Years): 36; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031014; Age (Years): 36; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031022; Age (Years): 35; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031022; Age (Years): 35; Gender: M; Race: WHITE							
2020-05-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-06-29	1*	G0	G0	0	G0	0
1		G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0
3		G0	G0	0	G0	0	G0
4		G0	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2031023; Age (Years): 37; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031023; Age (Years): 37; Gender: F; Race: WHITE							
2020-05-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-07	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE							
2020-07-02	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031040; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031040; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-30	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031043; Age (Years): 46; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031045; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031045; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-02	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031049; Age (Years): 37; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031049; Age (Years): 37; Gender: F; Race: WHITE							
2020-07-01	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031058; Age (Years): 48; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031071; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-02	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-06-30	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041005; Age (Years): 22; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041005; Age (Years): 22; Gender: F; Race: WHITE							
2020-05-29	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041011; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041011; Age (Years): 51; Gender: F; Race: WHITE							
2020-07-01	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-26	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G1
	2	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2041020; Age (Years): 45; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2041020; Age (Years): 45; Gender: M; Race: WHITE								
2020-06-03	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-01	1*	G0	G0	0	G0	0	G0
		2	G0	G0	0	G0	0	G0
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7		G0	G0	0	G0	0	G0	
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE								
2020-06-05	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-05	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041029; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	8	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041029; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041034; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041034; Age (Years): 45; Gender: F; Race: WHITE							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041042; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041043; Age (Years): 47; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041056; Age (Years): 23; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041059; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041062; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041062; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-30	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041078; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-08	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-06	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-08	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041090; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041090; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-08	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	1	G0
	3	G0	G0	1	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE							
2020-07-08	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE							
2020-07-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051044; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-05	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051044; Age (Years): 38; Gender: M; Race: WHITE							
2020-07-06	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061003; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	1	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061015; Age (Years): 19; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-05	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-08	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061022; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061022; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	G0	0	G0	0	G0
Subject ID: US2061024; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061024; Age (Years): 38; Gender: M; Race: WHITE							
2020-07-02	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061032; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061032; Age (Years): 50; Gender: F; Race: WHITE							
2020-07-07	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071012; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071012; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-07	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071014; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-03	1			0			
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071017; Age (Years): 36; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071022; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071022; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-03	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G1
	1*	G0	G0	0	G0	0	G0
2020-07-02	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071042; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071042; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-08	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE							
2020-07-08	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071050; Age (Years): 45; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071050; Age (Years): 45; Gender: M; Race: WHITE							
2020-07-07	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071059; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	3	G0
	2	G0	G0	0	G0	3	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071064; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2071064; Age (Years): 26; Gender: F; Race: WHITE								
2020-06-05	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-09	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-07-09	7	G0	G0	0	G0	0	G0	
	Subject ID: US2071066; Age (Years): 25; Gender: M; Race: WHITE							
	2020-06-09	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
		2	G0	G0	0	G0	0	G0
		3	G0	G0	0	G0	0	G0
		4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071066; Age (Years): 25; Gender: M; Race: WHITE							
2020-06-09	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071070; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071070; Age (Years): 34; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE							
2020-07-06	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081026; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081026; Age (Years): 49; Gender: F; Race: WHITE							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081042; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081042; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-10	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE							
2020-06-08	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE							
2020-06-09	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE							
2020-07-08	1*						
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-05	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G2
	7	G0	G0	0	G0	0	G1
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE							
2020-07-09	2	G0	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081058; Age (Years): 20; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011020; Age (Years): 27; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-01	2	G1	G0	0	G0	20	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-06-29	1	G1	G0	0	G0	9	G0
	2	G1	G0	0	G0	6	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-01	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	10	G0
	2	G1	G0	0	G0	10	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE							
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011061; Age (Years): 39; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-03	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011061; Age (Years): 39; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-30	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011087; Age (Years): 33; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011090; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011090; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-04	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011091; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011091; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-04	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011092; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G2	60	G0
	2	G1	G0	2	G0	0	G0
	3	G0	G0	2	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011092; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-07	1	G0	G0	2	G0	0	G0
	2	G1	G0	0	G2	60	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE							
2020-07-06	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	3	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	6	G0	3	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE							
2020-07-06	7	G0	G0	0	G0	0	G0
Subject ID: US2011102; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	5	G0
	2	G1	G0	0	G0	5	G0
	3	G1	G0	0	G0	3	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G1
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5						
	6	G0	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-08	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE							
2020-06-05	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE							
2020-06-05	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021090; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021090; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021147; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021147; Age (Years): 51; Gender: M; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI							
2020-07-07	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE						
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE							
2020-07-07	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE							
2020-07-07	7	G0	G0	0	G0	0	G0
Subject ID: US2031002; Age (Years): 42; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G1
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G1	G0	0	G0	0	G0
	1	G3\$	G0	0	G0	0	G0
	2	G3\$	G0	0	G0	1	G2
	3	G3\$	G0	0	G0	0	G2
	4	G3\$	G0	0	G0	0	G1
	5	G3\$	G0	0	G0	0	G0
	6	G3\$	G0	0	G0	0	G0
	7	G3\$	G0	0	G0	0	G0
Subject ID: US2031011; Age (Years): 52; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031011; Age (Years): 52; Gender: F; Race: WHITE							
2020-05-29	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031016; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031016; Age (Years): 21; Gender: M; Race: WHITE							
2020-06-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE							
2020-06-04	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031051; Age (Years): 48; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031051; Age (Years): 48; Gender: F; Race: WHITE							
2020-06-29	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031056; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031056; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-30	7	G0	G0	0	G0	0	G0
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031066; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2031066; Age (Years): 40; Gender: F; Race: WHITE								
2020-06-02	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-30	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G2	G0	0	G0	0	G0	
3		G1	G0	0	G0	0	G0	
4		G1	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-06-03	1*	G0	G0	0	G0	0	G0	
	1	G1	G0	0	G0	0	G1	
	2	G1	G0	0	G0	0	G0	
	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031072; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-04	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-30	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041003; Age (Years): 18; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041003; Age (Years): 18; Gender: F; Race: WHITE							
2020-06-30	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041006; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041006; Age (Years): 33; Gender: F; Race: WHITE							
2020-07-02	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041007; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041007; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-29	7	G0	G0	0	G0	0	G0
Subject ID: US2041012; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	10	G0
	3	G1	G0	0	G0	10	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G1	G0	0	G0	10	G0
	1	G0	G0	0	G0	20	G0
	2	G1	G0	0	G0	20	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041013; Age (Years): 38; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE							
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-14	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2041023; Age (Years): 53; Gender: F; Race: WHITE						
2020-06-01	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041023; Age (Years): 53; Gender: F; Race: WHITE							
2020-06-29	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041027; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-01	1*	G1	G0	0	G0	1	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G3	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041027; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-29	7	G0	G0	0	G0	0	G0
Subject ID: US2041030; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041036; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE							
2020-06-02	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041049; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G1	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-14	1*	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041049; Age (Years): 23; Gender: F; Race: WHITE							
2020-07-14	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-30	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041053; Age (Years): 28; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G1	25	G0
	3	G0	G0	0	G0	20	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041055; Age (Years): 20; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041058; Age (Years): 39; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041064; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041064; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-08	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-14	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE							
2020-06-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041075; Age (Years): 35; Gender: M; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041075; Age (Years): 35; Gender: M; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE							
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-06	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE							
2020-07-01	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041088; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-10	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041088; Age (Years): 18; Gender: M; Race: WHITE							
2020-07-10	7	G0	G0	0	G0	0	G0
Subject ID: US2041091; Age (Years): 21; Gender: F; Race: WHITE							
2020-06-10	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-08	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-14	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051008; Age (Years): 48; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051008; Age (Years): 48; Gender: F; Race: WHITE							
2020-05-29	4	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	1	G0
	2	G2	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
Subject ID: US2051009; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051009; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-30	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051018; Age (Years): 25; Gender: F; Race: WHITE							
2020-06-08	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051027; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G1
	1	G2	G0	19	G0	0	G1
	2	G2	G0	14	G0	0	G2
	3	G2	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051031; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051031; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	2	G1	G0	0	G0	1	G0
	3						
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE							
2020-06-02	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-04	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G1	50	G0
	2	G1	G0	0	G1	25	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE							
2020-07-01	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051038; Age (Years): 28; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	6	G0
	1	G0	G0	0	G0	6	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-05	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G1	25	G1
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G1	35	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051043; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	4	G0	6	G0
	3	G1	G0	4	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
Subject ID: US2051048; Age (Years): 31; Gender: F; Race: WHITE							
2020-06-09	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051048; Age (Years): 31; Gender: F; Race: WHITE							
2020-06-09	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE							
2020-06-08	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE							
2020-06-04	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061006; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-03	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1
	2	G1	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061006; Age (Years): 35; Gender: F; Race: WHITE							
2020-07-01	1	G2	G0	0	G0	0	G1
	2	G2	G0	0	G0	1	G2
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061011; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061013; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	6	G0	0	G0
	4	G1	G0	3	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061019; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061019; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-03	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-05	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	2	G0	1	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE							
2020-05-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G2	60	G0	0	G0
	1	G1	G0	20	G0	0	G0
	2	G1	G2	57	G2	55	G0
	3	G1	G2	67	G1	48	G0
	4	G0	G1	45	G1	32	G0
	5	G0	G0	0	G1	30	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071003; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071003; Age (Years): 42; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	5	G0	5	G0
	2	G1	G1	25	G1	30	G0
	3	G1	G1	40	G1	40	G0
	4	G1	G0	0	G1	45	G0
	5	G0	G0	0	G1	25	G0
	6	G1	G0	0	G0	20	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
2020-07-08	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071029; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071029; Age (Years): 18; Gender: M; Race: WHITE							
2020-07-10	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G1	25	G1	45	G0
	3	G1	G0	15	G1	45	G0
	4	G1	G0	0	G1	40	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G2	65	G2	65	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE							
2020-07-06	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071032; Age (Years): 24; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-10	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071033; Age (Years): 26; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071063; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071063; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071067; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	4	G0	4	G0
	3	G1	G0	2	G0	2	G0
	4	G1	G0	1	G0	1	G0
5	G1	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071067; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-05	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071074; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071074; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G1	28	G1	30	G0
	3	G1	G1	34	G1	28	G0
	4	G0	G1	33	G0	24	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE							
2020-07-07	2	G1	G1	40	G1	40	G0
	3	G0	G1	50	G1	35	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE							
2020-07-09	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081039; Age (Years): 21; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081041; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-05	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-07-09	1	G1	G0	0	G0	0
2		G1	G0	0	G0	0	G0
3		G1	G0	0	G0	0	G0
4		G1	G0	0	G0	0	G0
5		G1	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-05	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	20	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE							
2020-06-08	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011018; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-30	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
2020-06-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN							
2020-06-02	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN							
2020-06-02	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-01	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011041; Age (Years): 28; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
2020-06-30	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011041; Age (Years): 28; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-30	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2011046; Age (Years): 21; Gender: F; Race: WHITE						
2020-06-02	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G2	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011046; Age (Years): 21; Gender: F; Race: WHITE							
2020-07-01	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE							
2020-06-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011059; Age (Years): 46; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011065; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	1	G0	0	G0
	2	G1	G0	1	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G1	G0	0	G0	0	G0
	1	G1	G0	1	G0	1	G0
	2	G1	G0	1	G0	0	G0
	3	G1	G0	1	G0	0	G0
	4	G1	G0	1	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011080; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	2	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011080; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-03	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-01	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G2	G0	0	G0	0	G0
	4	G2	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011085; Age (Years): 31; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011085; Age (Years): 31; Gender: F; Race: WHITE							
2020-06-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-05	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G2	G0	0	G0	0	G0
	4	G0	G0	7	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011103; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011103; Age (Years): 51; Gender: M; Race: WHITE							
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN							
2020-07-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021063; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G1	30	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021063; Age (Years): 40; Gender: F; Race: WHITE							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021067; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021068; Age (Years): 40; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE							
2020-06-02	2	G3	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	2	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-05	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G1
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G2
	2	G2	G0	0	G0	4	G2
	3	G1	G0	0	G0	4	G1
	4	G1	G0	0	G0	2	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021093; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021093; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE							
2020-07-09	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE							
2020-06-03	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	76	G0
	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE							
2020-07-01	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021145; Age (Years): 43; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021151; Age (Years): 30; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-05	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-05	2	G1	G0	0	G0	0	G1
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-08	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1
	2	G0	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-08	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G1\$	G0	0	G0	0	G1
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G1
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	2	G0	2	G0
	3	G0	G0	2	G0	2	G0
	4	G0	G0	0	G0	2	G0
5	G0	G0	0	G0	2	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-08	6	G0	G0	0	G0	1	G0
	7	G0	G0	0	G1\$		G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	3	G1\$		G0
	2	G1	G0	3	G1\$		G0
	3	G1	G0	2	G1\$		G0
	4	G1	G0	2	G1\$		G0
	5	G0	G0	0	G1\$		G0
	6	G0	G0	0	G1\$		G0
7	G0	G0	2	G1\$		G0	
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G2
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031012; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031012; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031013; Age (Years): 41; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G1	30	G0	0	G0
	3	G1	G2	70	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031013; Age (Years): 41; Gender: F; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031019; Age (Years): 52; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031019; Age (Years): 52; Gender: M; Race: WHITE							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031020; Age (Years): 50; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031021; Age (Years): 41; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031026; Age (Years): 54; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2031026; Age (Years): 54; Gender: F; Race: WHITE								
2020-05-29	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-26	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-06-01	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031027; Age (Years): 46; Gender: M; Race: WHITE							
2020-06-01	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE							
2020-06-03	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE							
2020-06-29	1	G1	G1	25	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2031037; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G1
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031037; Age (Years): 35; Gender: M; Race: WHITE							
2020-06-30	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031047; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031047; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031050; Age (Years): 51; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	5	G0
	2	G1	G0	3	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031060; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	2	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031062; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031062; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-04	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-02	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G1	50	G1	50	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	1	G0	0	G0
	2	G1	G0	1	G0	0	G1
	3	G1	G0	1	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE							
2020-06-02	4	G0	G0	0	G0	0	G1
	5	G1	G0	0	G0	0	G1
	6	G0	G0	0	G0	0	G1
	7	G0	G0	0	G0	0	G1
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE							
2020-06-04	1*	G1	G0	0	G0	1	G0
	1	G1	G0	0	G0	1	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	1	G0
	2	G1	G0	0	G0	1	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031084; Age (Years): 50; Gender: M; Race: WHITE							
2020-06-10	1*	G0	G0	0	G0	0	G0
	1	G1	G0	1	G0	0	G0
	2	G1	G0	0	G0	20	G0
	3	G1	G0	0	G0	2	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	2	G0	0	G0
	2	G1	G0	2	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031084; Age (Years): 50; Gender: M; Race: WHITE							
2020-07-08	3	G0	G0	2	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE							
2020-07-01	5	G0	G0	0	G0	0	G0
	6						
	7	G0	G0	0	G0	0	G0
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-29	7	G0	G0	0	G0	0	G0
Subject ID: US2041024; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G1	35	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041026; Age (Years): 50; Gender: M; Race: WHITE							
2020-06-02	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041041; Age (Years): 37; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2041041; Age (Years): 37; Gender: M; Race: WHITE								
2020-06-01	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-06	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-07-06	7	G0	G0	0	G0	0	G0	
	Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE							
	2020-06-04	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
		2	G1	G0	0	G0	0	G0
		3	G0	G0	0	G0	0	G0
		4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE							
2020-06-04	5	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	2	G1	G0	2	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2041048; Age (Years): 25; Gender: F; Race: WHITE						
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-01	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G1
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041048; Age (Years): 25; Gender: F; Race: WHITE							
2020-07-01	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041060; Age (Years): 19; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1
	2	G1	G0	0	G1\$		G0
	3	G1	G0	0	G1\$		G0
	4	G1	G0	0	G1\$		G0
	5	G1	G0	0	G1\$		G0
	6	G1	G0	0	G1\$		G0
	7	G1	G0	0	G1\$		G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	6	G1
	3	G1	G0	0	G0	6	G1
	4	G1	G0	0	G0	5	G0
	5	G1	G0	0	G0	5	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041060; Age (Years): 19; Gender: F; Race: WHITE							
2020-07-01	6	G1	G0	0	G0	5	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	3	G0
	1	G0	G0	0	G0	3	G0
	2	G1	G0	0	G0	2	G0
	3	G1	G0	0	G0	5	G0
	4	G0	G0	0	G0	4	G0
	5	G0	G0	0	G0	3	G0
	6	G0	G0	0	G0	2	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041079; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041079; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-03	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041080; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041080; Age (Years): 26; Gender: F; Race: WHITE							
2020-06-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041084; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041084; Age (Years): 52; Gender: F; Race: WHITE							
2020-06-04	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051001; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051001; Age (Years): 31; Gender: M; Race: WHITE							
2020-07-02	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051002; Age (Years): 30; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051002; Age (Years): 30; Gender: F; Race: WHITE							
2020-07-02	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051003; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-05-29	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-23	1*	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE							
2020-06-02	2	G1	G1	30	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051013; Age (Years): 22; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G2
	2	G2	G0	0	G0	0	G2
	3	G2	G0	0	G0	0	G2
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051013; Age (Years): 22; Gender: M; Race: WHITE							
2020-06-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G1	G0	0	G0	0	G1
	1	G2	G0	0	G1	25	G2
	2	G2	G0	0	G0	22	G2
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE							
2020-06-05	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE							
2020-06-09	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE							
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE							
2020-07-02	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051024; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051024; Age (Years): 50; Gender: F; Race: WHITE							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051025; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-09	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051026; Age (Years): 49; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G2	G0	0	G0	0	G0
	4	G2	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051028; Age (Years): 23; Gender: M; Race: ASIAN							
2020-06-04	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051028; Age (Years): 23; Gender: M; Race: ASIAN							
2020-06-04	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051029; Age (Years): 28; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-09	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051030; Age (Years): 43; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE							
2020-06-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE							
2020-06-10	2	G1	G0	0	G0	2	G0
	3	G2	G0	0	G0	2	G1
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	4	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE							
2020-06-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061010; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061010; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061020; Age (Years): 54; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-07	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061020; Age (Years): 54; Gender: M; Race: WHITE							
2020-07-07	1	G1	G0	0	G0	0	G0
	2	G3	G0	0	G0	0	G0
	3	G3\$	G0	0	G1	50	G0
	4	G3\$	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1\$	G0	0	G0	0	G1
	7	G1\$	G0	0	G0	0	G1
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-07-06	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061025; Age (Years): 32; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061027; Age (Years): 44; Gender: F; Race: WHITE							
2020-06-05	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	2	G0	2	G1
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE								
2020-06-01	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-30	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G1\$		G0
2		G1	G1	35	G1	35	G0	
3		G1	G1	30	G1	30	G0	
4		G1	G0	19	G1\$		G0	
5		G1	G0	15	G1\$		G0	
6		G0	G0	0	G1\$		G0	
7	G0	G0	0	G1\$		G0		
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE								
2020-06-03	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE							
2020-06-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE							
2020-06-08	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	12	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE							
2020-07-13	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071038; Age (Years): 27; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	10	G0	1	G0
	3	G1	G1	30	G0	1	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-13	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071038; Age (Years): 27; Gender: M; Race: WHITE							
2020-07-13	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G1	50	G1	50	G0
	4	G1	G3	150	G1	25	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE							
2020-07-13	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071040; Age (Years): 33; Gender: F; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	2	G0
	2	G1	G0	0	G0	3	G0
	3	G1	G0	0	G0	2	G0
	4	G0	G0	0	G0	1	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-13	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	2	G0
	2	G1	G0	6	G0	5	G0
	3	G1	G0	6	G0	5	G1
	4	G1	G0	0	G0	4	G1
	5	G0	G0	0	G0	2	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071051; Age (Years): 32; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G1	40	G1	40	G0
	3	G1	G1	50	G1	40	G0
	4	G0	G1	45	G0	20	G0
	5	G0	G0	10	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G1	35	G1	35	G0
	3	G1	G0	20	G1	35	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071068; Age (Years): 53; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071068; Age (Years): 53; Gender: M; Race: WHITE							
2020-06-08	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071069; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	2	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071069; Age (Years): 18; Gender: M; Race: WHITE							
2020-06-08	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071071; Age (Years): 45; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	15	G0	5	G0
	3	G1	G0	20	G1	35	G0
	4	G1	G0	0	G0	2	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071071; Age (Years): 45; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G1	30	G1	30	G0
	3	G1	G2	70	G0	20	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-08	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	6	G0
	3	G0	G0	0	G0	5	G0
	4	G0	G0	0	G0	5	G0
	5	G0	G0	0	G0	5	G0
	6	G0	G0	0	G0	4	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	8	G0
	3	G0	G0	0	G0	5	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-07-07	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071077; Age (Years): 29; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081023; Age (Years): 53; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081023; Age (Years): 53; Gender: M; Race: WHITE							
2020-06-03	3	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE							
2020-06-03	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE							
2020-07-07	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE							
2020-06-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	10	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	5	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE							
2020-07-07	3	G1	G1	30	G1	25	G0
	4	G1	G0	15	G0	20	G0
	5	G0	G0	0	G0	5	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081051; Age (Years): 50; Gender: F; Race: WHITE							
2020-06-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081051; Age (Years): 50; Gender: F; Race: WHITE							
2020-07-08	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081062; Age (Years): 36; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	20	G1
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-09	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	20	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE							
2020-06-08	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE								
2020-06-08	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G1	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-09	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G2	G0	0	G0	0	G0	
3		G1	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
7		G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011007; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G1\$		G0	0	G0
	2	G0	G1\$		G0	0	G0
	3	G0	G1\$		G0	0	G0
	4	G0	G1\$		G0	0	G0
	5	G0	G1\$		G0	0	G0
	6	G0	G1\$		G0	0	G0
	7	G0	G1\$		G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE							
2020-05-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011109; Age (Years): 76; Gender: F; Race: ASIAN							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011109; Age (Years): 76; Gender: F; Race: ASIAN							
2020-06-26	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011114; Age (Years): 61; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011114; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011116; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011116; Age (Years): 69; Gender: F; Race: WHITE							
2020-07-27	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-27	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011124; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G1	G0	0	G0	0	G0
Subject ID: US2011126; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011126; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-26	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE							
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE							
2020-07-27	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-24	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-27	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011155; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011156; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-30	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE							
2020-05-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021021; Age (Years): 71; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021021; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE							
2020-07-06	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1	G0	0	G0	2	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE							
2020-07-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE							
2020-07-29	7	G0	G0	0	G0	0	G0
Subject ID: US2021185; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	6	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	4	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021189; Age (Years): 75; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-02	2	G0	G0	17	G0	3	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-08-03	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021198; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021198; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-29	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE							
2020-08-06	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021219; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021219; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-31	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021222; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021222; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-31	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031085; Age (Years): 71; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-29	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE							
2020-06-30	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031095; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031095; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-29	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031098; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031098; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE							
2020-08-03	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE							
2020-08-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE							
2020-07-30	7	G0	G0	0	G0	0	G0
Subject ID: US2031110; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031116; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031124; Age (Years): 59; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031124; Age (Years): 59; Gender: M; Race: WHITE							
2020-06-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-07-29	1*	G0	G0	0	G0	0
2		G0	G0	0	G0	0	G0
3		G0	G0	0	G0	0	G0
4		G0	G0	0	G0	0	G0
5		G0	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-01	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031131; Age (Years): 72; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031131; Age (Years): 72; Gender: F; Race: WHITE							
2020-07-31	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041102; Age (Years): 61; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	1	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041102; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-24	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE							
2020-08-03	7	G0	G0	0	G0	0	G0
Subject ID: US2041115; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041121; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041121; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-01	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-31	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041132; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041132; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-02	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-31	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041151; Age (Years): 57; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G1
	6	G0	G0	0	G0	0	G1
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041151; Age (Years): 57; Gender: M; Race: WHITE							
2020-08-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE							
2020-08-04	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041166; Age (Years): 65; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-03	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051055; Age (Years): 59; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051063; Age (Years): 56; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051063; Age (Years): 56; Gender: M; Race: WHITE							
2020-06-30	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-28	1	G0	G0	3	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE							
2020-07-06	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051073; Age (Years): 74; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-05	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051073; Age (Years): 74; Gender: F; Race: WHITE							
2020-08-05	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2051086; Age (Years): 77; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051086; Age (Years): 77; Gender: M; Race: WHITE							
2020-08-04	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051087; Age (Years): 74; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051087; Age (Years): 74; Gender: F; Race: WHITE							
2020-08-04	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051089; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-30	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051098; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-05	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051112; Age (Years): 60; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051112; Age (Years): 60; Gender: F; Race: WHITE							
2020-07-06	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-20	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-27	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-27	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-27	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1						
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-30	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061055; Age (Years): 84; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2						
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-02	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071041; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2071041; Age (Years): 64; Gender: M; Race: WHITE								
2020-06-02	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-02	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-07-02	7	G0	G0	0	G0	0	G0	
	Subject ID: US2071084; Age (Years): 64; Gender: M; Race: WHITE							
	2020-06-26	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
		2	G0	G0	0	G0	0	G0
		3	G0	G0	0	G0	0	G0
		4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071084; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071086; Age (Years): 68; Gender: M; Race: WHITE							
2020-06-26	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071086; Age (Years): 68; Gender: M; Race: WHITE							
2020-07-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071088; Age (Years): 70; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G1	40	G0
	3	G0	G0	0	G0	18	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071088; Age (Years): 70; Gender: M; Race: WHITE							
2020-07-27	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-21	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-21	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071094; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-04	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071098; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-01	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-08-05	2	G0	G0	0	G0	0
4		G0	G0	0	G0	0	G0
5		G0	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE							
2020-07-06	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-28	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE							
2020-08-06	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071105; Age (Years): 65; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071105; Age (Years): 65; Gender: M; Race: WHITE							
2020-08-10	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081004; Age (Years): 60; Gender: F; Race: WHITE							
2020-05-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-01	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-30	7	G0	G0	0	G0	0	G0
Subject ID: US2081015; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-01	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-02	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-06	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081029; Age (Years): 55; Gender: M; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081029; Age (Years): 55; Gender: M; Race: WHITE							
2020-06-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-02	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081065; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081065; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-24	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE							
2020-06-26	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE							
2020-07-24	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-24	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081077; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-30	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-03	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081080; Age (Years): 69; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081087; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081087; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-30	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081097; Age (Years): 76; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081097; Age (Years): 76; Gender: F; Race: WHITE							
2020-07-01	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE							
2020-08-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081113; Age (Years): 60; Gender: M; Race: WHITE							
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-10	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081113; Age (Years): 60; Gender: M; Race: WHITE							
2020-08-10	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081119; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-11	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081119; Age (Years): 64; Gender: F; Race: WHITE							
2020-08-11	6	G0	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2081125; Age (Years): 62; Gender: M; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-03	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011012; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-01	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2011032; Age (Years): 58; Gender: M; Race: WHITE								
2020-06-02	3	G1	G1	45	G0	0	G0	
	4	G1	G0	0	G0	0	G0	
	5	G1	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-01	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G2	G2	55	G0	0	G0	
3		G1	G2	90	G0	0	G0	
4		G1	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7	G0	G0	0	G0	0	G0		
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN								
2020-06-01	1*	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	2	G0	
	3	G1	G0	0	G0	4	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-06-01	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G1
	6	G0	G0	0	G0	0	G1
7	G0	G0	0	G0	0	G0	
Subject ID: US2011117; Age (Years): 79; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011117; Age (Years): 79; Gender: M; Race: WHITE							
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE							
2020-07-24	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011127; Age (Years): 63; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011127; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-24	7	G0	G0	0	G0	0	G0
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	3	G0
	2	G1	G1	25	G2	76	G0
	3	G1	G0	0	G1	50	G0
	4	G1	G0	0	G1	50	G0
	5	G0	G0	0	G1	25	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011138; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011153; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011153; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-29	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-27	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021004; Age (Years): 72; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	6	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021004; Age (Years): 72; Gender: F; Race: WHITE							
2020-05-29	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G1	40	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-01	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	5	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE							
2020-07-13	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE							
2020-07-02	2	G1	G0	0	G0	3	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021020; Age (Years): 72; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G1
	6	G1	G0	0	G0	0	G0
	7						
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G2	G0	0	G0	1	G2
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021020; Age (Years): 72; Gender: F; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021047; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021133; Age (Years): 75; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G1	25	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021190; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021190; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-29	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021192; Age (Years): 62; Gender: M; Race: ASIAN							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	4	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021192; Age (Years): 62; Gender: M; Race: ASIAN							
2020-06-26	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G1	G0	2	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE							
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G2
	3	G2	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	3	G1	30	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	2	G0	1	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-29	2	G1	G0	0	G0	1	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021220; Age (Years): 76; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021220; Age (Years): 76; Gender: M; Race: BLACK OR AFRICAN AMERICAN							
2020-07-29	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-04	7	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE							
2020-08-04	7	G0	G0	0	G0	0	G0
Subject ID: US2031086; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031096; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031096; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-26	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G1	50	G0
	3	G1	G1	25	G1	30	G0
	4	G1	G1	25	G1	25	G0
	5	G1	G0	15	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE								
2020-06-30	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-08-03	1*	G0	G0	0	G0	0	G1
		1	G0	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7		G0	G0	0	G0	0	G0	
Subject ID: US2031104; Age (Years): 55; Gender: F; Race: WHITE								
2020-06-26	1*	G0	G0	0	G0	0	G0	
	1	G1	G0	0	G0	0	G0	
	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031104; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-26	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	G0	0	G0	0	G0
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE							
2020-07-28	1*	G1	G0	0	G0	0	G1
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-29	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-27	7	G0	G0	0	G0	0	G0
Subject ID: US2031108; Age (Years): 67; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031109; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-01	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-07-29	1*	G0	G0	0	G0	0
1		G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0
3		G0	G0	0	G0	0	G0
4		G0	G0	0	G0	0	G0
5		G0	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
2020-06-30	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-30	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031128; Age (Years): 74; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031128; Age (Years): 74; Gender: F; Race: WHITE							
2020-07-01	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041094; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041094; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2041100; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	1	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041100; Age (Years): 57; Gender: F; Race: WHITE							
2020-07-28	2	G2	G0	0	G0	2	G2
	3	G1	G0	4	G0	3	G0
	4	G1	G0	0	G0	2	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE							
2020-07-24	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2						
	3						
	4	G0	G0	0	G0	0	G0
	5						
	6	G1	G0	0	G0	0	G0
	7						
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G1
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-24	7	G0	G0	0	G0	0	G0
Subject ID: US2041106; Age (Years): 76; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041111; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041111; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-27	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041113; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	1	G0
	3	G1	G0	0	G0	0	G0
Subject ID: US2041118; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	1*	G3	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041118; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE								
2020-07-06	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-08-04	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-06-26	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G0	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041127; Age (Years): 69; Gender: M; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-24	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041139; Age (Years): 69; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-28	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041139; Age (Years): 69; Gender: M; Race: WHITE							
2020-07-28	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041145; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G1	35	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	20	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041145; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-31	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE							
2020-08-03	7	G0	G0	0	G0	0	G0
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1*	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G1	G0	0	G0	0	G0
	1	G2\$	G0	0	G0	0	G0
	2	G2\$	G0	0	G0	0	G1
	3	G2\$	G0	0	G0	0	G1
	4	G2\$	G0	0	G0	0	G1
	5	G2\$	G0	0	G0	0	G1
	6	G2\$	G0	0	G0	0	G1
	7	G2\$	G0	0	G0	0	G1
Subject ID: US2051059; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2051059; Age (Years): 57; Gender: F; Race: WHITE								
2020-06-26	3	G0	G0	0	G0	0	G0	
	4	G1	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-27	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G2	G0	10	G0	10	G1	
3		G2	G0	10	G1	50	G2	
4		G1	G0	5	G1	40	G1	
5		G1	G0	0	G1	35	G1	
6		G1	G0	0	G1	25	G1	
7	G0	G0	0	G0	0	G0		
Subject ID: US2051060; Age (Years): 65; Gender: F; Race: WHITE								
2020-06-26	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051060; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE							
2020-07-28	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051071; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	1	G0
	3	G1	G0	0	G0	2	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051071; Age (Years): 71; Gender: M; Race: WHITE							
2020-07-27	7	G0	G0	0	G0	0	G0
Subject ID: US2051078; Age (Years): 73; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051081; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051092; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051092; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-07	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-08-06	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-06	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
Subject ID: US2051094; Age (Years): 57; Gender: M; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-04	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051094; Age (Years): 57; Gender: M; Race: WHITE							
2020-08-04	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051095; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051095; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-30	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	10	G0
	2	G1	G0	0	G0	5	G0
	3	G1	G0	0	G0	2	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN							
2020-08-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE							
2020-08-03	7	G0	G0	0	G0	0	G0
Subject ID: US2051100; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051103; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-30	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051105; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051105; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-02	2	G1	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G1
7	G0	G0	G0	0	G0	0	G0
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE							
2020-07-02	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE							
2020-07-02	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-06	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER							
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G2	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE							
2020-07-29	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061057; Age (Years): 79; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061057; Age (Years): 79; Gender: F; Race: WHITE							
2020-07-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061064; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061064; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-28	7	G0	G0	0	G0	0	G0
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	4	G0	5	G0
	3	G1	G0	4	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071007; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G1	35	G1	38	G0
	3	G1	G2	64	G2	92	G0
	4	G1	G2	70	G2	70	G0
	5	G1	G2	90	G2	60	G0
	6	G0	G0	0	G1	25	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071024; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071024; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-03	2	G1	G0	10	G0	10	G0
	3	G0	G0	5	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	1	G0	1	G0
	2	G0	G0	9	G0	9	G0
	3	G0	G0	20	G0	20	G0
	4	G0	G0	5	G0	5	G0
	5	G0	G0	0	G0	5	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-08	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071083; Age (Years): 87; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071083; Age (Years): 87; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-21	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	10	G0
	3	G1	G0	10	G0	10	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-29	1	G1	G0	0	G0	5	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071099; Age (Years): 62; Gender: M; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE						
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE							
2020-07-06	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G1	25	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE							
2020-07-06	7	G0	G0	0	G0	0	G0
Subject ID: US2081003; Age (Years): 64; Gender: F; Race: WHITE							
2020-05-29	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE								
2020-06-01	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-02	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
Subject ID: US2081020; Age (Years): 61; Gender: F; Race: WHITE	1*	G0	G0	0	G0	0	G0	
	1	G1	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081020; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-02	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE							
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE							
2020-07-29	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081085; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-11	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081085; Age (Years): 63; Gender: F; Race: WHITE							
2020-08-11	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081090; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE							
2020-07-02	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-02	2	G1	G0	0	G1	50	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-08-03	1	G1	G0	0	G0	0
2		G0	G0	0	G0	0	G0
3		G1	G2	64	G2	64	G0
4		G1	G2	51	G2	51	G0
5		G1	G0	0	G1	50	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2081110; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081110; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-03	7	G0	G0	0	G0	0	G0
2020-08-11	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-31	2	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011004; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-01	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE								
2020-06-01	3	G0	G0	1	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-29	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G1	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
2020-07-02	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011113; Age (Years): 63; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
2020-07-02	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2011118; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011118; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-30	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-24	3	G1	G0	3	G0	5	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011128; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011128; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011139; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011149; Age (Years): 74; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	3	G0
	2	G1	G0	0	G0	2	G0
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	4	G0
	2	G1	G0	6	G0	7	G0
	3	G1	G0	8	G0	7	G0
	4	G1	G0	7	G0	6	G0
	5	G1	G0	7	G0	6	G0
	6	G0	G0	0	G0	4	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011159; Age (Years): 72; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011159; Age (Years): 72; Gender: F; Race: WHITE							
2020-07-02	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-30	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2011162; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2011162; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-06	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE							
2020-05-29	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	3	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-29	1	G0	G0	0	G0	3	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE							
2020-06-26	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021031; Age (Years): 72; Gender: M; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-29	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021031; Age (Years): 72; Gender: M; Race: WHITE							
2020-06-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021114; Age (Years): 67; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021114; Age (Years): 67; Gender: M; Race: WHITE							
2020-07-29	7	G0	G0	0	G0	0	G0
Subject ID: US2021115; Age (Years): 59; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G1
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021186; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE								
2020-07-01	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-29	1*	G1	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G1	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE							
2020-07-02	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G2	G0	1	G0	1	G2
	2	G0	G0	0	G0	1	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE							
2020-08-03	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-31	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE							
2020-08-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2021232; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-06	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	
7	G0	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2021234; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031091; Age (Years): 61; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2031091; Age (Years): 61; Gender: F; Race: WHITE								
2020-06-26	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-27	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G0	G0	7	G0	7	G0	
4		G0	G0	0	G0	5	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7	G0	G0	0	G0	0	G0		
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE								
2020-07-01	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE							
2020-07-01	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G2	76	G0
	3	G0	G0	0	G2	63	G0
	4	G1	G0	0	G1	45	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2031101; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031101; Age (Years): 64; Gender: F; Race: WHITE							
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031111; Age (Years): 87; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031111; Age (Years): 87; Gender: F; Race: WHITE							
2020-07-27	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-27	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2031122; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-29	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041096; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041107; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041107; Age (Years): 64; Gender: M; Race: WHITE							
2020-06-26	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	3	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-27	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041108; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041108; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-26	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	5	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE							
2020-06-26	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	2	G1	G1	50	G1	50	G0
	3	G1	G1	50	G1	50	G0
	4	G1	G1	50	G1	50	G0
	5	G0	G0	20	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041117; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041117; Age (Years): 73; Gender: F; Race: WHITE							
2020-07-28	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G1	50	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE							
2020-07-28	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041122; Age (Years): 82; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	20	G0	0	G0
	3	G0	G0	2	G1	40	G0
	4	G0	G3	200	G0	2	G0
	5	G0	G1	40	G1	40	G0
	6	G0	G0	0	G0	7	G0
	7	G0	G0	0	G0	2	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041123; Age (Years): 60; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041125; Age (Years): 57; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2041125; Age (Years): 57; Gender: F; Race: WHITE								
2020-06-29	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-28	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE	2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE							
2020-06-26	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7						
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G1	48	G0	0	G0
	4	G1	G1	45	G1	45	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE							
2020-06-29	7	G0	G0	0	G0	0	G0
2020-08-10	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041136; Age (Years): 56; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041136; Age (Years): 56; Gender: M; Race: WHITE							
2020-08-03	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	1	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	1	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE							
2020-07-24	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	18	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-28	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2041149; Age (Years): 65; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE							
2020-07-06	1*	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051054; Age (Years): 63; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051054; Age (Years): 63; Gender: M; Race: WHITE							
2020-06-26	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051064; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051064; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-01	3	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G2	70	G0	0	G0
	4	G1	G2	60	G0	0	G0
	5	G0	G1	40	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-26	1*	G1	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	3	G0
	3	G1	G0	0	G0	2	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE							
2020-06-26	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	2	G1
	2	G1	G0	0	G0	3	G0
	3	G1	G0	3	G0	2	G0
	4	G1	G0	0	G0	2	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	2	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051070; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051070; Age (Years): 63; Gender: M; Race: WHITE							
2020-08-03	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G1
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE							
2020-07-28	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051075; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051075; Age (Years): 69; Gender: F; Race: WHITE							
2020-07-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051077; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051077; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-29	7	G0	G0	0	G0	0	G0
Subject ID: US2051084; Age (Years): 61; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051085; Age (Years): 65; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-30	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE								
2020-06-30	3	G1	G0	0	G0	0	G0	
	4	G1	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-07-28	1*	G0	G0	0	G0	0	G0
		1	G1	G0	0	G0	0	G0
2		G1	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
Subject ID: US2051097; Age (Years): 70; Gender: F; Race: WHITE	1*	G0	G0	0	G0	0	G0	
	1	G1	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G1	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051097; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-06	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	10	G0	2	G0
	4	G1	G3	400	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2051101; Age (Years): 62; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
6	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051101; Age (Years): 62; Gender: F; Race: WHITE							
2020-08-10	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE							
2020-08-03	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051104; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	1	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	3	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE							
2020-07-06	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	5	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE							
2020-08-10	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
Subject ID: US2051111; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-04	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2051111; Age (Years): 70; Gender: F; Race: WHITE							
2020-08-04	3	G0	G0	0	G0	0	G1
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061036; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061036; Age (Years): 56; Gender: F; Race: WHITE							
2020-07-27	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2061045; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G3	200	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2061045; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-27	7	G0	G0	0	G0	0	G0
Subject ID: US2061063; Age (Years): 56; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071006; Age (Years): 71; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	4	G0	3	G0
	3	G1	G0	4	G0	3	G0
	4	G1	G0	3	G0	2	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	3	G0	2	G0
	2	G1	G0	7	G0	4	G0
	3	G1	G0	6	G0	3	G0
	4	G1	G0	4	G0	2	G0
	5	G1	G0	3	G0	2	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071013; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071013; Age (Years): 73; Gender: F; Race: WHITE							
2020-06-02	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	2020-07-09	1*	G0	G0	0	G0	0
1		G1	G0	0	G1	25	G0
2		G1	G0	0	G3	250	G0
3		G1	G0	0	G0	0	G0
4		G1	G0	0	G0	0	G0
5		G0	G0	0	G0	0	G0
6		G0	G0	0	G0	0	G0
7		G0	G0	0	G0	0	G0
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	4	G0	0	G0
	2	G1	G0	0	G0	24	G0
	3	G1	G1	25	G1	27	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE							
2020-06-03	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-07	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G1	32	G0
	2	G1	G0	0	G2	98	G1
	3	G1	G0	0	G1	45	G0
	4	G1	G0	0	G1	50	G1
	5	G1	G0	0	G1	40	G0
	6	G0	G0	0	G1	40	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-28	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE							
2020-07-28	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G1	50	G0
	3	G1	G0	0	G2	75	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	2	G0	2	G0
	2	G0	G0	2	G0	1	G0
	3	G0	G0	3	G0	0	G0
	4	G0	G0	1	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-30	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE							
2020-07-30	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5						
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	2	G0
	2	G1	G0	0	G0	4	G0
	3	G0	G0	0	G0	3	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	6	G0
	3	G0	G0	5	G0	5	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-27	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	2	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE							
2020-07-27	7	G0	G0	0	G0	0	G0
Subject ID: US2071093; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-29	2				G1\$		
	3				G1\$		
	4				G1\$		
2020-07-29	1*	G0	G0	0	G0	0	G0
	1						
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE							
2020-06-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	4	G0	4	G0
	3	G1	G0	2	G0	2	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE							
2020-06-29	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-28	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	5	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE							
2020-07-02	7	G0	G0	0	G0	0	G0
2020-08-05	2	G0	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE						
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-06-24	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE							
2020-06-24	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081002; Age (Years): 69; Gender: F; Race: WHITE							
2020-05-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-25	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081002; Age (Years): 69; Gender: F; Race: WHITE							
2020-06-25	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081014; Age (Years): 67; Gender: F; Race: WHITE							
2020-06-01	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	3	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-06-29	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081019; Age (Years): 76; Gender: F; Race: WHITE							
2020-06-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2081019; Age (Years): 76; Gender: F; Race: WHITE								
2020-06-02	3	G1	G1	50	G1	50	G0	
	4	G1	G1	50	G1	25	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-06-30	1*	G0	G0	0	G0	0	G0
		1	G0	G0	0	G0	0	G0
2		G0	G0	0	G0	0	G0	
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7		G0	G0	0	G0	0	G0	
Subject ID: US2081035; Age (Years): 68; Gender: F; Race: WHITE								
2020-06-02	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081035; Age (Years): 68; Gender: F; Race: WHITE							
2020-06-02	6	G0	G0	0	G0	0	G0
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE							
2020-06-26	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	5	G0
	3	G1	G0	0	G0	5	G0
	4	G1	G0	0	G0	5	G0
	5	G0	G0	0	G0	3	G0
	6	G0	G0	0	G0	3	G0
	7	G0	G0	0	G0	3	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE							
2020-07-24	2	G1	G0	0	G0	6	G0
	3	G1	G0	3	G0	1	G0
	4	G0	G0	0	G0	3	G0
	5	G0	G0	0	G0	1	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE							
2020-06-26	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-24	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE							
2020-07-24	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE							
2020-06-30	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE							
2020-07-29	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	10	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-05	7	G0	G0	0	G0	0	G0
	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G1\$		G0
	2	G2	G1	40	G1	40	G0
	3	G1	G3	120	G2	80	G1
	4	G1	G1	50	G1	35	G0
	5	G1	G1\$		G1\$		G0
6	G1	G0	0	G1\$		G0	
7	G1	G0	0	G1\$		G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081081; Age (Years): 56; Gender: F; Race: WHITE							
2020-06-29	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081088; Age (Years): 63; Gender: M; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	15	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade	
			Grade	Injection Site (mm)	Grade	Injection Site (mm)		
Subject ID: US2081088; Age (Years): 63; Gender: M; Race: WHITE								
2020-07-02	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	
	6	G0	G0	0	G0	0	G0	
	7	G0	G0	0	G0	0	G0	
	2020-08-03	1	G1	G0	0	G0	0	G0
		2	G0	G0	0	G0	0	G0
3		G0	G0	0	G0	0	G0	
4		G0	G0	0	G0	0	G0	
5		G0	G0	0	G0	0	G0	
6		G0	G0	0	G0	0	G0	
7		G0	G0	0	G0	0	G0	
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE								
2020-07-03	1*	G0	G0	0	G0	0	G0	
	1	G0	G0	0	G0	0	G0	
	2	G1	G0	0	G0	0	G0	
	3	G0	G0	0	G0	0	G0	
	4	G0	G0	0	G0	0	G0	
	5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE							
2020-07-03	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE							
2020-08-03	2	G1	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE							
2020-06-26	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-29	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G1

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE							
2020-07-29	4	G1	G0	0	G0	0	G1
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081108; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-03	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-07-31	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081108; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-31	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
Subject ID: US2081116; Age (Years): 75; Gender: M; Race: WHITE							
2020-06-29	1*	G0	G0	2	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
2020-07-29	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	6	G0	3	G0
	3	G1	G0	8	G0	8	G0
	4	G1	G0	8	G0	8	G0
	5	G0	G0	5	G0	4	G0
6	G0	G0	6	G0	0	G0	
7	G0	G0	5	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081117; Age (Years): 66; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-11	1*	G1	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G2	68	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE							
2020-07-01	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE							
2020-07-01	2	G0	G0	0	G0	0	G0
	3	G0	G0	0	G0	0	G0
	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
	1*	G0	G0	0	G0	0	G0
2020-07-29	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G1	G0	0	G0	0	G0
	7	G1	G0	0	G0	0	G0
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-06	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE							
2020-07-06	4	G0	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-10	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
	5	G0	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-02	1*	G0	G0	0	G0	0	G0
	1	G0	G0	0	G0	0	G0
	2	G1	G0	0	G0	0	G0
	3	G1	G0	0	G0	0	G0
	4	G1	G0	0	G0	0	G0
5	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.2
Solicited Local Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Pain	Erythema (Redness)		Swelling (Hardness)		Axillary Swelling/ Tenderness Grade
			Grade	Injection Site (mm)	Grade	Injection Site (mm)	
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE							
2020-07-02	6	G0	G0	0	G0	0	G0
	7	G0	G0	0	G0	0	G0
2020-08-03	1*	G0	G0	0	G0	0	G0
	1	G1	G0	0	G0	0	G0
	2	G2	G0	0	G0	0	G0
	3	G2	G0	0	G0	0	G0
	4	G2	G0	0	G0	0	G0
	5	G1	G0	0	G0	0	G0
	6	G0	G0	0	G0	0	G0
7	G0	G0	0	G0	0	G0	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020702.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011030; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011042; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-08	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011043; Age (Years): 52; Gender: F; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-29	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011056; Age (Years): 30; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011057; Age (Years): 50; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011057; Age (Years): 50; Gender: M; Race: WHITE											
2020-06-02	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	Yes
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	Yes
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-30	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011064; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-03	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G1	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	Yes	G1	G1	G0	G0	G2	G0	No
2020-07-07	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G1/38.28	No	No	G0	G1	G0	G0	G1	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-30	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011069; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011070; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No							
	4	G0/36.72	No	No							
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G2	G2	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011086; Age (Years): 21; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-30	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011088; Age (Years): 47; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021061; Age (Years): 38; Gender: M; Race: ASIAN											
2020-06-02	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-04	1*	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	Yes	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-04	6	G0/36.06	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	Yes	G1	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-30	4	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021078; Age (Years): 40; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021082; Age (Years): 47; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021089; Age (Years): 40; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021089; Age (Years): 40; Gender: M; Race: WHITE											
2020-06-08	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-03	1*	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-03	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	Yes	G0	G2	G0	G0	G0	G0	No
	5	G0/37.11	No	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G2	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	Yes	G0	G1	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G3\$	G0	G0	G0	G0	No
Subject ID: US2021107; Age (Years): 26; Gender: F; Race: ASIAN											
2020-06-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021107; Age (Years): 26; Gender: F; Race: ASIAN											
2020-07-02	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-21	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	Yes	G1	G1	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021135; Age (Years): 43; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-05	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE											
2020-07-07	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021138; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.83	No	No							
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G1	G0	G1	G0	G0	No
	3	G0/36.56	No	Yes	G0	G1\$	G0	G2	G0	G0	No
	4	G0/36.72	No	No	G0	G1\$	G1	G1	G0	G0	No
	5	G0/36.61	No	No	G0	G1\$	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE											
2020-06-05	6	G0/36.39	No	No	G0	G1	G1\$	G1\$	G0	G0	No
	7	G0/37.28	No	No	G0	G1	G1	G1	G0	G0	No
2020-07-06	1*	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.33	No	No	G0	G0	G1	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021155; Age (Years): 46; Gender: M; Race: WHITE											
2020-07-13	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021161; Age (Years): 53; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021162; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G1	G3\$	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G3\$	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G3\$	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G3\$	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G3\$	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE											
2020-07-08	6	G0/36.67	No	No	G0	G3\$	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G3\$	G0	G0	G0	G0	No
Subject ID: US2031001; Age (Years): 42; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031009; Age (Years): 36; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031009; Age (Years): 36; Gender: M; Race: WHITE											
2020-06-01	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G1	G1	G0	G0	G0	G0	No
	7	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G1	G1	G0	G0	No
	7	G0/37.33	No	No	G1	G1	G1	G1	G0	G0	No
Subject ID: US2031014; Age (Years): 36; Gender: F; Race: WHITE											
2020-05-29	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031014; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-29	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031022; Age (Years): 35; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031023; Age (Years): 37; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031038; Age (Years): 30; Gender: M; Race: WHITE											
2020-07-02	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031040; Age (Years): 30; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-02	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G1	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.83	No	No	G0	G1	G0	G0	G0	G2	No
	6	G0/37.28	No	No	G1	G0	G0	G0	G0	G2	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031043; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031043; Age (Years): 46; Gender: M; Race: WHITE											
2020-07-02	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031045; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031048; Age (Years): 21; Gender: M; Race: WHITE											
2020-06-01	5	G0/35.00	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031049; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031049; Age (Years): 37; Gender: F; Race: WHITE											
2020-07-01	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031058; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031071; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G2	G2	G0	G0	No
	4	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-02	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1\$	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G0	G0	G1	G0	No
	3	G0/36.22	No	No	G1\$	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G1\$	G1	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G1	G1	G0	G0	G1	G0	No
	6	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE											
2020-07-02	5	G0/35.89	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041005; Age (Years): 22; Gender: F; Race: WHITE											
2020-05-29	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041011; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2041011; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-01	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041014; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041020; Age (Years): 45; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041020; Age (Years): 45; Gender: M; Race: WHITE											
2020-06-03	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041022; Age (Years): 40; Gender: F; Race: WHITE											
2020-07-06	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041025; Age (Years): 47; Gender: F; Race: WHITE											
2020-06-30	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041029; Age (Years): 48; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	Yes
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041034; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041034; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-01	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041042; Age (Years): 35; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041042; Age (Years): 35; Gender: F; Race: WHITE											
2020-07-06	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041043; Age (Years): 47; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041056; Age (Years): 23; Gender: M; Race: WHITE											
2020-06-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2041056; Age (Years): 23; Gender: M; Race: WHITE											
2020-06-02	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041059; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2041062; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041062; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-30	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041078; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041086; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-08	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-08	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041089; Age (Years): 31; Gender: M; Race: WHITE											
2020-07-10	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2041090; Age (Years): 21; Gender: M; Race: WHITE											
2020-06-08	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE											
2020-06-03	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	Yes	G1	G1	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G1	G2	G0	G0	G0	G0	No
	3	G0/36.06	No	Yes	G1	G1	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G1	G0	G0	G0	G1	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	Yes	G0	G0	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051035; Age (Years): 20; Gender: F; Race: WHITE											
2020-06-04	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE											
2020-07-02	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051044; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2061003; Age (Years): 35; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061015; Age (Years): 19; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G1	G0	G0	G0	G1	No
	2	G0/37.22	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061015; Age (Years): 19; Gender: F; Race: WHITE											
2020-06-03	6	G0/37.00	No	No	G3	G1\$	G0	G0	G2	G0	No
	7	G0/36.78	No	No	G3\$	G1	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2061018; Age (Years): 50; Gender: F; Race: WHITE											
2020-07-08	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061022; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/35.56	No	No	G1	G1	G0	G1	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G1	G0	G0	G0	G1	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061024; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061024; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-03	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061032; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061032; Age (Years): 50; Gender: F; Race: WHITE											
2020-07-07	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071012; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-03	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071014; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-03	1	G0/36.39	No	No							
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071017; Age (Years): 36; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071017; Age (Years): 36; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071022; Age (Years): 29; Gender: M; Race: WHITE											
2020-06-03	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071022; Age (Years): 29; Gender: M; Race: WHITE											
2020-07-02	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071042; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-04	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071044; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-08	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G1	G0	G1	G0	G2	G0	No
	4	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071046; Age (Years): 23; Gender: F; Race: WHITE											
2020-07-07	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071049; Age (Years): 28; Gender: F; Race: WHITE											
2020-07-08	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071050; Age (Years): 45; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G1	G2	G1	G0	G1	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071059; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071059; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-08	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.56	No	No	G0	G1	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	Yes
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	Yes
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE											
2020-07-07	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2071064; Age (Years): 26; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071066; Age (Years): 25; Gender: M; Race: WHITE											
2020-06-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071070; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G1	G1	G0	G0	G1	G1	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071070; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-08	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071072; Age (Years): 39; Gender: F; Race: WHITE											
2020-07-06	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081026; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-02	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	Yes	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE											
2020-07-09	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081042; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-10	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE											
2020-06-09	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE											
2020-06-09	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.17	No	No							
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-05	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G2	G0	G0	G0	G2	No
	3	G0/36.83	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.56	No	Yes	G2	G2	G2	G0	G0	G0	No
	5	G0/36.44	No	Yes	G2	G1	G0	G0	G0	G0	No
	6	G0/36.72	No	Yes	G0	G2	G2	G2	G0	G0	No
	7	G0/36.50	No	No	G0	G1	G1	G1	G0	G0	No
2020-07-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081057; Age (Years): 45; Gender: F; Race: WHITE											
2020-07-09	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081058; Age (Years): 20; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain To Prevent	Fever/Pain To Treat							
Subject ID: US2011020; Age (Years): 27; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G1	G2	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011029; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-01	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	No	G1	G2	G2	G2	G0	G0	No
	3	G0/36.61	No	No	G0	G1	G1	G0	G0	G0	No
	4	G0/37.11	No	No	G1	G2	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-01	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011048; Age (Years): 42; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-29	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G1	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	Yes	G0	G1	G1	G1	G0	G1	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G1	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G1	G1	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011061; Age (Years): 39; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-03	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011061; Age (Years): 39; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-07-02	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	Yes
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	Yes
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2011087; Age (Years): 33; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	Yes	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011090; Age (Years): 29; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2011090; Age (Years): 29; Gender: M; Race: WHITE											
2020-07-02	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011091; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011091; Age (Years): 54; Gender: F; Race: WHITE											
2020-07-02	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011092; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-05	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.11	No	Yes	G1	G2	G0	G0	G1	G2	No
	3	G0/37.72	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011093; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-08	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G1	No
	3	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.61	No	Yes	G0	G0	G2	G2	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G2	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	Yes
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE											
2020-07-06	2	G0/35.94	No	No	G1	G2	G2	G1	G0	G0	No
	3	G0/36.89	No	No	G1	G2	G2	G1	G0	G0	Yes
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G1	G1	G1	G0	Yes
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011102; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G1	G0	G1	G1	G0	G0	No
	4	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	Yes	G1	G0	G2	G0	G0	G2	No
	3	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.67	No	No	G1	G1	G1	G1	G0	G0	No
	1	G0/36.78	No	No	G1	G2	G2	G1	G1	G1	No
	2	G0/36.89	No	Yes	G1	G1	G2	G1	G0	G0	No
	3	G0/36.78	No	Yes	G2	G1	G1	G1	G0	G1	No
	4	G0/36.78	No	Yes	G2	G1	G1	G1	G0	G0	No
	5	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.00	No	No	G1	G1	G0	G0	G0	G0	No
	1	G3\$/			G2	G3	G3	G3	G1	G3	No
	2	G3\$/			G2	G3\$	G3	G3	G0	G3\$	No
	3	G0/36.94	No	No	G1	G3\$	G3\$	G3\$	G0	G1	No
	4	G0/36.06	No	No	G2	G3\$	G3\$	G3\$	G0	G0	No
	5					G3\$	G3\$	G3\$			
	6	G0/36.17	No	No	G0	G3\$	G3\$	G3\$	G0	G0	No
	7	G0/36.89	No	No	G1	G3\$	G3\$	G3\$	G0	G0	No
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-08	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.56	No	No	G0	G1	G0	G1	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	Yes	G2	G2	G0	G0	G0	G1	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE											
2020-07-07	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	Yes
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021090; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	Yes	G1	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021147; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G0	G1	G2	G1	G0	G2	No
	3	G0/36.17	No	No	G1	G1	G1	G1	G0	G1	No
	4	G0/35.11	No	No	G1	G1	G1	G0	G0	G1	No
	5	G0/36.00	No	No	G1	G1	G1	G1	G0	G0	No
	6	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI											
2020-06-05	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI											
2020-06-05	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	Yes	G0	G0	G1	G1	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.44	No	No	G1	G1	G0	G0	G0	G0	No
	7	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G3\$/			G1	G0	G0	G0	G0	G2	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021167; Age (Years): 23; Gender: F; Race: WHITE											
2020-07-07	4	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	Yes
2020-07-07	1				G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G1	G0	G0	G1	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031002; Age (Years): 42; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031002; Age (Years): 42; Gender: F; Race: WHITE											
2020-05-29	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE											
2020-05-29	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	Yes	G2	G1	G1	G1	G1	G0	No
	3	G0/36.39	No	No	G1	G1	G1	G1	G0	G0	No
	4	G0/36.94	No	No	G0	G2	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6				G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE											
2020-05-29	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	1				G1	G1	G3\$	G3\$	G0	G0	No
	2	G0/37.11	No	Yes	G2	G2	G3	G3	G2	G2	No
	3	G0/36.28	No	Yes	G1	G0	G3\$	G3\$	G0	G0	No
	4	G0/36.39	No	No	G1	G0	G3\$	G3\$	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2031011; Age (Years): 52; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G1	G0	G1	G1	G1	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.50	No	No	G1	G0	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2031011; Age (Years): 52; Gender: F; Race: WHITE											
2020-07-01	5	G0/36.56	No	No	G1	G0	G0	G1	G0	G0	No
	6	G0/35.67	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/35.39	No	No	G1	G0	G0	G1	G0	G0	No
Subject ID: US2031016; Age (Years): 21; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G1	No
	1	G0/36.50	No	Yes	G3	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	Yes	G0	G0	G2	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2031030; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-03	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.56	No	No	G1	G0	G0	G0	G2	G2	No
	1	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G1	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G1	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE											
2020-06-04	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G2	G0	G2	G1	G1	G2	No
	3	G0/37.06	No	No	G1	G0	G2	G1	G0	G1	No
	4	G0/36.56	No	No	G1	G0	G1	G1	G0	G0	No
	5	G0/36.39	No	No	G1	G0	G1	G1	G0	G0	No
	6	G0/36.39	No	No	G1	G0	G1	G0	G0	G0	No
	7	G0/36.67	No	No	G1	G0	G2	G0	G0	G0	No
Subject ID: US2031051; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031051; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-29	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031056; Age (Years): 48; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G1	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G1	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G1	G0	G0	No
	2	G0/37.28	No	Yes	G1	G2	G2	G2	G0	G2	No
	4	G0/36.78	No	No	G0	G1	G1	G1	G0	G1	No
	5	G0/37.00	No	No	G0	G0	G1	G1	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE											
2020-06-03	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G2	G1	G1	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G1	G1	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031063; Age (Years): 35; Gender: M; Race: WHITE											
2020-07-02	3	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G1	G0	G0	G0	No
Subject ID: US2031066; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G1	G0	G1	G1	G0	G0	No
	2	G0/36.83	No	Yes	G1	G1	G2	G2	G0	G0	No
	3	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031072; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G1	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	Yes	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.11	No	Yes	G2	G3	G3	G2	G2	G2	No
	3	G0/35.78	No	Yes	G2	G1	G3\$	G1	G1	G1	No
	4				G1	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031080; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-04	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	Yes	G1	G0	G2	G2	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G2	G1	G1	G0	G0	G2	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041002; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-30	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041003; Age (Years): 18; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041006; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	Yes	G1	G0	G0	G0	G0	G0	No
Subject ID: US2041007; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041007; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-01	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041012; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-02	1*	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041012; Age (Years): 32; Gender: F; Race: WHITE											
2020-07-07	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041013; Age (Years): 38; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-05-29	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G1	G1	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE											
2020-06-02	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041016; Age (Years): 39; Gender: M; Race: WHITE											
2020-06-02	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-14	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041023; Age (Years): 53; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G1	G1	G0	G0	G1	G0	No
	4	G0/37.00	No	No	G2	G2	G0	G0	G1	G0	No
	5	G0/36.50	No	No	G0	G1	G0	G0	G1	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G1	G2	G0	G0	G2	G1	No
	3	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041023; Age (Years): 53; Gender: F; Race: WHITE											
2020-06-29	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041027; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G2	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	Yes	G0	G2	G2	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041030; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041030; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-01	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041036; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041036; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-30	2	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2041049; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-14	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	Yes	G2	G0	G1	G0	G1	G1	No
	3	G0/35.94	No	Yes	G1	G1	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041051; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-30	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041053; Age (Years): 28; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041055; Age (Years): 20; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-03	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2041058; Age (Years): 39; Gender: M; Race: WHITE											
2020-06-03	1*	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041064; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-08	1*	G0/37.50	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/37.67	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2041064; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-08	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-14	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	Yes	G1	G0	G0	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G1	G1	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041071; Age (Years): 23; Gender: F; Race: WHITE											
2020-07-06	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041075; Age (Years): 35; Gender: M; Race: MULTIPLE: WHITE, AMERICAN INDIAN OR ALASKA NATIVE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G1	G1	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G1	G1	G0	G0	G0	No
	3	G0/36.78	No	No	G1\$	G1	G1	G0	G0	G0	No
	4	G0/36.83	No	No	G1\$	G1	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G2	G1	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.17	No	No	G1	G1	G1	G0	G0	G0	No
	1	G0/37.11	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/37.00	Yes	No	G2	G2	G2	G0	G0	G0	No
	3	G0/36.83	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/37.11	No	No	G1\$	G1	G1	G0	G0	G0	No
	5	G0/37.06	No	No	G2	G2	G1	G0	G0	G0	Yes
	6	G0/36.78	No	No	G2	G2	G1	G0	G0	G0	No
	7	G0/37.11	No	No	G2	G2	G1	G0	G0	G0	No
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-03	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041088; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	Yes	G2	G2	G2	G0	G0	G1	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041088; Age (Years): 18; Gender: M; Race: WHITE											
2020-07-10	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041091; Age (Years): 21; Gender: F; Race: WHITE											
2020-06-10	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-08	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-08	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-14	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/36.11	No	No	G1	G1	G0	G1	G0	G0	No
	3	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051008; Age (Years): 48; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.94	No	No	G0	G2	G2	G2	G0	G2	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051008; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-30	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051009; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-02	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	Yes	G1	G2	G2	G0	G1	G2	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051011; Age (Years): 46; Gender: M; Race: WHITE											
2020-07-07	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051018; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.83	No	Yes	G3	G2	G0	G0	G0	G1	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2051018; Age (Years): 25; Gender: F; Race: WHITE											
2020-07-07	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051027; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-08	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.39	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/35.83	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/37.33	No	Yes	G3\$	G3\$	G3\$	G0	G0	G1	No
	2	G0/37.94	No	Yes	G3	G3	G3	G3	G2	G2	No
	3	G0/36.72	No	Yes	G3\$	G3\$	G3\$	G3\$	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051031; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051031; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No							
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	Yes	G1	G2	G0	G0	G0	G0	No
2020-06-30	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G1	G0	G1	G1	G0	G0	No
	4	G0/37.00	No	Yes	G1	G0	G1	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	Yes	G1	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE											
2020-06-30	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	Yes
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-04	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G1/38.17	No	No	G1	G2	G3	G3	G0	G2	No
	2	G2/38.78	No	Yes	G2	G2	G3\$	G3	G0	G2	No
	3	G0/37.39	Yes	Yes	G2	G2	G1	G3\$	G0	G0	No
	4	G0/37.50	No	No	G1	G1	G0	G3\$	G0	G0	No
	5	G0/36.83	No	No	G0	G1	G0	G3\$	G0	G0	No
	6	G0/37.39	No	No	G1	G2	G0	G3\$	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE											
2020-07-07	7	G0/36.78	No	No	G0	G1	G0	G3\$	G0	G0	No
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G2	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G2	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051038; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051038; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-03	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE											
2020-06-05	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	1	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	2	G0/37.33	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051043; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G2	G2	G2	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051048; Age (Years): 31; Gender: F; Race: WHITE											
2020-06-09	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G2	G0	G0	G0	G2	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051050; Age (Years): 46; Gender: F; Race: WHITE											
2020-07-08	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G1	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE											
2020-06-04	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE											
2020-07-10	6	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061006; Age (Years): 35; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G2	G2	G2	G1	G2	No
	2	G0/37.00	No	Yes	G2	G1	G1	G1	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	Yes	No	G2	G1	G1	G1	G1	G1	No
	2	G0/36.61	No	Yes	G2	G2	G2	G2	G1	G2	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G2	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2061009; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-03	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G1	G3	G3	G2	G1	G2	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2061011; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061011; Age (Years): 49; Gender: F; Race: WHITE											
2020-07-06	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061013; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G2	G1	G0	G0	G0	No
	2	G0/36.56	No	No	G1	G2	G2	G1	G0	G1	No
	3	G0/36.39	No	No	G0	G1	G1	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061019; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	Yes	G3	G0	G0	G0	G0	G0	No
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061026; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-05	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	Yes	G2	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G1	G1	G0	G0	G1	G0	No
	3	G0/36.61	Yes	Yes	G2	G0	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2071001; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-30	4	G0/37.06	No	Yes	G2	G0	G1	G0	G0	G0	No
	5	G0/37.22	No	Yes	G2	G0	G0	G0	G0	G0	No
	6	G0/37.33	No	Yes	G2	G0	G0	G0	G1	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G1	G0	No
Subject ID: US2071003; Age (Years): 42; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G2	G2	G0	G0	G1	G0	No
	3	G0/37.06	No	No	G1	G1	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	Yes	G1	G1	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G1\$	G1\$	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G1\$	G1\$	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G1\$	G1\$	G0	G0	G0	G0	No
	6	G0/36.50	No	Yes	G2	G2	G0	G0	G0	G0	No
	7	G0/36.61	No	Yes	G2	G2	G1	G0	G0	G0	No
Subject ID: US2071029; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071029; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-05	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.89	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE											
2020-07-06	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071032; Age (Years): 24; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2071033; Age (Years): 26; Gender: M; Race: WHITE											
2020-06-08	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071063; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071063; Age (Years): 37; Gender: M; Race: WHITE											
2020-07-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071067; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	Yes	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G2/38.67	No	Yes	G2	G2	G3	G3	G0	G2	No
	3	G0/37.56	No	Yes	G2	G3	G3	G3	G1	G3	No
	4	G0/37.06	No	Yes	G2	G2	G2	G2	G1	G0	No
	5	G0/37.06	No	No	G0	G1	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071067; Age (Years): 34; Gender: F; Race: WHITE											
2020-07-08	6	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071074; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	No	No	G1	G0	G1	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No							
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071081; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-08	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	Yes	G1	G1	G0	G1	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE											
2020-06-04	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	Yes	G2	G0	G1	G0	G0	G0	Yes
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	Yes
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081036; Age (Years): 48; Gender: M; Race: WHITE											
2020-07-09	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	Yes	G0	G1	G0	G1	G0	G0	No
	3	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	Yes
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2081039; Age (Years): 21; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	Yes	No	G2	G0	G0	G0	G1	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	Yes	G2	G2	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G2	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
2020-07-08	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G2	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081041; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.72	No	No	G0	G0	G1	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-05	1*				G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-05	6	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081054; Age (Years): 31; Gender: M; Race: WHITE											
2020-07-08	5	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.72	No	Yes	G0	G1	G1	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011018; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-01	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011019; Age (Years): 50; Gender: F; Race: ASIAN											
2020-06-02	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G2	G0	G3	G0	G2	G3	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011039; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-29	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011041; Age (Years): 28; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No							
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011046; Age (Years): 21; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011046; Age (Years): 21; Gender: F; Race: WHITE											
2020-06-02	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G1	G0	G1	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G2	G2	G2	G0	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011050; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-29	2	G0/36.83	No	No	G1	G1	G1	G1	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011059; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G2	G2	G2	G0	G1	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011065; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	Yes	G1	G1	G0	G0	G0	G0	No
	3	G0/36.50	No	Yes	G1	G1	G0	G0	G0	G0	No
	4	G0/36.44	No	Yes	G1	G1	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	Yes	G2	G2	G1	G0	G0	G0	No
	3	G0/36.67	No	Yes	G1	G1	G0	G0	G0	G0	No
	4	G0/36.61	No	Yes	G1	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	Yes	G2	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011080; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-03	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011080; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-03	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	Yes	G1	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.17	No	Yes	G0	G1	G0	G0	G0	G0	No
	4	G0/36.44	No	Yes	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011085; Age (Years): 31; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2011085; Age (Years): 31; Gender: F; Race: WHITE											
2020-07-01	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011103; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G1	G1	G0	G0	G1	No
	4	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2				G2	G2	G2	G2	G0	G2	No
	4	G0/36.28	No	No	G0	G2	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G1	G1	G1	G0	G0	G0	No
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN											
2020-06-02	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021059; Age (Years): 38; Gender: F; Race: OTHER: MEXICAN											
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021063; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.28	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G1	No
	2	G0/37.33	No	Yes	G0	G3	G3	G2	G0	G2	No
	3	G0/36.61	Yes	Yes	G0	G3\$	G3\$	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G3\$	G3\$	G0	G0	G0	No
	5	G0/36.67	No	Yes	G0	G3\$	G3\$	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021063; Age (Years): 40; Gender: F; Race: WHITE											
2020-07-07	6	G0/37.11	No	No	G0	G3\$	G3\$	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G3\$	G3\$	G0	G0	G0	No
Subject ID: US2021067; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021068; Age (Years): 40; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021068; Age (Years): 40; Gender: M; Race: WHITE											
2020-06-02	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.28	No	Yes	G0	G1	G0	G1	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	2	G1/38.39	No	Yes	G2	G3	G2	G2	G2	G2	No
	3	G0/37.00	No	Yes	G1	G3\$	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G1	G1	G0	G0	G0	No
	2	G0/37.22	Yes	No	G1	G1	G1	G0	G0	G0	No
	3	G0/36.89	Yes	Yes	G1	G1	G1	G0	G0	G0	No
	4	G0/35.72	Yes	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.11	Yes	No	G0	G1	G0	G0	G0	G0	No
	6	G0/35.83	Yes	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.11	Yes	No	G0	G1	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G2	G2	G2	G2	G0	G1	No
	2	G0/37.00	No	Yes	G3	G3	G3	G3	G1	G2	No
	3	G0/35.61	Yes	No	G2	G3\$	G3\$	G3\$	G1	G1	No
	4	G0/36.39	Yes	No	G1	G1	G3\$	G3\$	G0	G0	No
	5	G0/35.89	No	No	G0	G1	G3\$	G3\$	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE											
2020-07-08	6	G0/35.94	No	No	G0	G0	G3\$	G3\$	G0	G0	No
	7	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021093; Age (Years): 35; Gender: F; Race: WHITE											
2020-06-03	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.72	No	Yes	G2	G3	G3	G0	G2	G2	No
	3	G0/36.89	No	No	G0	G3\$	G3\$	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE											
2020-06-02	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE											
2020-06-08	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE											
2020-07-09	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	Yes	G1	G2	G2	G1	G1	G1	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021121; Age (Years): 22; Gender: F; Race: WHITE											
2020-07-01	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021145; Age (Years): 43; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-04	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.39	No	Yes	G2	G2	G2	G0	G2	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021151; Age (Years): 30; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G1	G0	G0	G1	No
	3	G0/37.06	No	No	G0	G0	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021151; Age (Years): 30; Gender: F; Race: WHITE											
2020-06-08	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G3/39.11	No	Yes	G3	G2	G2	G3\$	G2	G2	No
	3	G0/37.17	No	No	G3\$	G0	G1	G1	G0	G0	No
	4	G0/37.17	No	No	G3\$	G0	G0	G0	G0	G0	No
	5	G0/37.17	No	No	G3\$	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-05	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.39	No	No	G2	G2	G2	G0	G0	G0	No
	3	G0/37.11	No	Yes	G2	G1	G0	G0	G1	G0	No
	4	G0/37.11	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.72	No	Yes	G3\$	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE											
2020-07-08	2	G0/37.11	No	Yes	G3\$	G2	G2	G2	G1	G2	No
	3	G0/37.06	No	No	G3\$	G1	G0	G1	G0	G0	No
	4	G0/37.06	No	No	G3\$	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G3\$	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	Yes	G3\$	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G3\$	G0	G0	G0	G0	G0	No
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-08	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.39	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	Yes	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	Yes	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	Yes	G0	G0	G1	G0	G0	G1	No
	3	G0/36.94	Yes	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	Yes	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	Yes	G1	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	Yes	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.44	No	No	G1	G0	G0	G1	G0	G0	No
	1	G0/35.83	No	No	G1	G0	G0	G0	G0	G1	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	1	G3\$/			G1	G0	G0	G0	G0	G0	No
	2	G3\$/			G2	G0	G3	G3	G0	G2	No
	3	G3\$/			G0	G0	G3\$	G3\$	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021182; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-08	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031012; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031012; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-29	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031013; Age (Years): 41; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	Yes	G1	G2	G2	G1	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	Yes
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/37.17	No	Yes	G0	G0	G0	G0	G0	G0	Yes
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031019; Age (Years): 52; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031020; Age (Years): 50; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031020; Age (Years): 50; Gender: F; Race: WHITE											
2020-05-29	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031021; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G2	G2	G0	G0	G2	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031021; Age (Years): 41; Gender: M; Race: WHITE											
2020-06-29	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031026; Age (Years): 54; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	No	G0	G2	G0	G0	G2	G0	No
	3	G0/36.83	No	No	G0	G2	G0	G0	G2	G2	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031027; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031027; Age (Years): 46; Gender: M; Race: WHITE											
2020-06-01	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	No	No	G1	G1	G0	G0	G0	G1	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031033; Age (Years): 44; Gender: M; Race: WHITE											
2020-06-03	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G1	G1	G0	G0	G0	No
	2	G0/37.28	Yes	Yes	G1	G2	G2	G2	G0	G0	No
	3	G0/37.11	Yes	Yes	G1	G1	G1	G1	G0	G0	No
	4	G0/36.67	No	Yes	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE											
2020-06-29	5	G0/36.50	No	Yes	G1	G0	G1	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2031037; Age (Years): 35; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	Yes	Yes	G2	G2	G2	G2	G1	G2	No
	3	G0/37.39	Yes	No	G0	G1	G0	G0	G1	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031047; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031047; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-01	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G1	G0	G0	G1	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	Yes
	2	G1/38.17	No	Yes	G0	G1	G0	G2	G1	G1	Yes
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031050; Age (Years): 51; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031050; Age (Years): 51; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G3\$/			G2	G3	G3	G3	G0	G2	No
	3	G3/39.11	Yes	Yes	G2	G3\$	G3\$	G3	G2	G2	No
	4	G3\$/			G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031060; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G1	G0	G0	G1	No
	2	G0/36.72	No	Yes	G0	G2	G0	G0	G0	G2	No
	3	G0/36.17	No	Yes	G0	G1	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031060; Age (Years): 50; Gender: F; Race: WHITE											
2020-07-02	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031062; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031073; Age (Years): 34; Gender: M; Race: WHITE											
2020-06-02	2	G0/36.17	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G1	G0	G1	G1	G1	G1	No
	2	G0/36.33	No	No	G2	G2	G2	G2	G0	G1	No
	4	G0/36.50	No	No	G0	G1	G1	G1	G0	G0	No
	6	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.44	No	No	G0	G0	G1	G1	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G1	G1	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	Yes	G1	G2	G2	G2	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE											
2020-07-02	2	G0/36.39	No	No	G1	G0	G2	G2	G0	G0	No
	4	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G2	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031084; Age (Years): 50; Gender: M; Race: WHITE											
2020-06-10	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G1	G0	G1	G0	G0	G0	No
	2	G0/35.56	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G1	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	Yes	G1	G2	G1	G0	G0	G1	No
	3	G0/36.83	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G1\$	G0	G0	G0	G0	No
	6					G1\$					
	7	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041010; Age (Years): 44; Gender: F; Race: WHITE											
2020-05-29	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	Yes	G1	G0	G0	G0	G0	G0	No
	2	G0/37.83	No	Yes	G2	G2	G2	G2	G1	G2	No
	3	G0/35.61	No	No	G1	G1	G0	G0	G1	G0	No
	4	G0/36.44	No	No	G2	G0	G0	G0	G0	G0	No
	5	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041024; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G0	G1	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.72	No	No	G0	G2	G2	G1	G0	G1	No
	2	G2/38.50	No	Yes	G2	G3	G3	G2	G0	G2	No
	3	G0/36.72	Yes	No	G0	G1	G1	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041024; Age (Years): 51; Gender: M; Race: WHITE											
2020-07-02	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G1	G1	G0	G1	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G1	G1	G0	G0	G0	G0	No
Subject ID: US2041026; Age (Years): 50; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G1	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G1	G1	G1	G0	G0	G0	No
	7	G0/37.06	No	No	G1	G1	G0	G0	G0	G1	No
2020-06-30	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041041; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-01	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041041; Age (Years): 37; Gender: M; Race: WHITE											
2020-06-01	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G1	G2	G2	G2	G0	G1	No
	3	G0/36.78	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE											
2020-06-04	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G1	G0	G0	G0	Yes
	2	G0/37.06	No	Yes	G0	G1	G1	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041046; Age (Years): 23; Gender: M; Race: WHITE											
2020-07-02	2	G0/37.06	No	Yes	G0	G1	G1	G0	G0	G0	No
	3	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041048; Age (Years): 25; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G1	G2	G1	G1	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G1	G2	G2	G2	G2	G0	No
	2	G0/37.78	No	Yes	G2	G3	G3	G3	G1	G0	No
	3	G0/37.11	No	No	G1	G1	G1	G1	G0	G0	No
	4	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041060; Age (Years): 19; Gender: F; Race: WHITE											
2020-06-02	1*	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G1	G1	G0	G0	G0	G1	No
	2	G0/36.06	No	No	G0	G1	G0	G0	G0	G1	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.50	No	Yes	G0	G1	G1	G0	G1	G1	No
	2	G1/38.00	No	Yes	G1	G1	G1	G1	G1	G1	No
	3	G0/36.56	No	No	G0	G0	G1	G1	G0	G0	No
	4	G0/36.06	No	No	G0	G1	G1	G0	G0	G1	No
	5	G0/36.39	No	No	G0	G1	G1	G0	G0	G0	No
	6	G0/36.72	No	No	G1	G1	G1	G0	G0	G0	No
	7	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-02	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G1	G1	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-30	4	G0/36.06	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G1	G0	G0	G0	G0	No
Subject ID: US2041079; Age (Years): 26; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/37.11	No	Yes	G2	G3	G3	G0	G0	G1	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041080; Age (Years): 26; Gender: F; Race: WHITE											
2020-06-03	1*	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	Yes	G0	G0	G2	G1	G0	G0	No
	3	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041084; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041084; Age (Years): 52; Gender: F; Race: WHITE											
2020-06-04	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	Yes	G0	G1	G0	G0	G0	G0	No
	3	G0/36.94	No	Yes	G0	G2	G0	G0	G1	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051001; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	Yes	G0	G0	G0	G0	G0	G2	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051001; Age (Years): 31; Gender: M; Race: WHITE											
2020-07-02	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051002; Age (Years): 30; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G2	G1	G0	G2	G1	No
	2	G0/37.61	No	No	G0	G2	G2	G0	G0	G1	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051003; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-05-29	1	G0/36.94	No	Yes	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051003; Age (Years): 27; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-05-29	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-23	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	Yes
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/37.83	No	Yes	G2	G2	G1	G0	G0	G1	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE											
2020-07-01	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051013; Age (Years): 22; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G2	G1	G0	G0	G1	G0	No
	3	G0/35.44	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE											
2020-06-05	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051017; Age (Years): 22; Gender: M; Race: WHITE											
2020-06-05	2	G0/36.67	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1	G1	G1	G1	G0	G0	No
	2	G0/36.44	No	Yes	G2	G2	G2	G2	G0	G2	No
	3	G0/35.78	No	Yes	G2	G1	G1	G0	G0	G0	No
	4	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE											
2020-06-09	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	Yes	G1	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	Yes	G2	G0	G0	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051019; Age (Years): 39; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G1/38.11	No	Yes	G2	G2	G2	G2	G1	G0	No
	2	G0/36.89	No	Yes	G2	G2	G2	G2	G1	G1	No
	3	G0/36.67	No	Yes	G0	G1	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE											
2020-06-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051020; Age (Years): 54; Gender: F; Race: WHITE											
2020-07-02	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051024; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G2	G2	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051025; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051025; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-05	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051026; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2051026; Age (Years): 49; Gender: M; Race: WHITE											
2020-06-30	1	G0/36.28	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/37.94	No	Yes	G2	G2	G2	G0	G0	G2	No
	3	G0/36.67	No	Yes	G2	G3	G2	G0	G0	G2	No
	4	G0/36.72	No	No	G0	G3\$	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051028; Age (Years): 23; Gender: M; Race: ASIAN											
2020-06-04	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051029; Age (Years): 28; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051029; Age (Years): 28; Gender: M; Race: WHITE											
2020-07-09	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051030; Age (Years): 43; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	Yes	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.67	No	Yes	G1	G2	G2	G2	G0	G2	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051030; Age (Years): 43; Gender: F; Race: WHITE											
2020-07-06	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE											
2020-06-10	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G1	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.94	No	No	G0	G2	G0	G0	G0	G0	Yes
	3	G0/36.56	No	Yes	G2	G2	G1	G0	G0	G1	No
	4	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G1	G0	G1	G1	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.50	No	No	G2	G2	G1	G0	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE											
2020-06-03	3	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G1	G1	G0	G2	G0	G1	No
	2	G0/36.83	No	Yes	G1	G2	G1	G2	G1	G2	No
	3	G0/36.44	No	Yes	G1	G1	G0	G2	G0	G0	No
	4	G0/36.39	No	No	G0	G1	G1	G2	G0	G0	No
	5	G0/36.39	No	No	G0	G1	G1	G2	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G1	G1	G0	G0	No
Subject ID: US2061010; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061010; Age (Years): 43; Gender: M; Race: WHITE											
2020-07-08	1	G0/35.72	No	No	G1	G2	G2	G1	G0	G0	No
	2	G0/36.28	No	Yes	G0	G1	G2	G1	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061020; Age (Years): 54; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-05	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G1	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G1	G0	G0	G0	No
Subject ID: US2061025; Age (Years): 32; Gender: M; Race: WHITE											
2020-06-03	1*	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2061025; Age (Years): 32; Gender: M; Race: WHITE											
2020-06-03	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G1	G2	G2	G2	G1	G2	No
	3	G0/36.89	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061027; Age (Years): 44; Gender: F; Race: WHITE											
2020-06-05	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	Yes	G0	G1	G0	G0	G0	G0	No
	4	G0/35.50	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061027; Age (Years): 44; Gender: F; Race: WHITE											
2020-07-08	6	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	Yes	G0	G0	G1	G0	G0	G0	No
	2	G0/37.17	No	Yes	G2	G1	G0	G0	G0	G0	No
	3	G0/37.00	No	Yes	G1	G1	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	2	G1/38.28	No	Yes	G2	G2	G3	G3	G0	G2	No
	3	G2/38.89	No	Yes	G2	G3	G3	G3	G0	G2	No
	4	G1/38.33	No	Yes	G2	G2	G3	G3	G0	G2	No
	5	G1/38.39	No	Yes	G2	G2	G2	G2	G1	G1	No
	6	G2/38.44	No	Yes	G2	G2	G2	G2	G1	G1	No
	7	G0/37.22	No	Yes	G2	G2	G1	G1	G1	G0	No
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071016; Age (Years): 40; Gender: F; Race: WHITE											
2020-06-03	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071026; Age (Years): 32; Gender: M; Race: WHITE											
2020-07-13	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	Yes	G0	G1	G2	G0	G0	G1	No
	3	G0/36.17	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE											
2020-07-13	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071038; Age (Years): 27; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-13	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	Yes	Yes	G2	G2	G1	G2	G0	G2	No
	3	G0/36.00	Yes	Yes	G1	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE											
2020-06-05	3	G0/36.39	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.28	Yes	No	G0	G1	G0	G1	G0	G1	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071040; Age (Years): 33; Gender: F; Race: WHITE											
2020-06-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071040; Age (Years): 33; Gender: F; Race: WHITE											
2020-07-13	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	No	No	G0	G2	G2	G2	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071051; Age (Years): 32; Gender: F; Race: WHITE											
2020-06-05	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	Yes	G2	G1	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071051; Age (Years): 32; Gender: F; Race: WHITE											
2020-07-07	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071068; Age (Years): 53; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071069; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071069; Age (Years): 18; Gender: M; Race: WHITE											
2020-06-08	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G1	G2	G0	G0	G0	G2	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071071; Age (Years): 45; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071071; Age (Years): 45; Gender: F; Race: WHITE											
2020-07-07	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-08	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G2	G2	G2	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071077; Age (Years): 29; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2071077; Age (Years): 29; Gender: M; Race: WHITE											
2020-06-08	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-10	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081023; Age (Years): 53; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G2	G2	G1	G1	G1	G1	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081023; Age (Years): 53; Gender: M; Race: WHITE											
2020-07-07	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE											
2020-06-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G3	G2	G2	G1	G0	G2	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE											
2020-06-02	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE											
2020-06-04	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE											
2020-07-07	1				G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	Yes	G2	G2	G1	G0	G0	G2	Yes
	3	G0/37.28	No	Yes	G0	G2	G0	G0	G0	G2	No
	4				G0	G0	G0	G0	G0	G1	No
	5				G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7	G0/37.78	Yes	Yes	G1	G2	G2	G0	G1	G2	No
Subject ID: US2081051; Age (Years): 50; Gender: F; Race: WHITE											
2020-06-05	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081062; Age (Years): 36; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	Yes	G1	G1	G1	G1	G0	G1	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE											
2020-06-08	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE											
2020-06-08	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE											
2020-06-08	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G1	G0	G1	G0	G0	No
	5	G0/36.61	Yes	No	G0	G0	G0	G1	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.61	No	No	G2	G2	G3	G1	G2	G2	No
	2	G0/37.50	No	Yes	G2	G3	G3	G1	G0	G1	No
	3	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature(C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE											
2020-07-09	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011007; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2011011; Age (Years): 66; Gender: F; Race: WHITE											
2020-05-29	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011023; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-02	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011109; Age (Years): 76; Gender: F; Race: ASIAN											
2020-06-26	1*	G0/36.33	No	No	G0	G0	G0	G0	G2	G0	No
	1	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011114; Age (Years): 61; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G1	G2	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G1	G2	G0	G0	G0	G0	No
	3	G0/35.39	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G1	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011116; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-27	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011116; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-27	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-27	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011120; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-27	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011124; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	Yes	G1	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	Yes	G1	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011126; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011126; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011130; Age (Years): 64; Gender: M; Race: WHITE											
2020-07-24	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011142; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-29	1	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.67	No	No	G0	G0	G1	G1	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G1	G0	G0	No
	2	G0/36.22	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/36.44	No	Yes	G0	G0	G1	G0	G0	G0	No
	4	G0/36.44	No	Yes	G0	G0	G1	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	Yes	G0	G1	G1	G0	G0	G0	No
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G3	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011145; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-27	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011155; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.28	No	No	G0	G1	G0	G1	G0	G1	No
	6	G0/37.33	No	No	G0	G0	G1	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G1	G0	G0	G0	No
Subject ID: US2011156; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2011156; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-30	1	G0/36.28	No	No	G1	G2	G0	G0	G0	G0	No
	2	G0/36.50	No	Yes	G1	G1	G0	G0	G0	G0	No
	3	G0/36.50	No	Yes	G1	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G2	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011157; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-28	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2021015; Age (Years): 70; Gender: F; Race: WHITE											
2020-06-26	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021021; Age (Years): 71; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-01	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-01	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.61	No	No	G1	G1	G1	G1	G1	G1	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-02	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021185; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	Yes	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021189; Age (Years): 75; Gender: F; Race: WHITE											
2020-06-26	1*	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021189; Age (Years): 75; Gender: F; Race: WHITE											
2020-06-26	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G1	G1	G1	G1	G0	G0	No
	3	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-02	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE											
2020-08-03	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021198; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	Yes	G1	G0	G1	G1	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G1	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G1	G0	No
2020-08-04	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G1	G0	G1	G1	G0	G0	No
	6	G0/36.11	No	No	G1	G0	G1	G1	G0	G0	No
	7	G0/36.39	No	No	G1	G0	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021207; Age (Years): 58; Gender: F; Race: WHITE											
2020-08-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G1	G1	G0	G0	G0	G0	No
Subject ID: US2021219; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	Yes	G3	G0	G0	G0	G1	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021219; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-31	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021222; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	Yes	G3	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031085; Age (Years): 71; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031085; Age (Years): 71; Gender: F; Race: WHITE											
2020-06-26	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.22	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	Yes	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.00	No	Yes	G1	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	Yes	G0	G1	G0	G0	G0	G0	No
	5	G0/36.83	No	Yes	G1	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	Yes	G0	G1	G2	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031092; Age (Years): 75; Gender: F; Race: WHITE											
2020-07-29	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031095; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031098; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031098; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-29	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031100; Age (Years): 68; Gender: F; Race: WHITE											
2020-08-03	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031110; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2031110; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-26	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031116; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031116; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-30	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031124; Age (Years): 59; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G1	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2031125; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-26	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE											
2020-07-01	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031129; Age (Years): 61; Gender: M; Race: WHITE											
2020-07-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031131; Age (Years): 72; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G1	G1	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031131; Age (Years): 72; Gender: F; Race: WHITE											
2020-07-31	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041102; Age (Years): 61; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE											
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041114; Age (Years): 62; Gender: M; Race: WHITE											
2020-06-26	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041115; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G1	G1	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G1	G1	G1	G0	G0	No
2020-08-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041115; Age (Years): 70; Gender: F; Race: WHITE											
2020-08-04	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041121; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2041132; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE											
2020-07-02	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2041142; Age (Years): 63; Gender: M; Race: WHITE											
2020-07-02	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	Yes	G1	G0	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
		5	G0/36.50	No	No	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-31	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041151; Age (Years): 57; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G1	G1	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041152; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-07	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041166; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-06	1*	G0/37.06	No	No	G0	G1	G1	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041166; Age (Years): 65; Gender: M; Race: WHITE											
2020-08-03	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051055; Age (Years): 59; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051055; Age (Years): 59; Gender: M; Race: WHITE											
2020-07-30	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051063; Age (Years): 56; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE											
2020-07-06	2										
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051073; Age (Years): 74; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-05	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051073; Age (Years): 74; Gender: F; Race: WHITE											
2020-08-05	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051086; Age (Years): 77; Gender: M; Race: WHITE											
2020-07-06	1*				G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051087; Age (Years): 74; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051089; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051089; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-02	6	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.61	No	Yes	G2	G2	G0	G0	G2	G0	No
2020-07-30	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051098; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-06	1*	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-05	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051098; Age (Years): 55; Gender: F; Race: WHITE											
2020-08-05	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051112; Age (Years): 60; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-26	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-20	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G1	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-27	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/36.56	No	No	G0	G1\$	G1	G1	G0	G0	No
	4	G0/36.67	No	No	G0	G1	G1	G1	G0	G0	No
	5	G0/36.11	No	No	G0	G1\$	G1\$	G1	G0	G0	No
	6	G0/36.28	No	No	G0	G1	G1\$	G1	G0	G0	No
	7	G0/36.39	No	No	G0	G1	G1	G1	G0	G0	No
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061046; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-27	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No							
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G1	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061055; Age (Years): 84; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061055; Age (Years): 84; Gender: F; Race: WHITE											
2020-06-30	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071005; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-06	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071041; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-02	1*	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2071084; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G1	G0	G1	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE											
2020-06-26	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G1	G0	G0	No
2020-07-28	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G1	G0	G0	No
	6	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071086; Age (Years): 68; Gender: M; Race: WHITE											
2020-06-26	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071086; Age (Years): 68; Gender: M; Race: WHITE											
2020-07-29	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071088; Age (Years): 70; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2071092; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-21	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071094; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	Yes	G0	G0	G2	G2	G0	G0	No
	3	G0/36.33	No	Yes	G0	G0	G1	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2071094; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-06	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G1	G1	G0	G0	No
	7	G0/36.56	No	No	G0	G1	G0	G1	G0	G0	No
Subject ID: US2071098; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-01	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-05	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE											
2020-07-06	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G1	G0	G0	No
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071102; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-29	6	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-06	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2071103; Age (Years): 59; Gender: F; Race: WHITE											
2020-08-06	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071105; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	Yes	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	Yes	Yes	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081004; Age (Years): 60; Gender: F; Race: WHITE											
2020-05-29	1	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G1	G2	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/37.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-01	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081015; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-01	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081015; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-01	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	Yes	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.78	No	Yes	G1	G1	G0	G0	G0	G1	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	Yes	G1	G1	G0	G0	G0	G1	No
	5	G0/37.06	No	Yes	G1	G1	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2081029; Age (Years): 55; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081030; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-02	7	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081065; Age (Years): 64; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081065; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-24	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE											
2020-06-26	1	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081073; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-26	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081077; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081077; Age (Years): 66; Gender: F; Race: WHITE											
2020-08-03	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081080; Age (Years): 69; Gender: M; Race: WHITE											
2020-07-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G2	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G2	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081080; Age (Years): 69; Gender: M; Race: WHITE											
2020-07-31	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081087; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081097; Age (Years): 76; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081097; Age (Years): 76; Gender: F; Race: WHITE											
2020-07-01	2	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE											
2020-08-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-06	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081104; Age (Years): 59; Gender: F; Race: WHITE											
2020-08-06	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081113; Age (Years): 60; Gender: M; Race: WHITE											
2020-07-08	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2081119; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081119; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-06	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-11	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081125; Age (Years): 62; Gender: M; Race: WHITE											
2020-07-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081125; Age (Years): 62; Gender: M; Race: WHITE											
2020-08-03	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011012; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G2/38.61	No	No	G1	G2	G0	G1	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	Yes	G1	G0	G0	G1	G0	G0	No
	4	G0/36.00	No	Yes	G3	G0	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2011014; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-01	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	Yes	G3	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.44	No	Yes	G1	G1	G0	G0	G0	G0	No
	2	G0/37.33	No	Yes	G1	G2	G1	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	Yes	G1	G0	G0	G0	G0	G0	No
	5	G0/35.33	No	Yes	G1	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011032; Age (Years): 58; Gender: M; Race: WHITE											
2020-06-02	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G2	G1	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2011032; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-01	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G1	G1	G0	G0	G1	G0	No
	4	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.44	No	No	G1	G1	G1	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011117; Age (Years): 79; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No							
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G1	G2	G1	G0	G0	No
	3	G0/36.56	No	No	G0	G2	G2	G2	G0	G0	No
	4	G0/35.89	No	No	G0	G2	G1	G1	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G1	G1	G0	G0	No
	6	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-26	7	G0/36.44	No	No	G0	G0	G1	G1	G0	G0	No
2020-07-24	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G1	G2	G2	G0	G0	G0	No
	3	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G1	G1\$	G1\$	G0	G0	No
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011125; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-29	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011127; Age (Years): 63; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	Yes	G1	G0	G0	G0	G0	G0	No
2020-07-24	1*				G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	Yes	G1	G2	G1	G2	G0	G2	No
	3	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011138; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-27	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011138; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-27	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011153; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.89	No	No	G1	G3	G1	G1	G0	G1	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011153; Age (Years): 60; Gender: F; Race: WHITE											
2020-07-27	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021004; Age (Years): 72; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	Yes	G1	G0	G0	G1	G0	G0	No
	3	G0/36.67	No	No	G0	G1	G0	G1	G0	G0	No
	4	G0/36.83	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-01	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	Yes	Yes	G1	G1	G1	G1	G0	G1	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	Yes	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE											
2020-05-29	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-13	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G1	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.22	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE											
2020-05-29	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G1	G1	G0	G0	G0	G0	No
2020-07-02	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE											
2020-07-02	5	G0/36.78	Yes	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	Yes	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021020; Age (Years): 72; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G2	G0	G1	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G2	G2	G0	G0	G0	G0	No
	7				G1\$	G1\$					
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G1	G2	G2	G0	G0	No
	3	G0/36.83	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.33	No	No	G3	G2	G2	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G1	G1	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	Yes
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-01	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	No	Yes	G1	G2	G2	G2	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021047; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021047; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021133; Age (Years): 75; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021133; Age (Years): 75; Gender: M; Race: WHITE											
2020-07-29	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021190; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021192; Age (Years): 62; Gender: M; Race: ASIAN											
2020-06-26	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2021192; Age (Years): 62; Gender: M; Race: ASIAN											
2020-06-26	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G2	G1	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-31	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	Yes	G1	G2	G2	G2	G0	G1	No
	3	G0/36.33	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.06	No	Yes	G0	G2	G2	G2	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G1	G1	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021216; Age (Years): 57; Gender: F; Race: WHITE											
2020-08-03	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G2	G0	G0	G0	G1	Yes
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	Yes
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	Yes
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	Yes
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	Yes
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	Yes
2020-07-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G3	G3	G3	G2	G0	G2	Yes
	2	G0/37.00	No	No	G1	G3	G3	G0	G0	G3	Yes
	3	G0/37.28	No	No	G1	G3\$	G3\$	G0	G0	G1	Yes
	4	G0/36.83	No	Yes	G2	G3	G2	G0	G0	G2	No
	5	G0/36.22	No	No	G2	G3	G2	G0	G0	G2	No
	6	G0/36.17	No	No	G1	G3	G1	G0	G0	G1	No
	7	G0/36.67	No	No	G0	G3\$	G0	G0	G0	G0	No
Subject ID: US2021220; Age (Years): 76; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021220; Age (Years): 76; Gender: M; Race: BLACK OR AFRICAN AMERICAN											
2020-06-29	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE											
2020-08-04	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	No	G0	G1	G1	G0	G0	G1	No
	3	G0/36.56	No	No	G0	G0	G1\$	G0	G0	G1\$	No
	4	G0/36.22	No	No	G0	G0	G1\$	G0	G0	G1\$	No
	5	G0/36.11	No	No	G0	G0	G1\$	G0	G0	G1\$	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031086; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031096; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.67	No	Yes	G1	G1	G1	G1	G0	G0	No
	3	G0/37.50	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE											
2020-06-30	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031104; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2031104; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-31	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G1	G1	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G1\$	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G1\$	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G1	G1	G1	G0	G1	No
	3	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031106; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G1	G1	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G1	G0	G0	G1	G0	No
	6	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031107; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-27	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031108; Age (Years): 67; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031109; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031114; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-01	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE											
2020-07-28	4	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031128; Age (Years): 74; Gender: F; Race: WHITE											
2020-07-01	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041094; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G3	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G2	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G2	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G1	G1	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041100; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-29	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041100; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-29	6	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G1	G1	G0	G0	G1	No
	2	G0/37.83	No	Yes	G2	G3	G3	G3	G1	G2	No
	3	G0/37.11	No	No	G1	G2\$	G2\$	G2\$	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE											
2020-06-26	1*	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G1	G0	G0	G1	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G1	G0	G0	No
2020-07-24	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G1	G0	G0	G1	G0	G0	No
	3	G0/36.56	No	No	G1	G0	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE											
2020-07-24	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G1	G0	G0	No
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-26	1*	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No							
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No							
	6	G0/36.67	No	No							
	7	G0/36.61	No	No							
2020-07-24	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.78	No	No	G3	G1	G2	G0	G0	G1	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041106; Age (Years): 76; Gender: M; Race: WHITE											
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041106; Age (Years): 76; Gender: M; Race: WHITE											
2020-07-28	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	Yes	G1	G1	G0	G1	G0	G1	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041109; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-27	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041111; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041113; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041113; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-30	3	G0/35.56	No	No	G1	G1	G0	G0	G1	G0	No
	4				G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/37.67	No	Yes	G2	G2	G2	G2	G0	G2	No
	3	G0/37.56	No	Yes	G2	G2	G2	G2	G0	G2	No
Subject ID: US2041118; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-29	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041118; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-28	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041127; Age (Years): 69; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041127; Age (Years): 69; Gender: M; Race: WHITE											
2020-06-26	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No							
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1	G0/36.67	No	No	G1	G2	G2	G2	G1	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041130; Age (Years): 62; Gender: M; Race: WHITE											
2020-07-24	2	G0/36.67	No	No	G0	G2	G2	G2	G0	G0	No
	3	G0/36.17	No	No	G1	G1	G1	G1	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G2	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041139; Age (Years): 69; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041145; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G2	G0	G2	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.00	No	No	G0	G2	G0	G1	G0	G0	No
	5	G0/36.61	No	No	G0	G2	G0	G2	G0	G0	No
	6	G0/37.00	No	No	G0	G1	G0	G1	G0	G0	No
	7	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2041150; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-01	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-06	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G1	G1	G1	G0	G0	G0	No
	2	G0/36.89	No	Yes	G2	G1	G1	G1	G0	G0	No
	3	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	Yes	G2	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/35.61	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1	G0/36.89	No	Yes	G1	G1	G0	G0	G0	G0	No
	2	G0/37.61	No	Yes	G2	G2	G1	G0	G0	G1	No
	3	G0/36.56	Yes	No	G1	G1	G1	G0	G0	G1	No
	4	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	Yes	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE											
2020-08-03	6	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	1	G0/37.28	No	No	G0	G1	G2	G1	G0	G1	No
	2	G0/37.28	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/37.06	No	Yes	G1	G1	G1	G1	G0	G1	No
	4	G0/37.00	No	No	G0	G1	G1	G1	G0	G0	No
	5	G0/37.00	No	No	G1	G1	G1	G1	G0	G1	No
	6	G0/37.22	No	No	G0	G1	G1	G1	G0	G0	No
	7	G0/36.89	No	No	G0	G1	G0	G1	G0	G0	No
2020-07-24	1*	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	1	G0/37.22	No	No	G0	G1	G2	G1	G0	G0	No
	2	G0/37.33	No	No	G1	G1	G2	G2	G0	G1	No
	3	G0/37.22	No	Yes	G1	G2	G1	G1	G0	G1	No
	4	G0/37.22	No	No	G1	G1	G1	G1	G0	G0	No
	5	G0/37.06	No	No	G1	G1	G1	G1	G0	G0	No
	6	G0/37.06	No	No	G0	G1	G1	G1	G0	G0	No
	7	G0/37.06	No	No	G1	G1	G1	G0	G0	G0	No
Subject ID: US2051059; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051059; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-26	2	G0/36.44	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	Yes	G2	G2	G2	G2	G2	G0	No
	3	G0/36.56	No	Yes	G2	G2	G2	G2	G2	G0	No
	4	G0/36.72	No	Yes	G1	G0	G0	G1	G1	G0	No
	5	G0/36.39	Yes	No	G0	G0	G0	G1	G0	G0	No
	6	G0/36.67	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2051060; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-26	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051060; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-28	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-29	1*	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051066; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-27	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/37.11	No	No	G0	G1	G0	G1	G0	G0	No
	5	G0/37.06	No	No	G0	G1	G1	G1	G0	G0	No
	6	G0/36.56	No	No	G0	G1	G0	G1	G0	G0	No
2020-07-28	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G1	G0	G1	G0	G0	No
	2	G0/36.50	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/36.44	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.61	No	No	G0	G1	G1	G1	G0	G0	No
	5	G0/36.67	No	No	G0	G1	G1	G1	G0	G0	No
	6	G0/36.44	No	No	G0	G1	G1	G1	G0	G0	No
	7	G0/36.22	No	No	G0	G1	G1	G1	G0	G0	No
Subject ID: US2051071; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051071; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-29	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G1	G2	G1	G2	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	Yes	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	Yes
Subject ID: US2051078; Age (Years): 73; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051078; Age (Years): 73; Gender: M; Race: WHITE											
2020-07-29	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051081; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	Yes	G2	G1	G2	G2	G0	G1	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051092; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	Yes	G2	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051093; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-06	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051094; Age (Years): 57; Gender: M; Race: WHITE											
2020-07-07	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051094; Age (Years): 57; Gender: M; Race: WHITE											
2020-08-04	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051095; Age (Years): 58; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G2	G2	G0	G0	G0	G0	No
	3	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN											
2020-07-06	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051096; Age (Years): 58; Gender: F; Race: ASIAN											
2020-07-06	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G1	G2	G2	G2	G1	G0	No
	3	G0/37.33	No	No	G1	G1	G1	G1	G1	G1	No
	4	G0/37.61	No	No	G1	G1	G1	G1	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE											
2020-07-06	1*	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/35.00	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051099; Age (Years): 73; Gender: M; Race: WHITE											
2020-08-03	1	G0/35.56	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.67	No	No	G3	G3	G2	G2	G0	G2	No
	3	G0/36.44	No	No	G0	G2	G1	G0	G0	G0	No
	4	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051100; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-02	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	Yes	G1	G2	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051100; Age (Years): 68; Gender: F; Race: WHITE											
2020-08-04	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051103; Age (Years): 58; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G1	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G2	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G3	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	Yes	G3	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.28	No	Yes	G2	G2	G2	G1	G0	G0	No
	3	G0/35.89	No	Yes	G1	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	Yes	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	Yes	G0	G1	G0	G0	G0	G0	No
	6	G0/36.72	No	Yes	G3	G2	G2	G0	G2	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051105; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	Yes	Yes	G2	G2	G2	G2	G1	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051105; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-02	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G1	G1	G0	G0	G0	No
	2	G0/36.56	No	Yes	G0	G2	G2	G2	G0	G0	No
	3	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-02	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051107; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-31	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G2	G2	G2	G0	G0	No
	3	G0/36.00	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G1	G0	G1	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G1	G0	G1	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051109; Age (Years): 55; Gender: F; Race: WHITE											
2020-08-04	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER											
2020-06-26	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	Yes	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G1	G1	G0	G0	G0	G1	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	Yes	G2	G2	G2	G2	G0	G2	No
	2	G0/37.56	No	No	G2	G3	G3	G3	G0	G2	No
	3	G0/37.06	No	No	G0	G1	G1	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G1	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-01	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061057; Age (Years): 79; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2061057; Age (Years): 79; Gender: F; Race: WHITE											
2020-07-29	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061064; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071007; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071007; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-02	6	G0/36.22	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	Yes	G1	G1	G1	G1	G0	G0	No
	3	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	Yes	G1	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071024; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071024; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-06	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-08	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.06	No	Yes	G3	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071083; Age (Years): 87; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-21	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071090; Age (Years): 63; Gender: F; Race: WHITE											
2020-06-29	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071099; Age (Years): 62; Gender: M; Race: WHITE											
2020-07-07	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071101; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-29	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	2	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071104; Age (Years): 66; Gender: M; Race: WHITE											
2020-08-10	2	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081003; Age (Years): 64; Gender: F; Race: WHITE											
2020-05-29	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081003; Age (Years): 64; Gender: F; Race: WHITE											
2020-05-29	7	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	2	G0/36.39	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.50	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE										
2020-06-01	1*	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-02	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G2	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
6	G0/35.39	No	No	G1	G0	G0	G0	G0	G0	No	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081020; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	Yes	G1	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-26	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G1	G1	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE											
2020-06-30	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-29	2	G0/37.33	No	No	G0	G1	G2	G2	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	Yes	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081085; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-03	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	No	G0	G1	G0	G1	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-11	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G1	G3	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081090; Age (Years): 63; Gender: M; Race: WHITE											
2020-07-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G1	G2	G2	G2	G0	G1	No
	3	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.72	Yes	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.17	No	No	G0	G1\$	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G2	G0	G0	G0	G0	Yes
	6	G0/35.61	Yes	Yes	G0	G1	G0	G0	G0	G0	Yes
	7	G0/35.67	No	No	G0	G1	G0	G0	G0	G0	Yes

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE											
2020-07-31	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G1	G2	G0	G1	G1	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	Yes	G1	G2	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G1	G2	G2	G1	G1	G1	No
	5	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	Yes	G1	G1	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G1	G1	G0	G0	G0	G0	No
2020-08-03	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.78	No	No	G0	G2	G0	G0	G0	G1	No
	4	G0/37.28	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE											
2020-08-03	7	G0/36.83	No	No	G0	G1	G0	G0	G0	G0	No
Subject ID: US2081110; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-03	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-03	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	Yes	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081112; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-03	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-11	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.33	No	Yes	G0	G1	G0	G0	G0	G2	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-31	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011004; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.89	No	No	G1	G1	G0	G0	G0	G1	No
	2	G0/36.00	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011009; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-01	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.50	No	Yes	G1	G1	G2	G2	G0	G2	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE											
2020-06-29	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011113; Age (Years): 63; Gender: F; Race: BLACK OR AFRICAN AMERICAN											
2020-07-02	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G1	G0	G1	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011118; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE											
2020-07-02	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	Yes	G0	G0	G1	G2	G0	G0	No
	3	G0/36.44	No	No	G0	G2	G2	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	Yes	G3	G2	G0	G0	G2	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE											
2020-06-26	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	Yes	G0	G1	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G2	G1	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G1	G1	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G1	G1	G0	G0	G0	No
2020-07-24	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.28	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.72	No	Yes	G0	G1	G0	G0	G0	G1	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2011122; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-24	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011128; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G2/38.78	No	No	G0	G2	G0	G0	G0	G1	No
	3	G0/37.83	No	Yes	G1	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011139; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G1	G2	G0	G0	G1	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011149; Age (Years): 74; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2011149; Age (Years): 74; Gender: F; Race: WHITE											
2020-06-29	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G3/39.00	No	No	G3	G3	G2	G2	G2	G2	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011159; Age (Years): 72; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G1	G1	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	Yes	G0	G1	G0	G0	G0	G0	No
	2	G0/36.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2011159; Age (Years): 72; Gender: F; Race: WHITE											
2020-07-30	5	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2011162; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	No	G1	G2	G2	G1	G0	G2	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021003; Age (Years): 58; Gender: M; Race: WHITE											
2020-05-29	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G1	G1	G1	G0	G0	G0	No
	3	G0/36.44	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021007; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	Yes	G1	G1	G1	G0	G0	G1	No
	2	G0/36.94	No	Yes	G2	G2	G2	G1	G0	G2	No
	3	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-26	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE											
2020-06-26	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021031; Age (Years): 72; Gender: M; Race: WHITE											
2020-06-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021114; Age (Years): 67; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021114; Age (Years): 67; Gender: M; Race: WHITE											
2020-06-26	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.89	No	Yes	G1	G2	G2	G1	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021115; Age (Years): 59; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.06	No	Yes	G2	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2021115; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-31	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G1	G0	G1	G0	No
	2	G0/37.33	No	Yes	G2	G1	G2	G2	G1	G1	No
	3	G0/37.39	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.50	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021186; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	Yes	G1	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	Yes	G1	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	Yes	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021186; Age (Years): 60; Gender: F; Race: WHITE											
2020-07-27	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G1	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G1	G1	G0	G0	G1	G1	No
	3	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G1\$	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G1\$	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G1\$	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G1	G0	G0	G0	G0	G0	No
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE											
2020-07-02	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G1	G1	G1	G1	G0	G0	No
	3	G0/36.22	No	No	G0	G1	G1	G1	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE											
2020-07-24	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G1	G1	G1	G1	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.56	No	Yes	G0	G1	G2	G2	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021215; Age (Years): 58; Gender: F; Race: WHITE											
2020-08-03	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-30	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.94	No	Yes	G1	G2	G2	G2	G0	G2	No
	3	G0/37.06	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-06	1*	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			Fever/ Pain	Fever/ Pain							
Subject ID: US2021230; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-06	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021232; Age (Years): 61; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G1	G1	G1	G1	G0	G1	No
	3	G0/36.22	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/36.11	No	No	G1	G1	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G1	G1	G1	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-06	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2021232; Age (Years): 61; Gender: F; Race: WHITE											
2020-08-06	2	G0/37.39	No	Yes	G0	G1	G2	G0	G0	G1	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2021234; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-07	1*	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031091; Age (Years): 61; Gender: F; Race: WHITE											
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.61	No	Yes	G3\$	G3	G3	G2	G0	G2	No
	3	G0/36.78	No	No	G3\$	G0	G3\$	G0	G0	G0	No
	4	G0/36.50	No	No	G3\$	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G3\$	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G3\$	G0	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G3\$	G0	G0	G0	G0	G0	No
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031093; Age (Years): 57; Gender: F; Race: WHITE											
2020-07-01	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	No	G0	G1	G0	G0	G0	G1	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031101; Age (Years): 64; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2031101; Age (Years): 64; Gender: F; Race: WHITE											
2020-08-03	7	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031111; Age (Years): 87; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2031112; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G3\$	G0	G3\$	G3\$	G0	G0	No
	2	G0/37.06	No	No	G3	G3	G3	G2	G2	G2	No
	3	G0/36.39	No	No	G3\$	G3\$	G3\$	G3\$	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2031122; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2031122; Age (Years): 56; Gender: F; Race: WHITE											
2020-07-29	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041096; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-29	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	Yes	G1	G1	G1	G1	G0	G0	No
	2	G0/36.50	No	Yes	G1	G1	G1	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.22	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041107; Age (Years): 64; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G2	G0	G0	G0	G0	No
	2	G0/35.56	No	No	G0	G2	G2	G2	G0	G0	No
	3	G0/35.33	No	No	G0	G2	G1	G1	G0	G0	No
	4	G0/35.33	No	No	G0	G2	G0	G1	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G1	G0	G0	G0	No
Subject ID: US2041108; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-26	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041108; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-26	6	G0/36.94	No	No	G1	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.78	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE											
2020-06-26	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G2	G2	G1	G0	G1	No
	3	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G2	G0	G1	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE											
2020-07-28	5	G0/36.06	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041117; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.33	No	No	G1	G1	G1	G1	G0	G1	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041120; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-30	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G2	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G2	G2	G2	G0	G0	No
	7	G0/36.67	No	Yes	G0	G1	G1	G0	G0	G0	No
2020-07-28	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G3	G2	G1	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041122; Age (Years): 82; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2				G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041122; Age (Years): 82; Gender: F; Race: WHITE											
2020-07-27	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041123; Age (Years): 60; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	Yes	G0	G2	G2	G2	G1	G2	No
	3	G0/37.28	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2041125; Age (Years): 57; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.39	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-26	1*	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	Yes	G1	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE											
2020-06-26	7				G1\$						
2020-07-28	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	Yes	G1	G0	G0	G0	G0	G0	No
	2	G0/37.78	No	Yes	G2	G2	G2	G2	G0	G0	No
	3	G0/35.72	No	Yes	G1	G1	G0	G0	G0	G0	Yes
	4	G0/36.56	No	No	G1	G0	G0	G0	G0	G0	Yes
	5	G0/36.17	No	No	G1	G0	G0	G0	G0	G0	Yes
	6	G0/37.06	No	Yes	G1	G0	G0	G0	G0	G0	No
7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No	
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G1	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G1	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.72	No	Yes	G0	G0	G0	G0	G0	G0	No
7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No	
2020-08-10	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	Yes	G2	G2	G1	G1	G0	G2	No
	3	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041131; Age (Years): 62; Gender: M; Race: WHITE											
2020-08-10	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041136; Age (Years): 56; Gender: M; Race: WHITE											
2020-07-01	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2041138; Age (Years): 68; Gender: M; Race: WHITE											
2020-06-26	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G1	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2041144; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-28	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G1	G2	G1	G0	G0	G0	No
	3	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2041149; Age (Years): 65; Gender: F; Race: AMERICAN INDIAN OR ALASKA NATIVE											
2020-07-06	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051054; Age (Years): 63; Gender: M; Race: WHITE											
2020-06-26	1*	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.06	No	Yes	G0	G2	G2	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051064; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051064; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.67	No	Yes	G1	G2	G1	G0	G0	G0	No
	2	G0/37.28	No	No	G1	G1	G1	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.61	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.00	No	No	G0	G1\$	G0	G0	G1	G0	No
	4	G0/35.78	No	No	G0	G1\$	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G1\$	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G1\$	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G1	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G1	G1	G0	G0	G1	G0	No
	2	G0/37.83	No	Yes	G1	G2	G0	G1	G0	G2	No
	3	G0/36.83	No	No	G1	G2	G0	G0	G2	G1	No
	4	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE											
2020-07-28	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051070; Age (Years): 63; Gender: M; Race: WHITE											
2020-07-01	1*				G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051074; Age (Years): 59; Gender: M; Race: WHITE											
2020-06-30	2	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.39	No	Yes	G2	G2	G2	G2	G0	G1	No
	3	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051075; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-30	1*	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051075; Age (Years): 69; Gender: F; Race: WHITE											
2020-07-29	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	Yes	G0	G0	G1	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051077; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-30	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2051077; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-29	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051084; Age (Years): 61; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051085; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051085; Age (Years): 65; Gender: F; Race: WHITE											
2020-07-02	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.89	No	Yes	G1	G2	G2	G2	G0	G2	No
	3	G2/38.56	No	Yes	G1	G1	G1	G1	G0	G1	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	Yes
2020-07-28	1*	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-28	1	G1/38.00	No	Yes	G0	G1	G1	G1	G0	G0	No
	2	G0/37.44	No	Yes	G0	G1	G1	G1	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051097; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.39	No	No	G0	G0	G0	G0	G0	G2	No
	2	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.17	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/37.11	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051097; Age (Years): 70; Gender: F; Race: WHITE											
2020-08-03	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051101; Age (Years): 62; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G1	G0	G0	G0	No
	2	G0/37.00	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G1	G0	G0	G0	G0	G1	No
	2	G0/36.72	No	Yes	G2	G2	G2	G2	G0	G2	No
	3	G0/37.67	No	Yes	G2	G2	G2	G2	G0	G2	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.50	No	No	G0	G2	G1	G1	G0	G2	No
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2051102; Age (Years): 62; Gender: M; Race: WHITE											
2020-07-06	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G1	G0	G0	G1	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051104; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-07	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G1	G3\$	G3\$	G3\$	G0	G1	No
	2	G0/36.89	No	Yes	G1	G3\$	G3\$	G3\$	G1	G1	No
	3	G0/36.72	No	No	G0	G3\$	G3\$	G3\$	G2	G2	No
	4	G0/36.83	No	Yes	G2	G3	G3	G3	G3	G3	No
	5	G0/36.83	No	No	G0	G3\$	G3\$	G3\$	G1	G1	No
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2051106; Age (Years): 56; Gender: M; Race: WHITE											
2020-07-06	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G1	G0	G0	G0	No
	2	G0/37.33	No	Yes	G1	G1	G2	G0	G0	G2	No
	3	G1/38.17	No	Yes	G1	G2	G2	G0	G0	G2	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE											
2020-07-06	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE											
2020-08-10	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.28	No	No	G1	G0	G1	G0	G0	G0	No
	3	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2051111; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-04	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.78	No	No	G0	G2	G0	G0	G2	G2	No
	3	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2061036; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.11	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.39	No	Yes	G0	G1	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G2	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061045; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2061045; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-29	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G1	G2	G2	G0	G0	G1	No
	3	G1/38.11	No	No	G1	G1	G2	G0	G1	G2	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G1	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2061063; Age (Years): 56; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G1	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/ Vomiting	Chills	Rash
			To Prevent Fever/ Pain	To Treat Fever/ Pain							
Subject ID: US2061063; Age (Years): 56; Gender: M; Race: WHITE											
2020-07-28	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071006; Age (Years): 71; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G1	G1	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-01	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	Yes	G1	G1	G1	G1	G0	G1	No
	3	G0/37.06	No	No	G0	G0	G1	G1	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G1	G1	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071013; Age (Years): 73; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-09	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G1	G0	G1	G1	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G1	G1	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-03	1*	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071037; Age (Years): 71; Gender: M; Race: WHITE											
2020-06-03	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-07	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE											
2020-06-03	1*	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.11	No	No	G1	G2	G1	G0	G0	G0	No
	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-06	1*	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE											
2020-07-06	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.67	No	No	G0	G0	G0	G1	G0	G0	No
	6	G0/36.11	No	No	G0	G1	G0	G1	G0	G0	No
	7	G0/35.72	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071087; Age (Years): 81; Gender: F; Race: WHITE											
2020-06-26	1	G0/35.72	No	No							
	2	G0/36.78	No	No							
	3	G0/36.00	No	No							
	4	G0/36.44	No	No							
	5	G0/36.78	No	No							
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-30	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No							
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No							
	6	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2071089; Age (Years): 66; Gender: F; Race: WHITE											
2020-06-26	7	G0/36.06	No	No	G0	G0	G0	G0	G1	G0	No
2020-07-29	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-27	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G1	G1	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071091; Age (Years): 58; Gender: M; Race: WHITE											
2020-07-27	5	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071093; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-29	2										
	3										
	4										
2020-07-29	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE											
2020-06-29	1*	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2071095; Age (Years): 71; Gender: F; Race: WHITE											
2020-06-29	6	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-28	1*	G0/37.33	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE											
2020-07-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-05	2	G0/37.67	Yes	No	G1	G0	G1	G1	G1	G0	No
	3	G1/38.17	No	Yes	G2	G2	G2	G2	G0	G1	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2071096; Age (Years): 55; Gender: M; Race: WHITE											
2020-08-05	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE											
2020-05-29	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.83	No	No	G0	G0	G0	G0	G0	G2	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-24	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.17	No	Yes	G0	G0	G0	G0	G0	G0	No
	3				G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081002; Age (Years): 69; Gender: F; Race: WHITE											
2020-05-29	1*	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081002; Age (Years): 69; Gender: F; Race: WHITE											
2020-05-29	2	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-25	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081014; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-01	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081014; Age (Years): 67; Gender: F; Race: WHITE											
2020-06-30	1	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-01	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5				G0	G0	G0	G0	G0	G0	No
	6				G0	G0	G0	G0	G0	G0	No
	7				G0	G0	G0	G0	G0	G0	No
2020-06-29	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.00	No	Yes	G2	G2	G2	G0	G0	G2	No
	3	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.72	No	No	G0	G0	G0	G1	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G1	G0	G0	No
	7	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081019; Age (Years): 76; Gender: F; Race: WHITE											
2020-06-02	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/35.61	No	No	G0	G0	G0	G0	G0	G0	No
2020-06-30	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081035; Age (Years): 68; Gender: F; Race: WHITE											
2020-06-02	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G1	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081035; Age (Years): 68; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE											
2020-06-26	1	G0/36.72	No	No	G2	G2	G0	G0	G0	G0	No
	2				G0	G1	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G1\$	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G1	G0	G0	G0	G0	No
	7	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
2020-07-24	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	No	Yes	G1	G2	G0	G0	G0	G0	No
	3	G0/37.11	No	Yes	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent	To Treat							
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE											
2020-07-24	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE											
2020-06-26	1*	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.00	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	No	G0	G0	G0	G1	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-24	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.56	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.33	No	Yes	G3	G2	G2	G1	G0	G0	No
	3	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE											
2020-06-30	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081075; Age (Years): 56; Gender: M; Race: WHITE											
2020-06-30	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE											
2020-07-01	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-05	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE											
2020-08-05	1	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.67	No	Yes	G0	G3	G3	G0	G0	G2	No
	3	G0/37.44	No	No		G1\$	G2\$				
	4	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081081; Age (Years): 56; Gender: F; Race: WHITE											
2020-06-29	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.00	No	No	G1	G1	G0	G0	G0	G0	No
	2	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	3	G0/37.06	No	No	G1	G1	G1	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G1	G0	G0	G0	G0	No
	5	G0/37.06	No	No	G0	G1	G0	G0	G0	G0	No
	6	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081088; Age (Years): 63; Gender: M; Race: WHITE											
2020-07-02	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1	G0/37.28	No	Yes	G0	G3	G2	G0	G0	G2	No
	2	G1/38.17	No	Yes	G0	G2	G2	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G1	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-03	1*	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.94	No	No	G0	G0	G1	G1	G0	G0	No
	3	G0/36.67	No	Yes	G2	G0	G0	G0	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081091; Age (Years): 59; Gender: F; Race: WHITE											
2020-07-03	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G1/38.39	No	Yes	G2	G3	G3	G3	G0	G0	No
	3	G0/36.67	No	Yes	G1	G2\$	G2	G2	G0	G0	No
	4	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE										
2020-07-02	1*	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.89	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	7	G0/36.39	No	Yes	G0	G0	G0	G0	G0	G0	No
	1*	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
6	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No	

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE											
2020-08-03	7	G0/35.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE											
2020-06-26	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.61	No	No	G1	G0	G0	G0	G0	G0	No
	2	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G1	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/35.78	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G1	G0	G0	No
	2	G0/36.72	No	Yes	G1	G2	G0	G2	G0	G0	No
	3	G0/36.72	No	No	G1	G1	G0	G1	G0	G0	No
	4	G0/36.67	No	Yes	G1	G0	G0	G1	G0	G0	No
	5	G0/36.78	No	No	G1	G0	G0	G1	G0	G0	No
	6	G0/37.00	No	No	G1	G0	G0	G1	G0	G0	No
	7	G0/35.72	No	No	G1	G0	G0	G1	G0	G0	No
Subject ID: US2081108; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-03	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081108; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-03	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-31	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081116; Age (Years): 75; Gender: M; Race: WHITE											
2020-06-29	1*	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.06	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Pain							
Subject ID: US2081116; Age (Years): 75; Gender: M; Race: WHITE											
2020-07-29	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.44	No	Yes	G2	G2	G1	G1	G0	G2	Yes
	3	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081117; Age (Years): 66; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/37.06	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-11	1*	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.72	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.11	No	Yes	G0	G0	G0	G0	G1	G0	No
	3	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.17	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			To Prevent Pain	To Treat Fever/Pain							
Subject ID: US2081117; Age (Years): 66; Gender: F; Race: WHITE											
2020-08-11	7	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE											
2020-07-01	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	3	G0/36.78	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.11	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.28	No	No	G0	G0	G0	G0	G0	G0	No
2020-07-29	1*	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.22	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.22	No	No	G0	G1	G1	G1	G0	G0	No
	3	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.61	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.39	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-06	1*	G0/36.67	Yes	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	Yes	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE											
2020-07-06	3	G0/37.22	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.17	No	Yes	G1	G0	G2	G0	G0	G0	No
	5	G0/36.00	No	Yes	G1	G0	G0	G0	G0	G0	No
	6	G0/36.33	No	Yes	G0	G0	G0	G0	G0	G0	No
	7	G0/37.06	Yes	No	G0	G0	G0	G0	G0	G0	No
2020-08-10	1*	G0/36.56	No	No	G0	G0	G0	G0	G0	G0	No
	1				G0	G0	G0	G0	G0	G0	No
	2	G0/36.28	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/36.44	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.33	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/36.83	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE											
2020-07-02	1*	G0/36.89	No	No	G0	G0	G0	G0	G0	G0	No
	1	G0/36.94	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/36.61	No	Yes	G0	G0	G0	G0	G0	G0	No
	3	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	4	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No
	5	G0/36.50	No	No	G0	G0	G0	G0	G0	G0	No
	6	G0/37.11	No	No	G0	G0	G0	G0	G0	G0	No
	7	G0/37.39	No	No	G0	G0	G0	G0	G0	G0	No
2020-08-03	1*	G0/37.00	No	No	G0	G0	G0	G0	G0	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.3
Solicited Systemic Adverse Reactions
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Vaccination Date	Day	Fever/Maximum Temperature (C)	Took Medication		Headache	Fatigue	Myalgia	Arthralgia	Nausea/Vomiting	Chills	Rash
			Fever/Pain	Fever/Pain							
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE											
2020-08-03	1	G0/36.67	No	No	G0	G0	G0	G0	G0	G0	No
	2	G0/37.06	Yes	Yes	G2	G2\$	G2	G2	G1	G1	No
	3	G0/37.44	Yes	Yes	G2	G2	G2	G2	G1	G1	No
	4	G0/37.06	Yes	Yes	G2	G2	G2	G2	G1	G2	No
	5	G0/37.06	No	Yes	G1	G2	G2	G2	G1	G1	No
	6	G0/37.22	No	Yes	G0	G2\$	G0	G0	G0	G0	No
	7	G0/36.83	No	Yes	G2	G2	G0	G0	G2\$	G0	No

* indicates within 1 hour after vaccination (at study clinic), \$ indicates grade from investigator assessment.
The maximum grade from eDiary and AE eCRF is listed for each symptom.
Day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020703.sas 19NOV2020 01:39 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2011068	2	2020-06-30	PAIN AT INJECTION SITE SWELLING AT INJECTION SITE	2020-07-01 14:00 (2) 2020-06-30 (1)	2020-07-10 23:00 (11) 2020-07-15 (16)	No No
US2021096	2	2020-07-02	FATIGUE	2020-07-08 (7)	2020-07-10 (9)	No
US2021144	1	2020-06-05	FATIGUE JOINT ACHES ALL OVER BODY MUSCLE ACHES ALL OVER BODY	2020-06-06 20:12 (2) 2020-06-06 20:12 (2) 2020-06-09 (5)	2020-06-14 07:48 (9) 2020-06-14 07:12 (9) 2020-06-14 (10)	No No No
US2021175	2	2020-07-08	FATIGUE	2020-07-08 21:31 (1)	2020-07-17 14:13 (10)	No
US2031074	2	2020-06-30	HEADACHE	2020-06-30 22:00 (1)	2020-07-08 18:00 (9)	No

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2021058	2	2020-07-07	FATIGUE	2020-07-07 21:41 (1)	2020-07-15 12:00 (9)	No
			GENERALIZED BODY ACHES	2020-07-07 19:00 (1)	2020-07-14 22:22 (8)	No
			HEADACHES	2020-07-14 (8)	2020-07-15 (9)	No
			JOINT ACHES IN SEVERAL JOINT	2020-07-07 19:00 (1)	2020-07-14 22:22 (8)	No
US2031004	2	2020-06-29	BILATERAL AXILLARY TENDERNESS	2020-06-29 18:00 (1)	2020-07-07 10:00 (9)	No
US2031042	2	2020-07-06	MUSCLE ACHES ALL OVER BODY	2020-07-07 13:27 (1)	2020-07-17 22:56 (12)	No
US2041076	1	2020-06-02	FATIGUE	2020-06-02 17:00 (1)	2020-06-11 22:00 (10)	No
			HEADACHE	2020-06-03 (2)	2020-06-12 (11)	No
	2	2020-07-06	HEADACHE	2020-07-06 13:30 (1)	2020-07-15 (10)	No
			MYALGIA LEFT ARM	2020-07-06 13:30 (1)	2020-07-14 13:30 (9)	No
US2051033	2	2020-07-07	FATIGUE	2020-07-07 (1)	2020-07-15 (9)	No
			JOINT ACHES IN SEVERAL JOINTS	2020-07-07 (1)	2020-07-15 (9)	No
US2071004	2	2020-07-08	FATIGUE	2020-07-09 (2)	2020-07-16 (9)	Yes
			HEADACHE	2020-07-09 08:00 (1)	2020-07-16 (9)	Yes
			MUSCLE ACHES ALL OVER BODY	2020-07-14 (7)	2020-07-15 (8)	Yes

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2021080	1	2020-06-05	FATIGUE	2020-06-05 21:35 (1)	2020-06-18 08:32 (13)	No
US2021154	2	2020-07-08	HEADACHE	2020-07-08 20:56 (1)	2020-07-16 12:00 (8)	No
US2021164	1	2020-06-08	UNDERARM TENDERNESS	2020-06-14 (7)	2020-06-18 (11)	Yes
US2021180	1	2020-06-08	SWELLING AT INJECTION SITE	2020-06-14 (7)	2020-07-01 (24)	No
	2	2020-07-08	HARDNESS AT INJECTION SITE	2020-07-08 21:00 (1)	2020-07-17 09:00 (9)	No
			SWELLING AT INJECTION SITE	2020-07-08 21:00 (1)	2020-07-17 09:00 (9)	No
US2041008	2	2020-07-01	FATIGUE	2020-07-02 (2)	2020-07-10 (10)	No
US2041060	1	2020-06-02	HARDNESS AT INJECTION SITE	2020-06-03 (2)	2020-06-09 (8)	No
			SWELLING AT INJECTION SITE	2020-06-03 (2)	2020-06-09 (8)	No
US2041073	1	2020-06-02	FATIGUE	2020-06-03 09:38 (1)	2020-06-12 12:38 (10)	No
	2	2020-06-30	FATIGUE	2020-07-03 (4)	2020-07-11 (12)	No
US2061008	2	2020-07-06	JOINT ACHES, GENERALIZED	2020-07-06 20:00 (1)	2020-07-29 20:00 (24)	No
			MUSCLE ACHES, GENERALIZED	2020-07-12 06:00 (6)	2020-07-14 07:00 (8)	No
US2061023	1	2020-06-05	UNDERARM PAIN - LEFT ARM	2020-06-10 (6)	2020-06-12 (8)	Yes

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2061023	2	2020-07-06	MUSCLE ACHES, GENERALIZED	2020-07-12 (7)	2020-07-18 (13)	No
US2071002	2	2020-06-30	HEADACHE	2020-07-01 20:00 (2)	2020-07-12 08:00 (12)	Yes
			JOINT ACHES IN SEVERAL JOINTS ALL OVER BODY	2020-07-01 08:00 (1)	2020-07-08 08:00 (8)	Yes
			NAUSEA	2020-07-04 (5)	2020-07-09 (10)	Yes

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2011007	1	2020-06-01	REDNESS AT INJECTION SITE	2020-06-01 20:00 (1)	2020-06-10 (10)	No
US2061043	2	2020-07-27	FATIGUE	2020-07-28 11:00 (1)	2020-08-03 18:00 (8)	No
			JOINT ACHES - GENERALIZED	2020-07-28 11:00 (1)	2020-08-03 18:00 (8)	No
			MUSCLE ACHES	2020-07-28 11:00 (1)	2020-08-03 18:00 (8)	No
US2061051	1	2020-06-30	FATIGUE	2020-07-06 (7)	2020-07-07 (8)	No

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2021020	1	2020-06-01	FATIGUE	2020-06-06 (6)	2020-06-16 (16)	No
			HEADACHE	2020-06-06 (6)	2020-06-09 (9)	No
US2021217	2	2020-07-29	FATIGUE	2020-07-29 17:00 (1)	2020-08-05 16:23 (8)	No
US2031105	1	2020-06-26	FATIGUE	2020-06-28 (3)	2020-07-09 (14)	No
US2041155	2	2020-08-03	HEADACHE	2020-08-03 18:13 (1)	2020-08-11 13:09 (8)	No
US2051057	1	2020-06-26	FATIGUE	2020-06-26 (1)	2020-07-08 (13)	No
			JOINT ACHES IN SEVERAL JOINTS	2020-06-26 (1)	2020-07-06 (11)	No
	2	2020-07-24	FATIGUE	2020-07-24 (1)	2020-07-31 (8)	No
US2051068	2	2020-07-28	MUSCLE ACHES ALL OVER BODY	2020-07-24 (1)	2020-07-31 (8)	No
			PAIN AT THE INJECTION SITE	2020-07-24 10:00 (1)	2020-08-05 00:00 (12)	No
			FATIGUE	2020-07-28 19:28 (1)	2020-08-04 19:05 (8)	No
US2081092	1	2020-07-02	JOINT ACHES (IN SEVERAL JOINTS)	2020-07-28 19:28 (1)	2020-08-04 19:06 (8)	No
			MUSCLE ACHES (ALL OVER BODY)	2020-07-29 22:37 (2)	2020-08-04 19:06 (8)	No
US2081100	1	2020-07-02	FATIGUE	2020-07-02 (1)	2020-07-14 (13)	No
US2081100	1	2020-07-02	HEADACHE	2020-07-05 (4)	2020-07-11 (10)	No

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2081100	2	2020-08-03	FATIGUE REPORTED BEYOND DAY 7 IN EDIARY	2020-08-09 (7)	2020-08-11 (9)	No

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.4
Solicited Adverse Reactions Ongoing 7 Days after Injection
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose	Date of Injection	Solicited Adverse Reactions	Start Date and Time (Relative Day)	End Date and Time (Relative Day)	Receive Medical Attention?
US2021208	2	2020-07-29	HEADACHE	2020-07-29 17:28 (1)	2020-08-09 13:55 (11)	No
US2041126	1	2020-06-26	HEADACHE	2020-06-29 (4)	2020-07-04 (9)	No
US2081076	2	2020-08-05	HARDNESS AT INJECTION SITE (DAY 8)	2020-08-05 (1)	2020-08-13 (9)	No
			SWELLING AT INJECTION SITE (DAY 8)	2020-08-05 (1)	2020-08-13 (9)	No
US2081099	2	2020-07-29	GENERALIZED JOINT ACHES (DAY 8-DAY 14 AFTER INJECTION)	2020-08-06 (9)	2020-08-11 (14)	No
			HEADACHE (DAY 8 AFTER INJECTION)	2020-08-06 (9)	2020-08-08 (11)	No

Relative day is defined as days from the most recent injection date.

Solicited adverse reactions ongoing 7 days after injection collected on AE eCRF are listed.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020704.sas 19NOV2020 01:40 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2011060	1/ 2020-06-02	1	6	2020-06-09	Yes/ Investigator Site	LEFT FOREARM AND RIGHT UPPER THIGH	G1	RASH IS EXACERBATION OF POISON IVY (AE REPORTED), NOT RELATED TO IP.
US2041011	1/ 2020-06-01		5		No			CONFIRMED WITH PT RASH WAS REPORTED IN ERROR. 0 SYMPTOMS/REACTIONS WERE EXPERIENCED.
US2041029	1/ 2020-06-01		2		No			

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2011084	2/ 2020-06-30	1	3	2020-07-07	Yes/ Investigator Site	CHEST AND ABDOMEN	G1	NOT RELATED TO IP, PER PI. NOT SOLICITED SYMPTOM.
US2011095	2/ 2020-07-06	1	1	2020-07-06	Yes/ Investigator Site	RIGHT HIP	G1	DUE TO POISON IVY CONTACT
US2021084	2/ 2020-07-07		7		No			
US2021179	1/ 2020-06-08		7	2020-06-15	Yes/ Investigator Site	NO RASH	G0	SUBJECT WAS CALLED AND REPORTED THAT THEY ACCIDENTALLY ENTERED YES FOR RASH AND SUBJECT DOES NOT HAVE A RASH
US2031080	2/ 2020-07-02		6		No			REPORTED BY MISTAKE NO RASH PER PATIENT

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2041076	2/ 2020-07-06		5	2020-07-10	Yes/ Investigator Site	UNKNOWN	G0	
US2051032	2/ 2020-06-30	1	1	2020-07-01	Yes/ Investigator Site	LEFT DELTOID (INJECTION SITE)	G1	WHEN THE PATIENT RETURNED TO THE SITE ON 07/01/2020 THERE RASH WAS NO LONGER PRESENT. IT HAD CLEARED UP AND ONLY MET GRADE 1 CRITERIA, NO CON MEDS WERE TAKEN
US2071033	1/ 2020-06-08		1	2020-06-08	Yes/ Investigator Site	INJECTION SITE- RIGHT ARM.	G0	
US2081036	1/ 2020-06-04	2	2	2020-06-06	Yes/ Investigator Site	LEFT TORSO REGION	G1	RESOLVED 06JUN2020
	2/ 2020-07-09		3		No			RESOLVED 13JUL2020

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2081054	1/ 2020-06-05		5		No			PATIENT INADVERTENTLY MARKED "YES" FOR EXPERIENCING A RASH ON 09JUN2020. PATIENT WAS CONTACTED AND CONFIRMED THIS WAS AN ERROR AND REPORTS NO SYMPTOMS AT ALL

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2011080	1/ 2020-06-03		5		No			RASH REPORTED IN ERROR BY SUBJECT. CONFIRMED NO RASH.
US2031013	2/ 2020-06-30		4		No			SUBJECT WAS UNABLE TO COME TO SITE TO BE EVALUATED FOR THE RASH. SUBJECT STATED THAT ALL IS WELL AS OF TODAY. STARTED 01JUL2020 TO 05JUL 2020
US2031047	2/ 2020-06-29		1		No			SUBJECT MARKED RASH BY MISTAKE. NO RASH PRESENT
US2041046	1/ 2020-06-04		1		No			

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2051012	1/ 2020-06-02	1	2	2020-06-04	Yes/ Investigator Site	LEFT ARM AT INJECTION SITE	G1	AREA OF ERYTHEMA SURROUNDING INJECTION SITE WITH ON PRURITUS OR PAIN GRADE 1
US2051028	1/ 2020-06-04		3	2020-06-11	Yes/ Investigator Site	NO RASH	G0	SUBJECT CONTACTED REGARDING RASH SUBJECT CONFIRMED NO RASH HE ENTERED YES BY MISTAKE
	1/ 2020-06-04		5	2020-06-11	Yes/ Investigator Site	NO RASH	G0	SUBJECT WAS CONTACTED REGARDING RASH SUBJECT CONFIRMED NO RASH ENTERED YES BY MISTAKE
US2051045	2/ 2020-07-08		3		No			SUBJECT DID NOT HAVE A RASH ONLY REDNESS. SUBJECT MISUNDERSTOOD THE QUESTION

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2081045	2/ 2020-07-07		2		No			PATIENT INADVERTENTLY MARKED 'YES' FOR RASH WHEN HE DID NOT HAVE ONE

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2011116	1/ 2020-06-27		5		No			RASH REPORTED IN ERROR. NO RASH PRESENT.
US2051063	2/ 2020-07-28		5	2020-08-04	Yes/ Investigator Site	REPORTED AS REDNESS AND DISCOLORATION AT INJECTION SITE	G0	SUBJECT NOTICED REDNESS AND DISCOLORATION NO RASH AT INJECTION SITE LASTING ABOUT 24 HOURS

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2021020	2/ 2020-06-30		7		No			
US2021217	1/ 2020-06-29		4	2020-07-01	Yes/ Investigator Site	LEFT CHEEK	G0	PER SUB-I/PI IT WAS NOT A RASH. SUBJECT STATED THAT SHE USED SUNSCREEN ON FACE AFTER LEAVING HER APPOINTMENT ON 29JUN2020. (ASSESSMENTS WERE PERFORMED OVER VIDEO CHAT.
	2/ 2020-07-29		3	2020-07-29	Yes/ Investigator Site	NO RASH PER PI, RIGHT THIGH	G0	
US2051071	2/ 2020-07-27		7	2020-08-03	Yes/ Investigator Site	NO RASH SUBJECT ENTERED YES IN ERROR	G0	

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2081092	1/ 2020-07-02	1	5	2020-07-09	Yes/ Investigator Site	FOREHEAD AND ACROSS UPPER BACK	G1	PER PI, THIS IS NOT RELATED TO THE STUDY OR IP

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.5
Solicited Rash Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Date of Rash Assessment	Evaluated by a Healthcare Provider/ Specified Site	Rash Location	Investigator Assessed Grade	Additional Information
US2041126	2/ 2020-07-28		3		No			
US2051088	1/ 2020-06-30		7		No			SUBJECT SAID HE MUST OF HIT THE WRONG BUTTON WHEN DOING DIARY. HE HAS NOT HAD A RASH
US2081116	2/ 2020-07-29		2		No			PT. REPORTS REDNESS AT INJECTION SITE, NOT RASH DESPITE DIARY ENTRY. WILL FOLLOW UP WITH PATIENT AT DAY 36 VISIT TO ASSESS REDNESS, IF ANY

Relative day is defined as days from the most recent injection.
G0 = grade 0, G1 = grade 1, G2 = grade 2, G3 = grade 3, G4 = grade 4.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020705.sas 19NOV2020 01:41 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2021155	1/ 2020-06-08		2	No			
US2041019	1/ 2020-06-02		1	No			
US2071022	1/ 2020-06-03	1	1	Yes/ Investigator Site	2020-06-12	Yes	
US2081057	1/ 2020-06-05		6	Yes/ Investigator Site	2020-06-12	No	
	2/ 2020-07-09		2	No			
	2/ 2020-07-09		4	No			

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2011095	2/ 2020-07-06		7	No			
US2021058	1/ 2020-06-05		2	Yes/ Investigator Site	2020-06-05	No	
US2021084	1/ 2020-06-05		4	Yes/ Investigator Site	2020-06-07	No	
US2031004	1/ 2020-05-29		3	No			
	2/ 2020-06-29		3	Yes/ Investigator Site	2020-07-01	No	
US2031072	1/ 2020-06-03		2	No			
	2/ 2020-07-06		3	No			
US2041049	1/ 2020-06-04		2	No			
US2051008	2/ 2020-06-30		2	Yes/ Investigator Site	2020-07-06	No	NONE PRESENT
US2051027	2/ 2020-07-07		1	Yes/ Investigator Site	2020-07-14	No	NONE PRESENT

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2051027	2/ 2020-07-07		2	Yes/ Investigator Site	2020-07-14	No	NONE PRESENT
	2/ 2020-07-07		3	Yes/ Investigator Site	2020-07-14	No	NONE PRESENT
US2051042	1/ 2020-06-02		2	Yes/ Investigator Site	2020-06-09	No	NONE PRESENT
US2061006	2/ 2020-07-01		3	Yes/ Investigator Site	2020-07-08	No	

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2011089	1/ 2020-06-05	1	1	Yes/ Investigator Site	2020-06-12	Yes	
US2021080	1/ 2020-06-05		6	Yes/ Investigator Site	2020-06-10	No	
	2/ 2020-07-08		3	Yes/ Investigator Site	2020-07-08	No	SUBJECT REPORTED SWELLING THROUGH DAY 2-DAY 4 BUT IT WAS SORENESS NOT SWELLING
US2021154	1/ 2020-06-05		2	No			
	1/ 2020-06-05		3	No			
US2021164	1/ 2020-06-08	1	7	Yes/ Investigator Site	2020-06-08	Yes	
	2/ 2020-07-08		3	No			
US2021182	2/ 2020-07-07		3	Yes/ Investigator Site	2020-07-08	No	
US2031037	1/ 2020-06-02		7	No			7 DAYS AFTER VACCINE

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2031073	1/ 2020-06-02		2	No			
	1/ 2020-06-02		3	No			
	1/ 2020-06-02		4	No			
	1/ 2020-06-02		5	No			
	1/ 2020-06-02		6	No			
	1/ 2020-06-02		7	No			
	2/ 2020-07-01		1	No			
	1/ 2020-06-02		1	No			
US2041060	2/ 2020-07-01		2	No			
	1/ 2020-06-03		1	Yes/ Investigator Site	2020-06-10	No	NONE PRESENT
US2051013	1/ 2020-06-03		2	Yes/ Investigator Site	2020-06-10	No	NONE PRESENT
	1/ 2020-06-03		3	Yes/ Investigator Site	2020-06-10	No	NONE PRESENT
	1/ 2020-06-03						

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2051013	2/ 2020-07-01		1	Yes/ Investigator Site	2020-07-08	No	NONE PRESENT
	2/ 2020-07-01		2	Yes/ Investigator Site	2020-07-08	No	NONE PRESENT
	2/ 2020-07-01		3	Yes/ Investigator Site	2020-07-08	No	NONE PRESENT
	2/ 2020-07-01		4	Yes/ Investigator Site	2020-07-08	No	NONE PRESENT
US2051045	1/ 2020-06-10		3	Yes/ Investigator Site	2020-06-17	No	NONE PRESENT
	1/ 2020-06-10		4	Yes/ Investigator Site	2020-06-17	No	NONE PRESENT
US2061008	1/ 2020-06-03		2	No			
US2061023	1/ 2020-06-05		7	Yes/ Investigator Site	2020-06-11	No	
US2061027	2/ 2020-07-08		3	Yes/ Investigator Site	2020-07-15	No	
US2071040	2/ 2020-07-13	2	4	Yes/ Investigator Site	2020-07-15	Yes	
	2/ 2020-07-13	2	5	Yes/ Investigator Site	2020-07-16	Yes	

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2081025	1/ 2020-06-03		6	No			PT NOTED IN E-DIARY, NOT NOTED IN PHYSICAL
US2081062	1/ 2020-06-08		3	No			
	2/ 2020-07-09		3	Yes/ Investigator Site	2020-07-10	No	
US2081063	1/ 2020-06-08		4	No			THE SUBJECT REPORTED UNDERARM SWELLING 3 DAYS AFTER THE INJECTION. IT RESOLVED BY THE NEXT CLINIC VISIT AND COULD NOT BE EVALUATED BY INVESTIGATOR.

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2081064	1/ 2020-06-08		5	No			PATIENT REPORTED UNDERARM TENDERNESS ON DAY 4 AFTER INJECTION. THE TENDERNESS RESOLVED BY THE NEXT CLINIC VISIT ON 15JUN2020. IT COULD NOT BE EVALUATED AS IT HAD RESOLVED.

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2041151	1/ 2020-07-06		4	No			
	1/ 2020-07-06		5	No			
	1/ 2020-07-06		6	No			

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2011040	2/ 2020-06-29		5	No			
US2021020	1/ 2020-06-01	1	6	Yes/ Investigator Site	2020-06-05	Yes	
	2/ 2020-06-30	1	3	Yes/ Investigator Site	2020-07-01	Yes	
US2021216	2/ 2020-08-03		4	No			
US2031105	2/ 2020-07-28		4	Yes/ Investigator Site	2020-08-07	No	
US2041100	2/ 2020-07-28		2	No			
US2041104	1/ 2020-06-26		1	No			
US2051057	2/ 2020-07-24		2	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT
	2/ 2020-07-24		3	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT
	2/ 2020-07-24		4	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2051057	2/ 2020-07-24		5	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT
	2/ 2020-07-24		6	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT
	2/ 2020-07-24		7	Yes/ Investigator Site	2020-07-31	No	NO LONGER PRESENT AT VISIT
US2051059	2/ 2020-07-27		2	Yes/ Investigator Site	2020-08-03	No	NO SYMPTOM PRESENT AT ASSESSMENT
US2051099	2/ 2020-08-03		2	Yes/ Investigator Site	2020-08-10	No	SUBJECT ONLY HAD ON DAY 2 NOT PRESENT AFTER THE ONE DAY
US2051105	1/ 2020-07-02		2	Yes/ Investigator Site	2020-08-09	No	ONLY PRESENT ON DAY 2
	2/ 2020-07-31		3	Yes/ Investigator Site	2020-08-07	No	SWELLING OR TENDERNESS NO LONGER PRESENT
US2051107	1/ 2020-07-02		2	Yes/ Investigator Site	2020-07-10	No	LYMPH NODE EVALUATION NORMAL
US2081112	2/ 2020-08-11		2	No			

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2011149	1/ 2020-06-29		3	No			
US2021115	2/ 2020-07-31	1	3	Yes/ Investigator Site	2020-07-31	Yes	
US2021215	1/ 2020-06-29		2	No			
US2041096	2/ 2020-07-28		4	No			SUBJECT REPORTED UNDERARM SWELLING/TENDERNESS IN ERROR.
US2041126	2/ 2020-07-28		4	No			
US2041136	2/ 2020-08-03		3	No			
US2051069	2/ 2020-07-28		2	Yes/ Investigator Site	2020-08-03	No	
US2051074	1/ 2020-06-30		2	Yes/ Investigator Site	2020-07-07	No	NO LONGER PRESENT AT VISIT

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2051101	2/ 2020-08-10		3	Yes/ Investigator Site	2020-08-17	No	NO SWELLING OR TENDERNESS PRESENT, SUBJECT ONLY HAD ONE DAY
US2051111	2/ 2020-08-04		2	Yes/ Investigator Site	2020-08-10	No	SUBJECT REPORTED IN DIARY ON DAY 2 AND 3 AT DAY 36 VISIT NO SWELLING OR TENDERNESS PRESENT
US2071037	2/ 2020-07-07		3	No			
US2081076	2/ 2020-08-05		3	No			PATIENT REPORTED TENDERNESS/UNDERARM SWELLING LEFT ARM. PATIENT REPORTS IT IS NOT SIGNIFICANT. RESOLVED 08AUG2020.

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.6
Lymphadenopathy Assessed by Healthcare Provider
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Vaccination Dose/ Date of Injection	Duration (days)	Relative Day	Evaluated by a Healthcare Provider/ Specified Site	Date of Lymphadenopathy Assessment	Confirmed on Physical Exam	Additional Information
US2081099	2/ 2020-07-29		4	No			SUBJECT IS COMING IN FOR DAY 43 VISIT ON 13AUG2020 AND THE INVESTIGATOR WILL ASSESS AT THAT TIME. THE SUBJECT CONFIRMED BY PHONE THAT THE UNDERARM SWELLING HAS RESOLVED.

Relative day is defined as days from the most recent injection.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020706.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ EXASPERATION OF POISON IVY RASH LEFT FOREARM/RIGHT UPPER THIGH	2020-06-06 (5)/ 2020-06-13 (12)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Toothache/ TOOTH PAIN, LEFT LOWER SECOND MOLAR (FROM ROOT CANAL)	2020-07-23 (24)/ 2020-07-30 (31)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011064; Age (Years): 34; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ POISON OAK LEFT ARM	2020-07-24 (24)/ 2020-08-06 (37)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-09 (7)/ 2020-07-17 (45)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Dry throat/ DRY THROAT	2020-06-09 (7)/ 2020-07-30 (58)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-30 (1)/ 2020-07-15 (16)	Yes/ No/ Yes	1	No	R/R	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site bruising/ BRUISE AT INJECTION SITE	2020-06-30 10:50 (1)/ 2020-07-17 (18)	Yes/ No/ No	1	No	NR/R	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011068; Age (Years): 44; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	2020-07-01 14:00 (2)/ 2020-07-10 23:00 (11)	Yes/ No/ Yes	1	No	R/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011088; Age (Years): 47; Gender: M; Race: WHITE							
Infections and infestations/ Hordeolum/ STYE, LEFT EYE	2020-07-18 (12)/ 2020-07-25 (19)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Muscle strain/ MUSCLE STRAIN LEFT HAMSTRING	2020-06-09 (6)/ 2020-06-16 (13)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Lethargy/ LETHARGY	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021062; Age (Years): 44; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Sinus congestion/ SINUS CONGESTION	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA GENERALIZED	2020-06-25 (22)/ 2020-06-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Oral disorder/ LESION ON GUM (UNKNOWN) BENGIN	2020-06-25 (24)/ 2020-07-20 (49)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-26 (22)/ 2020-08-08 (65)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
Nervous system disorders/ Sinus headache/ SINUS HEADACHE	2020-06-29 (25)/ 2020-07-01 (27)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-06 (32)/ 2020-07-23 (49)	Yes/ Yes/ No	2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021096; Age (Years): 25; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-08 (7)/ 2020-07-10 (9)	Yes/ No/ Yes	3	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-07-12 (35)/ 2020-07-14 (37)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021111; Age (Years): 36; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-07-12 (35)/ 2020-07-16 (39)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-12 (35)/ 2020-07-18 (41)	Yes/ No/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-13 (36)/ 2020-07-19 (42)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-07 15:39 (29)/ 2020-07-15 14:00 (37)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES ALL OVER BODY	2020-06-06 20:12 (2)/ 2020-06-14 07:12 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021144; Age (Years): 18; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-06 20:12 (2)/ 2020-06-14 07:48 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-06-09 (5)/ 2020-06-14 (10)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021175; Age (Years): 36; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-08 21:31 (1)/ 2020-07-17 14:13 (10)	Yes/ No/ Yes	3	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-08-02 (26)/ 2020-08-02 (26)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031029; Age (Years): 40; Gender: F; Race: WHITE							
Renal and urinary disorders/ Hypertonic bladder/ OVER ACTIVE BLADDER	2020-06-17 (16)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-08-04 (29)/ 2020-08-10 (35)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE							
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-07-05 (5)/ 2020-07-11 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE							
Infections and infestations/ Otitis media/ BILATERAL ACUTE OTITIS MEDIA	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE							
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-30 22:00 (1)/ 2020-07-08 18:00 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-08-03 (33)/ 2020-08-03 (33)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Skin laceration/ LEFT HAND LACERATION	2020-07-06 (7)/ 2020-07-13 (14)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2051022; Age (Years): 22; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Odynophagia/ ODYNOPHAGIA	2020-07-28 (22)/ 2020-08-04 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051036; Age (Years): 49; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Acne/ ACNE VULGARIS ON BACK	2020-07-23 (22)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2061021; Age (Years): 43; Gender: M; Race: WHITE							
Investigations/ Heart rate decreased/ DECREASED HEART RATE	2020-07-02 15:05 (1)/ 2020-07-11 09:05 (9)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071062; Age (Years): 29; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ RASH ON GLUTEUS	2020-06-05 (2)/ 2020-06-06 (3)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE							
Infections and infestations/ Otitis externa/ SWIMMER'S EAR (LEFT EAR)	2020-07-13 (7)/ 2020-07-18 (12)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Skin laceration/ CUT ON LEFT FOREARM	2020-06-08 14:00 (1)/ 2020-06-15 (8)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081042; Age (Years): 49; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-09 12:00 (2)/ 2020-07-10 12:00 (3)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash papular/ PAPULAR RASH ON FOREARM (BILATERAL)	2020-06-08 (1)/ 2020-06-16 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE							
Infections and infestations/ Gastroenteritis/ GASTROENTERITIS	2020-07-17 (10)/ 2020-07-28 (21)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-27 (20)/ 2020-08-03 (27)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Oral candidiasis/ THRUSH (TONGUE)	2020-08-05 (29)/ 2020-08-12 (36)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ ALL OVER BODY RASH	2020-06-22 (21)/ 2020-07-02 (31)	Yes/ Yes/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-06-21 (20)/ 2020-06-24 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011055; Age (Years): 45; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES, ALL OVER BODY	2020-06-21 (20)/ 2020-06-24 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ MACULOPAPULAR RASH ON CHEST AND ABDOMEN, ALLERGIC REACTION TO NEW SOAP	2020-07-01 06:00 (1)/ 2020-07-13 (14)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site bruising/ BRUISE AT INJECTION SITE	2020-06-06 (2)/ 2020-06-20 (16)	Yes/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ PAIN IN LEFT HIP	2020-06-09 (5)/ 2020-06-09 (5)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011095; Age (Years): 26; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ PAIN IN LEFT HIP	2020-06-10 (6)/ 2020-06-10 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Dermatitis contact/ RASH, UPPER RT HIP (LIKELY DUE TO POISON IVY CONTACT)	2020-06-27 (23)/ 2020-07-12 (38)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINT	2020-07-07 19:00 (1)/ 2020-07-14 22:22 (8)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pain/ GENERALIZED BODY ACHES	2020-07-07 19:00 (1)/ 2020-07-14 22:22 (8)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-07 21:41 (1)/ 2020-07-15 12:00 (9)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Joint swelling/ SWELLING AT PROXIMAL JOINT 2ND DIGIT RIGHT HAND	2020-07-08 20:00 (2)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021058; Age (Years): 24; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHES	2020-07-14 (8)/ 2020-07-15 (9)	Yes/ No/ Yes	2	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Tooth fracture/ BROKEN TOOTH RIGHT MOLAR	2020-07-22 (16)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-06 (29)/ 2020-07-06 (29)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021064; Age (Years): 54; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-06 (29)/ 2020-07-06 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Chest discomfort/ CHEST PRESSURE	2020-07-06 (29)/ 2020-07-06 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Nasal pruritus/ ITCHY NOSE	2020-07-06 (29)/ 2020-07-08 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021084; Age (Years): 34; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ RASH RIGHT ELBOW	2020-07-08 08:00 (1)/ 2020-07-13 08:00 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI							
Musculoskeletal and connective tissue disorders/ Muscle spasms/ MUSCLE SPASM (BACK)	2020-06-22 (18)/ 2020-06-26 (22)	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021166; Age (Years): 28; Gender: F; Race: OTHER: ASHKENAZI							
Nervous system disorders/ Tension headache/ TENSION HEADACHE	2020-07-31 (25)/ 2020-08-02 (27)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021179; Age (Years): 38; Gender: F; Race: WHITE							
Neoplasms benign, malignant and unspecified (incl cysts and polyps)/ Benign neoplasm of skin/ BENIGN SKIN LESION RIGHT THIGH	2020-06-11 (4)/ 2020-07-03 (26)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE							
Nervous system disorders/ Syncope/ SYNCPAL EPISODE	2020-06-12 (15)/ 2020-06-12 (15)	Yes/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Axillary pain/ BILATERAL AXILLARY TENDERNESS	2020-06-29 18:00 (1)/ 2020-07-07 10:00 (9)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-12 (14)/ 2020-07-22 (24)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031042; Age (Years): 19; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-06 08:00 (32)/ 2020-07-13 08:00 (39)	Yes/ No/ Yes	2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-07 13:27 (1)/ 2020-07-17 22:56 (12)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031057; Age (Years): 26; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Nasal congestion/ NASAL CONGESTION	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-30 (30)/ 2020-08-01 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031072; Age (Years): 54; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Foreign body in eye/ RIGHT EYE IRRITATION SECONDARY TO FOREIGN OBJECT IN EYE	2020-06-17 (15)/ 2020-06-20 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-06-02 (1)/ 2020-08-13 (73)	Yes/ Yes/ No	1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-02 17:00 (1)/ 2020-06-11 22:00 (10)	Yes/ No/ Yes	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-06-03 (2)/ 2020-06-12 (11)	Yes/ No/ Yes	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE DUE TO SEASONAL ALLERGIES	2020-07-06 (1)/ 2020-07-25 (20)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MYALGIA LEFT ARM	2020-07-06 13:30 (1)/ 2020-07-14 13:30 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041076; Age (Years): 40; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-06 13:30 (1)/ 2020-07-15 (10)	Yes/ No/ Yes	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE							
Nervous system disorders/ Paraesthesia/ BILATERAL NUMBNESS/TINGLING IN HANDS	2020-07-05 (5)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE	2020-07-14 (14)/ ONGOING	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE							
Vascular disorders/ Hypertension/ HYPERTENSION	2020-06-24 (17)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051009; Age (Years): 51; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Back pain/ MUSCULOSKELETAL BACK PAIN	2020-06-19 (18)/ 2020-07-24 (53)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-06-14 (13)/ 2020-08-03 (63)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051032; Age (Years): 41; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RUNNY NOSE (UNKNOWN ETIOLOGY)	2020-06-23 (22)/ 2020-07-02 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	2020-07-07 (1)/ 2020-07-15 (9)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-07 (1)/ 2020-07-15 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051033; Age (Years): 40; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-09 (3)/ 2020-07-10 (4)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE							
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-06-09 (7)/ 2020-06-15 (13)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS (THIGHS, TRUNK, FOREARMS, ANKLES)	2020-06-20 (16)/ 2020-06-27 (23)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051042; Age (Years): 35; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Toothache/ TOOTHACHE	2020-06-04 (3)/ 2020-06-24 (23)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061001; Age (Years): 38; Gender: F; Race: WHITE							
Infections and infestations/ Nasopharyngitis/ COMMON COLD	2020-07-18 (9)/ 2020-08-01 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-09 (2)/ 2020-07-16 (9)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-09 08:00 (1)/ 2020-07-16 (9)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-14 (7)/ 2020-07-15 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE	2020-06-12 (10)/ 2020-06-18 (16)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	2020-06-12 (10)/ 2020-06-18 (16)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071030; Age (Years): 37; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site induration/ ENDURATION AT INJECTION SITE	2020-06-12 (10)/ 2020-07-18 (46)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081052; Age (Years): 37; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ LEFT TRAPEZIUS REGION, TRANSIENT LOCAL MUSCLE PAIN RELATED TO INJECTION	2020-06-05 12:03 (1)/ 2020-06-05 12:18 (1)	Yes/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081059; Age (Years): 39; Gender: F; Race: WHITE							
Immune system disorders/ Seasonal allergy/ RUNNY NOSE (SEASONAL ALLERGIES)	2020-08-05 (24)/ 2020-08-09 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Immune system disorders/ Seasonal allergy/ SORE THROAT (SEASONAL ALLERGIES)	2020-08-05 (24)/ 2020-08-09 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-06-27 (23)/ 2020-06-30 (26)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021074; Age (Years): 28; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	2020-06-02 18:00 (1)/ 2020-06-17 08:00 (15)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021080; Age (Years): 49; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-05 21:35 (1)/ 2020-06-18 08:32 (13)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Dry mouth/ DRY MOUTH	2020-07-09 08:00 (1)/ 2020-07-13 00:13 (5)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021099; Age (Years): 49; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Axillary mass/ LUMP RIGHT AXILLARY REGION IPSILATERAL-SAME SIDE OF VACCINATION SITE	2020-07-17 (18)/ 2020-07-17 (18)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021101; Age (Years): 35; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ PAIN AT INJECTION SITE	2020-06-20 (13)/ 2020-06-20 (13)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021151; Age (Years): 30; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Mass/ LEFT POSTERIOR HEAD LUMP	2020-07-05 (28)/ 2020-07-08 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RUNNY NOSE	2020-07-10 03:15 (1)/ 2020-07-10 08:00 (1)	Yes/ No/ No	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021154; Age (Years): 34; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Arthropod bite/ BUG BITE (BOTH ARMS)	2020-06-24 (20)/ 2020-06-28 (24)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-08 20:56 (1)/ 2020-07-16 12:00 (8)	Yes/ No/ Yes	3	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Acne/ WORSENING OF ACNE AROUND MOUTH	2020-06-10 (3)/ 2020-07-01 (24)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Axillary pain/ UNDERARM TENDERNESS	2020-06-14 (7)/ 2020-06-18 (11)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-14 (7)/ 2020-07-01 (24)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE	2020-07-08 21:00 (1)/ 2020-07-17 09:00 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-07-08 21:00 (1)/ 2020-07-17 09:00 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Injury, poisoning and procedural complications/ Muscle contusion/ BRUISING RIGHT POSTERIOR HAMSTRING UNKNOWN	2020-07-14 (7)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Muscle strain/ BACK STRAIN	2020-07-29 (22)/ 2020-08-01 (25)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031035; Age (Years): 48; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-27 (29)/ 2020-08-03 (36)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ RHINORRHEA	2020-07-27 (29)/ 2020-08-03 (36)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	2020-07-30 (29)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041008; Age (Years): 37; Gender: M; Race: WHITE General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-02 (2)/ 2020-07-10 (10)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041060; Age (Years): 19; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE	2020-06-03 (2)/ 2020-06-09 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-03 (2)/ 2020-06-09 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-06 (1)/ 2020-07-16 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-03 09:38 (1)/ 2020-06-12 12:38 (10)	Yes/ No/ Yes	1	No	R/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041073; Age (Years): 44; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-03 (4)/ 2020-07-11 (12)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051012; Age (Years): 28; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS LEFT ARM	2020-06-03 (2)/ 2020-06-05 00:00 (3)	Yes/ No/	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051045; Age (Years): 36; Gender: M; Race: WHITE							
Vascular disorders/ Diastolic hypertension/ DIASTOLIC HYPERTENSION	2020-07-16 (9)/ ONGOING	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES, GENERALIZED	2020-07-06 20:00 (1)/ 2020-07-29 20:00 (24)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061008; Age (Years): 31; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES, GENERALIZED	2020-07-12 06:00 (6)/ 2020-07-14 07:00 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
General disorders and administration site conditions/ Axillary pain/ UNDERARM PAIN - LEFT ARM	2020-06-10 (6)/ 2020-06-12 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES, GENERALIZED	2020-07-12 (7)/ 2020-07-18 (13)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS ALL OVER BODY	2020-07-01 08:00 (1)/ 2020-07-08 08:00 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-01 20:00 (2)/ 2020-07-12 08:00 (12)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-04 (5)/ 2020-07-09 (10)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071036; Age (Years): 18; Gender: M; Race: WHITE							
Psychiatric disorders/ Anxiety/ ANXIETY	2020-08-01 (20)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071039; Age (Years): 53; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ MILD PAIN AT INJECTION SITE	2020-06-15 (11)/ 2020-06-16 (12)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site erythema/ ERYTHEMA TO INJECTION SITE	2020-06-15 (11)/ 2020-06-17 (13)	Yes/ No/ No	2	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071073; Age (Years): 26; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE	2020-06-18 (11)/ 2020-06-20 (13)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE	2020-06-18 (11)/ 2020-06-20 (13)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Haemorrhoids/ HEMORRHOIDS	2020-08 (26)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081028; Age (Years): 51; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Muscle spasms/ MUSCLE SPASM [LOWER BACK]	2020-06-16 (15)/ 2020-07-07 (36)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Skin discolouration/ WHITE FINGERTIPS	2020-06-28 (25)/ 2020-06-28 (25)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Paraesthesia/ FEELING OF "PINS AND NEEDLES" IN EXTREMITIES [CAUSALITY, INVESTIGATIONAL PRODUCT]	2020-07-08 22:00 (2)/ 2020-07-15 07:00 (8)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081045; Age (Years): 43; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Paraesthesia oral/ FEELING OF "PINS AND NEEDLES" IN TONGUE [CAUSALITY, INVESTIGATIONAL PROTOCOL]	2020-07-08 22:00 (2)/ 2020-07-15 07:00 (8)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Abdominal discomfort/ STOMACH PRESSURE	2020-07-12 (6)/ 2020-07-14 (8)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081063; Age (Years): 22; Gender: M; Race: WHITE							
Psychiatric disorders/ Depression/ DEPRESSION	2020-07-20 (13)/ ONGOING	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE							
Infections and infestations/ Gastroenteritis/ ACUTE GASTROENTERITIS	2020-07-09 (1)/ 2020-07-10 (2)	Yes/ Yes/ No	2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011007; Age (Years): 69; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site erythema/ REDNESS AT INJECTION SITE	2020-06-01 20:00 (1)/ 2020-06-10 (10)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011131; Age (Years): 57; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Neck pain/ NECK/SHOULDER PAIN, DUE TO SLEEPING POSITION	2020-07-26 (3)/ 2020-07-26 (3)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011152; Age (Years): 66; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site bruising/ LEFT UPPER ARM BRUISING @ THE INJECTION SITE	2020-07-28 (2)/ 2020-09-02 (38)	Yes/ No/ No	1	No	NR/R	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021022; Age (Years): 67; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Tooth fracture/ BROKEN TOOTH	2020-07-19 (14)/ 2020-08-16 (42)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ POISON IVY ALLERGIC CONTACT DERMATITIS - BILATERAL LEGS	2020-06-10 (10)/ 2020-06-17 (17)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Immune system disorders/ Allergy to arthropod sting/ ALLERGIC REACTION WASP BITE	2020-06-16 (16)/ 2020-06-16 (16)	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021130; Age (Years): 80; Gender: F; Race: WHITE							
Investigations/ Blood pressure increased/ POST DOSE ELEVATED BLOOD PRESSURE	2020-06-26 12:10 (1)/ 2020-07-06 12:10 (11)	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Rash/ RASH RIGHT WRIST	2020-08-25 (28)/ 2020-08-27 (30)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021185; Age (Years): 55; Gender: F; Race: WHITE							
Reproductive system and breast disorders/ Postmenopausal haemorrhage/ POSTMENOPAUSAL BLEEDING	2020-07-04 (9)/ 2020-07-11 (16)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Large intestine polyp/ 2 POLYPS COLON BENIGN	2020-07-08 (7)/ 2020-07-15 (14)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Exostosis/ BONE SPUR 2ND RIGHT TOE	2020-07-08 (7)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS RIGHT HIP	2020-07-13 (12)/ 2020-07-16 (15)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021222; Age (Years): 65; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Arthropod bite/ FIRE ANT BITES EXTREMITIES	2020-08-22 (23)/ 2020-08-31 (32)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031089; Age (Years): 65; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ LEFT SHOULDER PAIN	2020-08-13 (16)/ ONGOING	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-08-28 (26)/ 2020-08-28 (26)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031103; Age (Years): 66; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Sinus congestion/ SINUS CONGESTION	2020-07-27 (29)/ 2020-07-28 (30)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE							
Infections and infestations/ Cellulitis/ CELLULITIS- RIGHT FOREARM	2020-07-05 (4)/ 2020-07-10 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Blood and lymphatic system disorders/ Leukopenia/ LEUKOPENIA	2020-07-31 (1)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-08-24 (22)/ 2020-09-21 (50)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051112; Age (Years): 60; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Abdominal tenderness/ ABDOMINAL TENDERNESS (ETIOLOGY UNKNOWN)	2020-08-26 (24)/ 2020-10-16 (75)	Yes/ No/ No	2	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061035; Age (Years): 71; Gender: M; Race: WHITE							
Investigations/ Heart rate decreased/ DECREASED HEART RATE	2020-06-26 13:41 (1)/ 2020-06-26 19:00 (1)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES - GENERALIZED	2020-07-28 11:00 (1)/ 2020-08-03 18:00 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES	2020-07-28 11:00 (1)/ 2020-08-03 18:00 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061043; Age (Years): 59; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-28 11:00 (1)/ 2020-08-03 18:00 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2061051; Age (Years): 58; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-06 (7)/ 2020-07-07 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071085; Age (Years): 75; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ ARTHRALGIA KNEE JOINT PAIN	2020-06-29 (4)/ 2020-07-06 (11)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Investigations/ Cardiac murmur/ SYSTOLIC MURMUR 2/4	2020-08-24 (28)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	2020-08-09 (6)/ 2020-08-12 (9)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Metabolism and nutrition disorders/ Hyperlipidaemia/ HYPERLIPIDEMIA	2020-08-24 (21)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081004; Age (Years): 60; Gender: F; Race: WHITE							
Renal and urinary disorders/ Haematuria/ HEMATURIA	2020-06-09 (12)/ 2020-07-01 (34)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Back pain/ LOWER BACK PAIN	2020-06-26 (29)/ 2020-06-28 (31)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Angioedema/ SWOLLEN BLISTERED LIPS (INTERMITTENT ANGIOEDEMA)	2020-06-09 (9)/ ONGOING	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE							
Investigations/ Blood pressure increased/ BLOOD PRESSURE ELEVATION	2020-06-01 10:05 (1)/ 2020-06-01 20:00 (1)	Yes/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081007; Age (Years): 64; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Upper respiratory tract inflammation/ PI NOTED INFLAMMATION OF OROPHARNYX AT DAY 15 VISIT	2020-06-17 (17)/ 2020-06-30 (30)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081017; Age (Years): 62; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-06-16 (15)/ 2020-06-18 (17)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081066; Age (Years): 66; Gender: M; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-08-02 (10)/ 2020-08-02 (10)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081103; Age (Years): 58; Gender: M; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-18 (17)/ 2020-07-24 (23)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Pyrexia/ FEVER	2020-07-18 (17)/ 2020-07-24 (23)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081125; Age (Years): 62; Gender: M; Race: WHITE							
Infections and infestations/ Nasopharyngitis/ COMMON COLD	2020-08-04 (2)/ 2020-08-10 (8)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
General disorders and administration site conditions/ Chest pain/ CHEST PAIN, UNKNOWN DETAILS	2020-06-02 22:49 (2)/ 2020-06-02 23:35 (2)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011123; Age (Years): 64; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Ecchymosis/ LEFT UPPER ARM ECCHYMOSIS, DUE TO INJURY	2020-07-03 (8)/ 2020-08-09 (45)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011137; Age (Years): 56; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-23 (28)/ 2020-07-23 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-23 (28)/ 2020-07-23 (28)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021012; Age (Years): 66; Gender: F; Race: WHITE							
Ear and labyrinth disorders/ Ear pain/ OTALGIA	2020-07-04 (6)/ 2020-07-15 (17)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE							
Infections and infestations/ Pharyngitis/ PHARYNGITIS	2020-06-22 (25)/ 2020-06-30 (33)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-01 (34)/ 2020-07-07 (40)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Back pain/ WORSENING OF BACK PAIN	2020-08-04 (23)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ RASH ON RIGHT KNEE NON-URTICARIAL	2020-06-01 (4)/ 2020-06-06 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Renal and urinary disorders/ Nephrolithiasis/ NEPHROLITHIASIS (RIGHT)	2020-06-24 (27)/ 2020-07-09 (42)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021020; Age (Years): 72; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-06-06 (6)/ 2020-06-09 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-06 (6)/ 2020-06-16 (16)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021045; Age (Years): 61; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Toothache/ TOOTHACHE	2020-07-03 (5)/ 2020-07-11 (13)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Pruritus/ GENERALIZED PRURITIS (UNKNOWN)	2020-06-30 (5)/ 2020-07-16 (21)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021205; Age (Years): 56; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Pruritus/ GENERALIZED PURITITIS	2020-08-01 08:00 (1) 2020-08-05 17:00 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021217; Age (Years): 66; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-29 17:00 (1) 2020-08-05 16:23 (8)	Yes/ No/ Yes	3	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021226; Age (Years): 68; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-08-05 08:00 (1)/ 2020-08-06 08:00 (2)	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Dental caries/ TOOTH DECAY	2020-08-19 (17)/ 2020-08-19 (17)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Rotator cuff syndrome/ RIGHT ROTATOR CUFF TEAR	2020-08-24 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2031105; Age (Years): 67; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-28 (3)/ 2020-07-09 (14)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031121; Age (Years): 67; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Peripheral swelling/ LOCALIZED SWELLING TO RIGHT LOWER EXTREMITY	2020-07-02 (3)/ 2020-07-15 (16)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE							
Investigations/ Platelet count decreased/ LOW PLATELETS	2020-07-24 10:40 (28)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	UNKNOWN

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE							
Gastrointestinal disorders/	2020-08-16 (24)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
Oesophageal food impaction/	2020-08-16 (24)	Yes/				CHANGED/	RESOLVED
ESOPHAGEAL FOOD BOLUS OBSTRUCTION		No				NONE	
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE							
Psychiatric disorders/	2020-07-01 (6)/	Yes/	1	No	NR/NR	DOSE NOT	NOT
Insomnia/	ONGOING	Yes/				CHANGED/	RECOVERED/
INSOMNIA		No				CONCOMITANT MEDICATION	NOT RESOLVED
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE							
Nervous system disorders/	2020-08-10 (7)/	Yes/	1	No	NR/NA	NOT APPLICABLE/	RECOVERING/
Nervous system cyst/	ONGOING	Yes/				NONE	RESOLVING
CYST ON SPINAL NERVE		No					

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Spondylolisthesis/ SPONDYLOLISTHESIS	2020-08-10 (7)/ ONGOING	Yes/ Yes/ No	1	No	NR/NA	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041155; Age (Years): 64; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-08-03 18:13 (1)/ 2020-08-11 13:09 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS	2020-06-26 (1)/ 2020-07-06 (11)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-06-26 (1)/ 2020-07-08 (13)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-24 (1)/ 2020-07-31 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-24 (1)/ 2020-07-31 (8)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051057; Age (Years): 61; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site pain/ PAIN AT THE INJECTION SITE	2020-07-24 10:00 (1) 2020-08-05 00:00 (12)	Yes/ No/ Yes	2	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-28 19:28 (1) 2020-08-04 19:05 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051068; Age (Years): 68; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES (IN SEVERAL JOINTS)	2020-07-28 19:28 (1)/ 2020-08-04 19:06 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES (ALL OVER BODY)	2020-07-29 22:37 (2)/ 2020-08-04 19:06 (8)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051103; Age (Years): 58; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Arthropod bite/ BUG BITE ON NECK	2020-07-03 (2)/ 2020-07-13 00:00 (11)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS BILATERAL ARMS AND BACK	2020-07-14 (13)/ 2020-07-22 (21)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061037; Age (Years): 56; Gender: F; Race: NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER							
Respiratory, thoracic and mediastinal disorders/ Rhinalgia/ NOSE PAIN	2020-06-26 00:00 (1)/ 2020-06-26 00:01 (1)	No/ No	1	No	NR/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2061053; Age (Years): 64; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Plantar fasciitis/ PLANTAR FASCIITIS - RIGHT	2020-07-10 (10)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE							
Nervous system disorders/ Dizziness/ DIZZINESS	2020-07-31 08:35 (31)/ 2020-07-31 08:40 (31)	Yes/ Yes/ No	2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ ANXIETY	2020-07-31 09:45 (31)/ 2020-07-31 14:30 (32)	Yes/ Yes/ No	2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE							
Nervous system disorders/ Syncope/ SYNCOPE OF UNCLEAR ORIGIN	2020-07-09 10:00 (1)/ 2020-07-09 10:05 (1)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071025; Age (Years): 59; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-09 10:30 (1)/ 2020-07-10 08:00 (2)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-07-11 (6)/ 2020-07-20 (15)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS	2020-07-02 13:30 (1)/ 2020-07-09 (8)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081070; Age (Years): 71; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Arthropod bite/ BED BUG BITES (BACK)	2020-08-10 (18)/ 2020-08-21 (29)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081071; Age (Years): 65; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT WITH MUCUS	2020-08-01 (4)/ 2020-08-03 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Pharyngeal erythema/ POST OPT SLIGHT ERYTHEMA (THROAT)	2020-08-05 (8)/ 2020-08-12 (15)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	2020-07-02 (1)/ 2020-07-02 12:00 (1)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-02 (1)/ 2020-07-14 (13)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis/ NONSPECIFIC DERMATITIS (RASH ACROSS FOREHEAD AND UPPER BACK)	2020-07-06 (5)/ 2020-07-12 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	2020-07-07 (6)/ 2020-07-07 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Diarrhoea/ DIARRHEA	2020-07-05 (4)/ 2020-07-05 (4)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-05 (4)/ 2020-07-11 (10)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Injection site pruritus/ ITCHING AROUND INJECTION SITE, NO REDNESS	2020-08-05 (3)/ 2020-08-07 (5)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081100; Age (Years): 59; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE REPORTED BEYOND DAY 7 IN EDIARY	2020-08-09 (7)/ 2020-08-11 (9)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081118; Age (Years): 70; Gender: F; Race: WHITE							
Renal and urinary disorders/ Hypertonic bladder/ OVERACTIVE BLADDER	2020-07-10 (10)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE							
Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Yes/ Yes/ No	3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)	NR/NR	DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood alkaline phosphatase increased/ ELEVATED ALKALINE PHOSPHATASE	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Investigations/ Platelet count increased/ ELEVATED PLATELET COUNT	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011004; Age (Years): 55; Gender: F; Race: WHITE							
Nervous system disorders/ Syncope/ SYNCOPE	2020-06-29 09:40 (28)/ 2020-06-29 09:41 (28)	Yes/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE							
Metabolism and nutrition disorders/ Gout/ GOUT, RIGHT GREAT TOE	2020-06-07 (7)/ 2020-06-16 (16)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE							
Infections and infestations/ Herpes simplex/ HERPES SIMPLEX I	2020-08-23 (25)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2011162; Age (Years): 62; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Ecchymosis/ ECCHYMOSIS, LT FOREARM	2020-07-06 14:35 (1)/ 2020-07-14 08:00 (9)	No/ No/ No	1	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Skin and subcutaneous tissue disorders/ Pruritus/ BACK ITCH	2020-07-13 (8)/ 2020-07-22 (17)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Diverticulum/ DIVERTICULOSIS	2020-06-05 (8)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-29 17:28 (1)/ 2020-08-09 13:55 (11)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Pharyngitis/ PHARYNGITIS	2020-08-04 (7)/ 2020-08-07 (10)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021208; Age (Years): 56; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Rhinorrhoea/ NASAL DRAINAGE (UNKNOWN)	2020-08-04 (7)/ 2020-08-07 (10)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-08-04 (7)/ 2020-08-07 (10)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE							
Infections and infestations/ Tooth infection/ INFECTION FROM FILLING IN TOOTH	2020-07-21 (20)/ 2020-07-27 (26)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021214; Age (Years): 73; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Joint injury/ RE-INJURED RIGHT HIP	2020-07-14 (19)/ 2020-07-29 (34)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021218; Age (Years): 56; Gender: F; Race: WHITE							
Immune system disorders/ Seasonal allergy/ WORSENING OF SEASONAL ALLERGIES	2020-07-05 (6)/ 2020-07-14 (15)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021234; Age (Years): 70; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Neck pain/ WORSENING OF NECK PAIN	2020-08-12 (9)/ 2020-08-28 (25)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041112; Age (Years): 61; Gender: M; Race: WHITE							
Investigations/ Blood pressure diastolic increased/ ELEVATED DIASTOLIC BLOOD PRESSURE GRADE 0 TO GRADE 2 POST VACCINATION	2020-06-26 14:17 (1)/ 2020-07-06 12:40 (10)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041122; Age (Years): 82; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site erythema/ CIRCUMFERENTIAL REDNESS ABOVE INJECTION SITE ON LEFT ARM	2020-07-08 (10)/ 2020-07-16 (18)	Yes/ No/ No	1	No	R/R	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041126; Age (Years): 62; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-06-29 (4)/ 2020-07-04 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051069; Age (Years): 64; Gender: F; Race: WHITE							
Infections and infestations/ Gastroenteritis viral/ STOMACH VIRUS	2020-08-18 (22)/ 2020-08-20 (24)	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051084; Age (Years): 61; Gender: F; Race: WHITE							
Nervous system disorders/ Dysgeusia/ DYSGUESIA	2020-07-13 (13)/ 2020-07-27 (27)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051088; Age (Years): 58; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Back pain/ BACK PAIN	2020-08-01 (5)/ 2020-08-02 (6)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS RIGHT FOREARM AND RIGHT THIGH	2020-07-16 (11)/ 2020-08-17 (43)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Meniscus injury/ LEFT MEDIAL MENISCUS TEAR	2020-08-01 (27)/ 2020-09-10 (67)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Erythema/ ERYTHEMA LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ TENDERNESS LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2081001; Age (Years): 57; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Pyrexia/ UNREPORTED FEVER OF 101.4	2020-06-25 06:00 (1)/ 2020-06-25 09:00 (2)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081014; Age (Years): 67; Gender: F; Race: WHITE							
Investigations/ White blood cell count decreased/ LOW WHITE BLOOD CELL COUNT	2020-06-30 09:20 (29)/ 2020-07-28 09:13 (57)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE							
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-07-14 (16)/ 2020-07-23 (25)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081069; Age (Years): 70; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site mass/ LUMP AT INJECTION SITE	2020-06-27 (2)/ ONGOING	Yes/ No/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Nervous system disorders/ Sinus headache/ SINUS HEADACHE	2020-07-26 (3)/ 2020-07-26 (3)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081072; Age (Years): 59; Gender: M; Race: WHITE							
Immune system disorders/ Seasonal allergy/ WHEEZING (SEASONAL ALLERGY RELATED)	2020-07-03 (8)/ 2020-07-12 (17)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site induration/ HARDNESS AT INJECTION SITE (DAY 8)	2020-08-05 (1)/ 2020-08-13 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081076; Age (Years): 55; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Injection site swelling/ SWELLING AT INJECTION SITE (DAY 8)	2020-08-05 (1)/ 2020-08-13 (9)	Yes/ No/ Yes	1	No	R/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081088; Age (Years): 63; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal chest pain/ CHEST TIGHTNESS (MUSCULOSKELETAL)	2020-07-07 (6)/ 2020-07-07 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081093; Age (Years): 66; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	2020-07-03 (2)/ 2020-07-03 12:00 (2)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Musculoskeletal pain/ SHOULDER PAIN R/T PLAYING PICKLE BALL	2020-07-09 (8)/ 2020-07-09 (8)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081099; Age (Years): 55; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE (DAY 8 AFTER INJECTION)	2020-08-06 (9)/ 2020-08-08 (11)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Arthralgia/ GENERALIZED JOINT ACHES (DAY 8-DAY 14 AFTER INJECTION)	2020-08-06 (9)/ 2020-08-11 (14)	Yes/ No/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081120; Age (Years): 72; Gender: M; Race: WHITE							
Investigations/ Haematocrit increased/ CS HEMATOCRIT LAB (INCREASED)	2020-07-29 (1)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Investigations/ Haemoglobin increased/ CS HEMOGLOBIN LAB (INCREASED)	2020-07-29 (1)/ ONGOING	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Oropharyngeal pain/ SORE THROAT	2020-07-09 (4)/ 2020-07-11 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal stiffness/ STIFF NECK	2020-07-09 (4)/ 2020-07-11 (6)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Apthous ulcer/ CANKER SORE	2020-07-09 (4)/ 2020-07-15 (10)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-13 (8)/ 2020-07-15 (10)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081121; Age (Years): 63; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Musculoskeletal stiffness/ STIFF NECK	2020-07-13 (8)/ 2020-07-15 (10)	Yes/ No/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE POST DOSE	2020-08-10 14:00 (1)/ 2020-08-11 09:50 (1)	Yes/ No/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE							
Nervous system disorders/ Dizziness/ DIZZINESS	2020-08-07 07:00 (4)/ 2020-08-12 (10)	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.7
Unsolicited Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Malaise/ MALAISE	2020-08-10 (8)/ 2020-08-10 (8)	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020707.sas 19NOV2020 01:42 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- tated AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	--	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	---------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	-------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	---------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE							
Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Yes/ Yes/ No	3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)	NR/NR	DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.8
Serious Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	---------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020708.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-06 (32)/ 2020-07-23 (49)	Yes/ Yes/ No	2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	--	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	--	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	--	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE							
Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Yes/ Yes/ No	3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)	NR/NR	DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.9
Unsolicited Adverse Events Leading to Discontinuation from Study Vaccine
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	-------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020709.sas 19NOV2020 01:43 Database Lock Date: 05NOV2020

Listing 16.2.7.10

Unsolicited Adverse Events Leading to Discontinuation from Participation in the Study
Safety Set

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	---	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this listing.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020710.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011060; Age (Years): 49; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ EXASPERATION OF POISON IVY RASH LEFT FOREARM/RIGHT UPPER THIGH	2020-06-06 (5)/ 2020-06-13 (12)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Toothache/ TOOTH PAIN, LEFT LOWER SECOND MOLAR (FROM ROOT CANAL)	2020-07-23 (24)/ 2020-07-30 (31)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011067; Age (Years): 28; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-09 (7) / 2020-07-17 (45)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Respiratory, thoracic and mediastinal disorders/ Dry throat/ DRY THROAT	2020-06-09 (7) / 2020-07-30 (58)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021073; Age (Years): 51; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Oral disorder/ LESION ON GUM (UNKNOWN) BENGIN	2020-06-25 (24)/ 2020-07-20 (49)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-06 (32)/ 2020-07-23 (49)	Yes/ Yes/ No	2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-07 15:39 (29)/ 2020-07-15 14:00 (37)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031041; Age (Years): 28; Gender: F; Race: WHITE							
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-07-05 (5)/ 2020-07-11 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031074; Age (Years): 52; Gender: F; Race: WHITE							
Infections and infestations/ Otitis media/ BILATERAL ACUTE OTITIS MEDIA	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-06-10 (9)/ 2020-06-19 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2041019; Age (Years): 20; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Skin laceration/ LEFT HAND LACERATION	2020-07-06 (7)/ 2020-07-13 (14)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081033; Age (Years): 43; Gender: F; Race: WHITE							
Infections and infestations/ Otitis externa/ SWIMMER'S EAR (LEFT EAR)	2020-07-13 (7)/ 2020-07-18 (12)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081038; Age (Years): 30; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Skin laceration/ CUT ON LEFT FOREARM	2020-06-08 14:00 (1)/ 2020-06-15 (8)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081046; Age (Years): 45; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash papular/ PAPULAR RASH ON FOREARM (BILATERAL)	2020-06-08 (1)/ 2020-06-16 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE							
Infections and infestations/ Gastroenteritis/ GASTROENTERITIS	2020-07-17 (10)/ 2020-07-28 (21)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081049; Age (Years): 47; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-27 (20)/ 2020-08-03 (27)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Infections and infestations/ Oral candidiasis/ THRUSH (TONGUE)	2020-08-05 (29)/ 2020-08-12 (36)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011051; Age (Years): 20; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ ALL OVER BODY RASH	2020-06-22 (21)/ 2020-07-02 (31)	Yes/ Yes/ No	2	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011084; Age (Years): 49; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ MACULOPAPULAR RASH ON CHEST AND ABDOMEN, ALLERGIC REACTION TO NEW SOAP	2020-07-01 06:00 (1)/ 2020-07-13 (14)	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031004; Age (Years): 31; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-12 (14)/ 2020-07-22 (24)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031072; Age (Years): 54; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Foreign body in eye/ RIGHT EYE IRRITATION SECONDARY TO FOREIGN OBJECT IN EYE	2020-06-17 (15)/ 2020-06-20 (18)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-06-02 (1)/ 2020-08-13 (73)	Yes/ Yes/ No	1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2041077; Age (Years): 37; Gender: F; Race: WHITE							
Nervous system disorders/ Paraesthesia/ BILATERAL NUMBNESS/TINGLING IN HANDS	2020-07-05 (5)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED
Investigations/ Blood pressure increased/ ELEVATED BLOOD PRESSURE	2020-07-14 (14)/ ONGOING	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041092; Age (Years): 52; Gender: F; Race: WHITE							
Vascular disorders/ Hypertension/ HYPERTENSION	2020-06-24 (17)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051010; Age (Years): 42; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-06-14 (13)/ 2020-08-03 (63)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051034; Age (Years): 36; Gender: M; Race: WHITE							
Infections and infestations/ Upper respiratory tract infection/ UPPER RESPIRATORY INFECTION	2020-06-09 (7)/ 2020-06-15 (13)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051040; Age (Years): 48; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS (THIGHS, TRUNK, FOREARMS, ANKLES)	2020-06-20 (16)/ 2020-06-27 (23)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
General disorders and administration site conditions/ Fatigue/ FATIGUE	2020-07-09 (2)/ 2020-07-16 (9)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Headache/ HEADACHE	2020-07-09 08:00 (1)/ 2020-07-16 (9)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day) / End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071004; Age (Years): 39; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Myalgia/ MUSCLE ACHES ALL OVER BODY	2020-07-14 (7) / 2020-07-15 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011089; Age (Years): 32; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-06-27 (23)/ 2020-06-30 (26)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021164; Age (Years): 34; Gender: F; Race: WHITE							
General disorders and administration site conditions/ Axillary pain/ UNDERARM TENDERNESS	2020-06-14 (7)/ 2020-06-18 (11)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021180; Age (Years): 31; Gender: M; Race: WHITE							
Injury, poisoning and procedural complications/ Muscle strain/ BACK STRAIN	2020-07-29 (22)/ 2020-08-01 (25)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2031079; Age (Years): 34; Gender: F; Race: WHITE							
Psychiatric disorders/ Depression/ WORSENING OF DEPRESSION	2020-07-30 (29)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2041061; Age (Years): 52; Gender: F; Race: WHITE							
Infections and infestations/ Urinary tract infection/ URINARY TRACT INFECTION	2020-07-06 (1)/ 2020-07-16 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061023; Age (Years): 19; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
General disorders and administration site conditions/ Axillary pain/ UNDERARM PAIN - LEFT ARM	2020-06-10 (6)/ 2020-06-12 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Arthralgia/ JOINT ACHES IN SEVERAL JOINTS ALL OVER BODY	2020-07-01 08:00 (1)/ 2020-07-08 08:00 (8)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071002; Age (Years): 39; Gender: F; Race: WHITE							
Nervous system disorders/ Headache/ HEADACHE	2020-07-01 20:00 (2)/ 2020-07-12 08:00 (12)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Gastrointestinal disorders/ Nausea/ NAUSEA	2020-07-04 (5)/ 2020-07-09 (10)	Yes/ Yes/ Yes	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081025; Age (Years): 38; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Haemorrhoids/ HEMORRHIDS	2020-08 (26)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081064; Age (Years): 48; Gender: M; Race: WHITE							
Infections and infestations/ Gastroenteritis/ ACUTE GASTROENTERITIS	2020-07-09 (1)/ 2020-07-10 (2)	Yes/ Yes/ No	2	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021043; Age (Years): 65; Gender: M; Race: WHITE							
Immune system disorders/ Allergy to arthropod sting/ ALLERGIC REACTION WASP BITE	2020-06-16 (16)/ 2020-06-16 (16)	Yes/ Yes/ No	3	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2021196; Age (Years): 63; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Large intestine polyp/ 2 POLYPS COLON BENIGN	2020-07-08 (7)/ 2020-07-15 (14)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021206; Age (Years): 64; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Exostosis/ BONE SPUR 2ND RIGHT TOE	2020-07-08 (7)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED
Musculoskeletal and connective tissue disorders/ Bursitis/ BURSITIS RIGHT HIP	2020-07-13 (12)/ 2020-07-16 (15)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041146; Age (Years): 59; Gender: F; Race: WHITE							
Infections and infestations/ Cellulitis/ CELLULITIS- RIGHT FOREARM	2020-07-05 (4)/ 2020-07-10 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-08-24 (22)/ 2020-09-21 (50)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071100; Age (Years): 61; Gender: M; Race: WHITE							
Metabolism and nutrition disorders/ Hyperlipidaemia/ HYPERLIPIDEMIA	2020-08-24 (21)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED
Subject ID: US2081005; Age (Years): 55; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Angioedema/ SWOLLEN BLISTERED LIPS (INTERMITTENT ANGIOEDEMA)	2020-06-09 (9)/ ONGOING	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011040; Age (Years): 66; Gender: F; Race: BLACK OR AFRICAN AMERICAN							
General disorders and administration site conditions/ Chest pain/ CHEST PAIN, UNKNOWN DETAILS	2020-06-02 22:49 (2)/ 2020-06-02 23:35 (2)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2021018; Age (Years): 71; Gender: F; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Back pain/ WORSENING OF BACK PAIN	2020-08-04 (23)/ ONGOING	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021019; Age (Years): 59; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Rash/ RASH ON RIGHT KNEE NON-URTICARIAL	2020-06-01 (4)/ 2020-06-06 (9)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Renal and urinary disorders/ Nephrolithiasis/ NEPHROLITHIASIS (RIGHT)	2020-06-24 (27)/ 2020-07-09 (42)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION, CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031097; Age (Years): 86; Gender: F; Race: WHITE							
Gastrointestinal disorders/ Dental caries/ TOOTH DECAY	2020-08-19 (17)/ 2020-08-19 (17)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT PROCEDURE	RECOVERED/ RESOLVED
Musculoskeletal and connective tissue disorders/ Rotator cuff syndrome/ RIGHT ROTATOR CUFF TEAR	2020-08-24 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	NOT RECOVERED/ NOT RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041103; Age (Years): 66; Gender: M; Race: WHITE							
Gastrointestinal disorders/	2020-08-16 (24)/	Yes/	1	No	NR/NR	DOSE NOT	RECOVERED/
Oesophageal food impaction/	2020-08-16 (24)	Yes/				CHANGED/	RESOLVED
ESOPHAGEAL FOOD BOLUS OBSTRUCTION		No				NONE	
Subject ID: US2041104; Age (Years): 68; Gender: F; Race: WHITE							
Psychiatric disorders/	2020-07-01 (6)/	Yes/	1	No	NR/NR	DOSE NOT	NOT
Insomnia/	ONGOING	Yes/				CHANGED/	RECOVERED/
INSOMNIA		No				CONCOMITANT MEDICATION	NOT RESOLVED
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE							
Nervous system disorders/	2020-08-10 (7)/	Yes/	1	No	NR/NA	NOT APPLICABLE/	RECOVERING/
Nervous system cyst/	ONGOING	Yes/				NONE	RESOLVING
CYST ON SPINAL NERVE		No					

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041119; Age (Years): 68; Gender: M; Race: WHITE							
Musculoskeletal and connective tissue disorders/ Spondylolisthesis/ SPONDYLOLISTHESIS	2020-08-10 (7)/ ONGOING	Yes/ Yes/ No	1	No	NR/NA	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Subject ID: US2051103; Age (Years): 58; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Arthropod bite/ BUG BITE ON NECK	2020-07-03 (2)/ 2020-07-13 00:00 (11)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2061068; Age (Years): 63; Gender: F; Race: WHITE							
Nervous system disorders/ Dizziness/ DIZZINESS	2020-07-31 08:35 (31)/ 2020-07-31 08:40 (31)	Yes/ Yes/ No	2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Psychiatric disorders/ Anxiety/ ANXIETY	2020-07-31 09:45 (31)/ 2020-07-31 14:30 (32)	Yes/ Yes/ No	2	No	NR/R	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-07-11 (6)/ 2020-07-20 (15)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081009; Age (Years): 59; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS	2020-07-02 13:30 (1)/ 2020-07-09 (8)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2081092; Age (Years): 77; Gender: F; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis/ NONSPECIFIC DERMATITIS (RASH ACROSS FOREHEAD AND UPPER BACK)	2020-07-06 (5)/ 2020-07-12 (11)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081123; Age (Years): 65; Gender: M; Race: WHITE							
Infections and infestations/ Pneumonia/ DOUBLE PNEUMONIA (COMMUNITY ACQUIRED)	2020-08-01 (33)/ 2020-08-26 (58)	Yes/ Yes/ No	3	Yes/ 2, 3 (2020-08-01/ 2020-08-05)	NR/NR	DRUG WITHDRAWN/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Investigations/ Blood alkaline phosphatase increased/ ELEVATED ALKALINE PHOSPHATASE	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Investigations/ Platelet count increased/ ELEVATED PLATELET COUNT	2020-08-11 (43)/ 2020-09-08 (71)	Yes/ Yes/ No	2	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2011028; Age (Years): 60; Gender: M; Race: WHITE							
Metabolism and nutrition disorders/ Gout/ GOUT, RIGHT GREAT TOE	2020-06-07 (7)/ 2020-06-16 (16)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2011121; Age (Years): 61; Gender: F; Race: WHITE							
Infections and infestations/ Herpes simplex/ HERPES SIMPLEX I	2020-08-23 (25)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021011; Age (Years): 58; Gender: M; Race: WHITE							
Gastrointestinal disorders/ Diverticulum/ DIVERTICULOSIS	2020-06-05 (8)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERING/ RESOLVING
Subject ID: US2021211; Age (Years): 78; Gender: F; Race: WHITE							
Infections and infestations/ Tooth infection/ INFECTION FROM FILLING IN TOOTH	2020-07-21 (20)/ 2020-07-27 (26)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2051108; Age (Years): 65; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Dermatitis contact/ CONTACT DERMATITIS RIGHT FOREARM AND RIGHT THIGH	2020-07-16 (11)/ 2020-08-17 (43)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2071043; Age (Years): 69; Gender: F; Race: WHITE							
Injury, poisoning and procedural complications/ Meniscus injury/ LEFT MEDIAL MENISCUS TEAR	2020-08-01 (27)/ 2020-09-10 (67)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071082; Age (Years): 57; Gender: M; Race: WHITE							
Skin and subcutaneous tissue disorders/ Erythema/ ERYTHEMA LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING
Musculoskeletal and connective tissue disorders/ Arthralgia/ TENDERNESS LEFT METATARSOPHALANGEAL JOINTS	2020-08-18 (22)/ ONGOING	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERING/ RESOLVING

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.11
Unsolicited Medically-Attended Adverse Events
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2081016; Age (Years): 55; Gender: F; Race: WHITE							
Infections and infestations/ Sinusitis/ SINUS INFECTION	2020-07-14 (16)/ 2020-07-23 (25)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Subject ID: US2081129; Age (Years): 58; Gender: F; Race: WHITE							
Nervous system disorders/ Dizziness/ DIZZINESS	2020-08-07 07:00 (4)/ 2020-08-12 (10)	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
General disorders and administration site conditions/ Malaise/ MALAISE	2020-08-10 (8)/ 2020-08-10 (8)	Yes/ Yes/ No	1	No	R/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020711.sas 19NOV2020 01:44 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021094; Age (Years): 53; Gender: M; Race: WHITE							
Respiratory, thoracic and mediastinal disorders/ Cough/ COUGH	2020-06-26 (22)/ 2020-08-08 (65)	Yes/ No/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Nervous system disorders/ Sinus headache/ SINUS HEADACHE	2020-06-29 (25)/ 2020-07-01 (27)	Yes/ No/ No	1	No	NR/NR	DOSE DELAYED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-06 (32)/ 2020-07-23 (49)	Yes/ Yes/ No	2	No	NR/NR	DRUG WITHDRAWN/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2021137; Age (Years): 26; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION (POSITIVE)	2020-07-07 15:39 (29)/ 2020-07-15 14:00 (37)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED
Subject ID: US2031081; Age (Years): 36; Gender: F; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-08-03 (33)/ 2020-08-03 (33)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2041047; Age (Years): 33; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-06-02 (1)/ 2020-08-13 (73)	Yes/ Yes/ No	1	No	NR/NA	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12
Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	--	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2031102; Age (Years): 57; Gender: F; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-08-28 (26)/ 2020-08-28 (26)	Yes/ No/ No	1	No	NR/NR	NOT APPLICABLE/ NONE	RECOVERED/ RESOLVED
Subject ID: US2051072; Age (Years): 69; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID-19 INFECTION	2020-08-24 (22)/ 2020-09-21 (50)	Yes/ Yes/ No	2	No	NR/NR	DOSE NOT CHANGED/ NONE	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Soli- cited AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US2071106; Age (Years): 64; Gender: M; Race: WHITE							
Infections and infestations/ COVID-19/ COVID 19 INFECTION	2020-07-11 (6)/ 2020-07-20 (15)	Yes/ Yes/ No	1	No	NR/NR	DOSE NOT CHANGED/ CONCOMITANT MEDICATION	RECOVERED/ RESOLVED

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020

Listing 16.2.7.12

Unsolicited Adverse Events for Subjects with SARS-CoV-2 Infection or COVID-19
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solici- ted AR	Sev. [1]	SAE/ Criteria [2]	Relation- ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
--	---	-------------------------------------	-------------	----------------------	-----------------------------------	---	---------

There are no observations for this section.

TEAE = Treatment-Emergent Adverse Event; MAAE = Medically-Attended Adverse Event; AR = Adverse Reaction; SAE = Serious Adverse Event; IP = Investigational Product; SP = Study Procedure.

Relative day is defined as days from the most recent injection date.

MedDRA version 23.0

[1] Sev. = Severity, 1 = Grade 1/Mild, 2 = Grade 2/Moderate, 3 = Grade 3/Severe, 4 = Grade 4.

[2] 1 = Death, 2 = Life threatening, 3 = Requires inpatient or prolongation of existing Hospitalization (Hospital Admission Date/ Hospital Discharge Date), 4 = Persistent or significant disability or incapacity, 5 = Congenital anomaly or birth defect, 6 = Other medically important event.

[3] R = Related, NR = Not Related, NA = Not Applicable.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020712.sas 19NOV2020 01:45 Database Lock Date: 05NOV2020